November 15-19, 2024 San Diego
1002-FRI | Mechanosensitive regulation of LXR by YAP/TAZ determines hepatic cholesterol accumulation | Na Young Lee | Received |
1003-FRI | Liver single-cell RNA transcriptome evolution in response to diet-induced MASH/fibrosis | Simeng Wang | Received |
1005-FRI | Soluble Siglec-9 improves intestinal barrier function in a mouse model of metabolic-dysfunction associated steatohepatitis (MASH) | Hisanori Muto | Received |
1006-FRI | A new therapeutic approach for MASLD/MASH treatment | Takashi Tsuchiya | Received |
1007-FRI | 11β-HSD1 inhibition on non-alcoholic fatty liver disease: Investigating immune cell dynamics via single-cell mass cytometry | Dae Won Jun | Received |
1008-FRI | DGAT2 Inhibition Blocks Activation of SREBP-1 and Improves Hepatic Steatosis by Increasing ER Phosphatidylethanolamine | Shunxing Rong | Received |
1009-FRI | Cytoplasmic export of circPOLD1 promotes metabolic dysfunction-associated steatohepatitis liver disease through interaction with HuR | Qingmin Zeng | Received |
1012-FRI | Hepatic chenodeoxycholic acid promotes MASH with HCC in high-fat/high-sucrose diet-fed mice with human-like bile acid composition | Hajime Ueda | Received |
1015-FRI | The role of BH3-only protein Noxa in metabolic dysfunction-associated steatotic liver disease. | SHINNOSUKE KUDO | Received |
1016-FRI | The increased IL-1β secretion of macrophages accompanying autophagy dysfunction enhances the inflammatory chemokine expression of LSECs, contributing to the progression of MASH pathology | Kenji Fukumoto | Received |
1019-FRI | Extracellular vesicles derived from the iPS-derived mesenchymal stem cells ameliorated liver fibrosis and fatty deposition in MASLD-related cirrhotic mice. | Tsuyoshi Fujioka | Received |
1021-FRI | Generating hepatic cells expressing the various PNPLA3-I148M variants by prime editing. | Takuro Uchida | Received |
1024-FRI | Murine MASH livers display bias towards a hypertrophic mechanism of regeneration following partial hepatectomy | Maylene Yu | Received |
1025-FRI | Endothelial-stellate cell crosstalk underlies fibrosis resolution in liver | Kenneth Li | Received |
1027-FRI | Impact of adult-onset, hepatocyte-specific, loss of the growth hormone receptor on MASH progression | Mercedes del Rio-Moreno | Received |
1028-FRI | Oxidized LDL´s Role in MASLD: Insights from Liver Spheroid Transcriptomics | Ana Maretti-Mira | Received |
1030-FRI | WFDC2 promotes MASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia | Peiyu Wu | Received |
1034-FRI | ROLE OF STARD1 IN HEPATIC MITOCHONDRIAL-DERIVED OXYSTEROLS IN THE DEVELOPMENT OF CARDIOVASCULAR DYSFUNCTION IN MASH | Sandra Torres | Received |
1035-FRI | Hepatocyte arginase-2 protects from metabolic dysfunction-associated steatohepatitis by regulating mitochondrial fatty acid oxidation. | Hui Han | Received |
1037-FRI | The pan-PPAR agonist lanifibranor improves liver inflammation, ballooning, and fibrosis in a diet-induced obese MASH hamster model of binge drinking | Francois Briand | Received |
1038-FRI | Neutrophil Depletion attenuated NLRP3-Induced Liver Inflammation and Fibrosis in NASH | Lin Kui | Received |
1039-FRI | A novel steatohepatitis model in the FAH-deficient swine | Silvana Wilken | Received |
1040-FRI | The exercise-induced metabokine beta-aminoisobutyric acid regulates hepatic lipid metabolism and reduces hepatic metabolic dysfunction and fatty liver in a dietary obese mouse model | Shaimaa Gad | Received |
1042-FRI | Hepatocyte-Specific Deletion of the Novel Hexokinase, HKDC1, Protects Against MASH-induced Fibrosis in Female Mice. | Irene Corona-Avila | Received |
1043-FRI | Adipocyte activating transcription factor 3 is a gatekeeper in preventing non-alcoholic steatohepatitis | Shuwei Hu | Received |
1044-FRI | C/EBPβ-VCAM1 axis in Kupffer cells promotes hepatic inflammation in metabolic dysfunction-associated steatohepatitis | Shuangzhe Lin | Received |
1045-FRI | Inhibition of visceral adipose tissue-derived pathogenic signals by activation of adenosine A2AR improves cardiac dysfunction of NASH mice | Ying-Ying Yang | Received |
1046-FRI | The Gene Expression Characteristic in MASLD-HCC Progression with Diet-Induced Metabolic Shifts | yuyun song | Received |
1048-FRI | Carriage of multiple genetic risk factors for MASH stimulates an altered inflammatory secretome in a human stem cell-based in vitro model | Alexandra Gatzios | Received |
1049-FRI | Fam172a Gene Knockdown aggravates Hepatocyte Lipotoxic Injury through Activating the ERK Pathway | Mengqi Li | Received |
1051-FRI | The effects of CSE deficiency on high-fat diet-induced nonalcoholic fatty liver | Se Young Jang | Received |
1052-FRI | Hepatic mitochondrial quality control regulates skeletal muscle adaptation to exercise through selenoprotein P in MASH-related hepatocarcinogenic mice | Keisuke Hino | Received |
1058-FRI | An Oral inhibitor of CBP/β-catenin signaling, C-82, improves liver steatosis, function, inflammation and fibrosis in the GAN diet-induced obese mouse model of MASH | Kenzaburo Yamaji | Received |
1059-FRI | Therapeutic Implications of DNA Methylation in MASLD Progression | Hyunahm Sohn | Received |
1062-FRI | PUM1 knockdown aggravates lipid deposition in metabolic dysfunction-associated steatotic liver disease | Zhiping Wan | Received |
1063-FRI | Intestine-Specific Faf2 Depletion Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Impairing Lipid Absorption | Jingjing ZHANG | Received |
1066-FRI | The influence and mechanism of vitamin C on PM2.5 exposure metabolic dysfunction associated fatty liver disease | Lili Zhao | Received |
1067-FRI | Targeting BRD4 mitigates hepatocellular lipotoxicity by suppressing the NLRP3 inflammasome activation and GSDMD-mediated hepatocytes pyroptosis | Fangyuan Chen | Received |
1071-FRI | Novel Hepatic Lipid-Induced Enhancer activation modulates Steatohepatitis via S100A11 | P. Vineeth Daniel | Received |
1074-FRI | A PNPLA3-deficient iPSC-derived hepatocyte screen identifies pathways to potentially reduce steatosis in Metabolic Dysfunction-Associated Fatty Liver Disease | Caren Doueiry | Received |
1075-FRI | Potential of Novel Regulatory Bile Acid, 3β-Sulfate-5-Cholestenoic Acid (3SCA) in MASLD Therapy | Yaping Wang | Received |
1076-FRI | A Fructose-enriched diet consumption promotes a specific transcriptomic signature defining an aggressive phenotype. | Lisette Chávez Rodríguez | Received |
1078-FRI | In vitro cellular studies implicate HSD17B13 in lipid and immune associated pathways in cultured primary human hepatocytes | Wensheng Xie | Received |
1080-FRI | Liver-derived extracellular matrix hydrogels augment the survival and function of primary rat liver sinusoidal endothelial cells | Junyu Wang | Received |
1084-FRI | Glucagon engagement is essential for the direct anti-inflammation and anti-fibrosis effect of efocipegtrutide in TAA-induced mouse model of liver injury and fibrosis | yohan kim | Received |
1085-FRI | Sulfonated albumin activates hepatic stellate cells to accelerate NASH liver fibrosis | Tiantian Liu | Received |
1086-FRI | Phocaeicola coprocola alleviates metabolic dysfunction-associated steatotic liver disease by modulating lipogenesis | JeongHa Park | Received |
1089-FRI | Reproducible therapeutic effects of semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH | Malte Nielsen | Received |
1090-FRI | Reproducible therapeutic effects of resmetirom in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH | Malte Nielsen | Received |
1092-FRI | NSrp70 deficiency worsens metabolic dysfunction-associated steatohepatitis by regulating lipogenesis | Daram Yang | Received |
1093-FRI | Unravelling MASLD heterogeneity at single cell level in the switching towards progressive disease | Paola Dongiovanni | Received |
1094-FRI | High frequency ultrasound shear wave elastography for preclinical liver investigation: a pilot study on an OGT mouse model | jean-luc gennisson | Received |
1095-FRI | New steps forward in learning about the use of DGAT1 and DGAT2 inhibitors for metabolic dysfunction-associated steatotic liver disease (MASLD) management: benefits for their single or combined application | Miriam Longo | Received |
1096-FRI | AKT Isoform Specific Regulation of Hepatic Steatosis Induced by Bioactive Lipids | Mario Alba | Received |
1097-FRI | Treatment with the CCR2/CCR5 antagonist Cenicriviroc does not affect MASH and fibrosis development in Ldlr-/-.Leiden mice, translational to clinical phase 3 trial results | Martine Morrison | Received |
1098-FRI | Liver fibrosis induced by CDAHFD and surfactant Polysorbate 80 | Masaki Yamamoto | Received |
1100-FRI | Highly sensitive metabolic flux analysis using 14C-microtracers combined with accelerator mass spectrometry - A proof of concept study on de novo lipogenesis | Martine Morrison | Received |
1101-FRI | Hepatoprotective effects of longer-term treatment intervention with Semaglutide and Tirzepatide in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH | Jacob Nøhr-Meldgaard | Received |
1102-FRI | Synergistic hepatoprotective effects of semaglutide and resmetirom combination therapy in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH | Jacob Nøhr-Meldgaard | Received |
1103-FRI | Treatment with retinoic acid improves diet-induced MASLD in male mice | Katharina Burger | Received |
1105-FRI | Understanding how HMGCS2-derived ketone body metabolites impact MASLD progression | Jessica Shay | Received |
1106-FRI | Toll-like receptor ligands pattern in alcohol-related liver disease and metabolic dysfunction-associated steatotic liver disease patients | Raphaela Staltner | Received |
1108-FRI | Neutralizing the OX40L-OX40 axis attenuates fibrosis and recruitment of monocyte-derived macrophages in murine metabolic dysfunction-associated steatohepatitis. | Lucia Valenzuela Perez | Received |
1111-FRI | Glycogen Synthase Kinase 3β Hepatocyte Deletion Ameliorates Murine Metabolic Dysfunction-Associated Steatohepatitis | Khaled Warasnhe | Received |
1113-FRI | JiGuCao capsule alleviates metabolic dysfunction-associated fatty liver disease by regulating the gut microbiota and lipid metabolism | Wenying Qi | Received |
1114-FRI | The effects of hydroxynonenal on hepatocytes and its association with the pathogenesis of NAFLD | Masahiro Yanagi | Received |
1116-FRI | Blockade of CXCR3 attenuates CD4 T cell-mediated liver injury in murine metabolic dysfunction-associated steatohepatitis | Hyun Se Kim Lee | Received |
1120-FRI | Expression of hepatic drug metabolizing enzymes is altered by concomitant obesogenic lipids and ethanol in mice and adult human hepatic organoids | Joseph Dempsey | Received |
1121-FRI | Modulation of Gut Microbiota and Metabolic and Histological Improvements through Methyl Group Donor Supplementation in a MetALD model | Carolina Diaz Canul | Received |
1122-FRI | The Role of MicroRNA-122 in Metabolic Dysfunction-Associated Steatotic Liver Disease | Khang Tran | Received |
1123-FRI | Retatrutide improves steatohepatitis in a new accelerated mouse model of diet-induced steatohepatitis with a fructose binge | Greta Viebahn | Received |
1129-FRI | ENTPD1/CD39 regulates inflammatory process in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Vanessa Garcia-Fernandez | Received |
1134-FRI | In vivo experiments and network pharmacology to investigate mechanisms of JiGuCao capsule for metabolic-associated fatty liver disease | Wenying Qi | Received |
1135-FRI | Reduced HNF4α Expression in MASLD iPSC-Derived Hepatocytes and Associated Epigenetic Modifications | Dounia Le Guillou | Received |
1136-FRI | Frataxin deficiency induces hepatocyte ferroptosis and liver injury in metabolic dysfunction-associated steatotic liver disease | Somesh Banerjee | Received |
1138-FRI | Manipulating bile acid pool size to target dietary fat absorption in MASLD | Alvin Chan | Received |
1139-FRI | Unlocking S-Pindolol´s Potential for MASLD: Beneficial effects on muscle mass and function and liver histology in western-diet fed mice | Daniel Cabrera | Received |
1141-FRI | Enhanced muscle mass mitigates MASLD in myostatin knockout mice without impacting exercise performance. | Daniel Cabrera | Received |
1142-FRI | Nuclear sequestration of Y box-binding protein 1 reprograms hepatocytes for adipogenicity | James Jordan | Received |
1143-FRI | Syphilitic Hepatitis: A Rare Case of Hepatic Injury from a Commonly Transmitted Venereal Disease | Karthic Drishna Perumal | Received |
1144-FRI | Clinical Utility of Two-Step Hepatitis E Virus IgM Antibody Testing in a Low-Prevalence Setting: A 10-year Retrospective Multicenter Study | Chia-Yu Chiu | Received |
1145-FRI | Successful development of a loop-mediated isothermal amplification assay (LAMP-PCR) for detection HDV-RNA | Saruul Enkhjargal | Received |
1149-FRI | The prevalence and clinical characteristics of concurrent hepatitis D infection in chronic hepatitis B patients in Xinjiang region: A multicenter, retrospective, cross-sectional study. | WEI SUN | Received |
1151-FRI | Summary of clinical features of 1800 cases of bacterial liver abscesses | diandian Hao | Received |
1155-FRI | Real world outcomes of Hepatitis Delta patients with mild or moderate fibrosis | Sabela Lens | Received |
1156-FRI | Utility of the fungal biomarker beta-D-glucan (BDG) for diagnosis of invasive fungal infections, antifungal prescription and correlation with mortality for critically ill patients in a liver intensive care unit | Anita Verma | Received |
1157-FRI | Recent seroprevalence and epidemiological characteristics of HDV infection among HBsAg-positive inpatients in China | Shiyang Pan | Received |
1158-FRI | Establishment and application of a new method for dual detection of HDV RNA and HBV DNA based on CRISPR technology | Feng Ren | Received |
1160-FRI | Effect of Sex Steroid Hormones on HEV replication - Clinical Implication | Premashis Kar | Received |
1161-FRI | DELTA DESCRIBE, the French collaborative project: Profile and management of hepatits delta patients in metropolitan France | Veronique Loustaud-Ratti | Received |
1163-FRI | Sero-prevalence and genotype distribution of HDV among 67 HBsAg-positive pregnant women in Siem Reap, Cambodia, using in-house direct ELISA test method. | Golda Akuffo | Received |
1164-FRI | Establishment of BALB/cAJcl-nu/nu Mice Xenograft Model and Drug Screening Platform for Acute Hepatitis A | Reina Sasaki-Tanaka | Received |
1165-FRI | Clinical characteristics and prognosis of HEV hepatitis: a retrospective study of 628 Chinese patients | Wen An | Received |
1166-FRI | Bulevirtide monotherapy may reduce liver decompensation in patients with HDV-related compensated cirrhosis: a case control study with propensity score weighted analysis | Elisabetta Degasperi | Received |
1167-FRI | Epidemiologic and Clinical Characteristics of Acute Viral Hepatitis in South Korea: A Prospective, Nationwide Multicenter Study | In Hee Kim | Received |
1169-FRI | Effect of Bulevirtide treatment on the HDV induced antiviral state and cell damage in infected humanized mice and patients with chronic hepatitis D | Maura Dandri | Received |
1170-FRI | Association of Socioeconomic Status on the Prevalence of Hepatitis D Co-infection in patients with Chronic Hepatitis B in San Diego County. | Karine Moussa | Received |
1171-FRI | Hepatitis D virus (HDV) screening program in a single tertiary liver center in the United States | Rohullah Rasikh | Received |
1173-FRI | Day 3 MELD Score as a reliable guide for early liver transplant in Autoimmune hepatitis - A prospective study | Shubham Jain | Received |
1174-FRI | Review of evidence to Support the Use of Surrogate Endpoints and Fibroscan in Hepatitis D Infection | Prajakta Bhounsule | Received |
1175-FRI | Associations Between Liver Biomarkers and Clinical Events in Patients with Hepatitis D Virus infection: A Retrospective Real-world Study | Yunhao Liu | Received |
1176-FRI | PREVALENCE AND CLINICAL CHARACTERISTICS OF HEPATITIS DELTA VIRUS (HDV) INFECTED INDIVIDUALS IN BRITISH COLUMBIA AND ONTARIO: A MULTI-CENTRE UPDATE. | Valeriya Zaborska | Received |
1178-FRI | Defining the data requirement to improve hepatitis D co-infection detection in the United Kingdom: the Somerset Liver Improvement Project | Emma Saunsbury | Received |
1179-FRI | Seroprevalence and genotype distribution of hepatitis A and E viruses among general residents in Binh Thuan Province, Southern Vietnam | Chanroth Chhoung | Received |
1180-FRI | A Systematic Review and Meta-analysis Assessing the Safety and Efficacy of Hepatitis E Virus Vaccine. | Islam Mohamed | Received |
1181-FRI | Zinc acetate inhibits hepatitis A virus replication in vitro | Tatsuo Kanda | Received |
1183-FRI | Development and implementation of an hepatitis D detection and linkage to care program in Catalonia. Preliminary results. | Adriana Palom | Received |
1184-FRI | Differential placental estrogen receptor expression is responsible for the adverse clinical outcomes in Hepatitis E virus and COVID-19 infected pregnant women | Maryam Javed | Received |
1185-FRI | Bulevirtide for patients with chronic Hepatitis D (CHD) in Italy: a multicenter prospective nationwide real-life study (D-SHIELD) | Maria Paola Anolli | Received |
1186-FRI | HBcrAg mirrors HDV RNA decline and ALT normalisation during bulevirtide therapy in patients with chronic hepatitis delta | Ivana Carey | Received |
1188-FRI | Quantification of plasma HDV RNA in untreated and Bulevirtide-treated patients with CHD: a comparison between Robogene 2.0, Eurobioplex and Altostar | Maria Paola Anolli | Received |
1191-FRI | Evaluation of COVID-19-related Decompensation and long-term assessment of Post COVID Condition in Patients with Cirrhosis (Eva-Long COVID study) | Madhumita Premkumar | Received |
1192-FRI | The asymmetry of the liver and spleen stiffness measures between patients with chronic hepatitis B and D reflects important clinic-pathologic differences | Francesco Damone | Received |
1195-FRI | Hepatitis A infection decreases amino acid and SCFA metabolism by gut bacteria, compromising gut barrier integrity and contributing to acute liver failure | Anoushka Saxena | Received |
1196-FRI | Hepatitis E virus induced metabolomic and immune shift in acute liver failure is associated with obstetric complications during pregnancy | Anoushka Saxena | Received |
1199-FRI | Spectrum of Hepatitis A viral infection and related mortality from a tertiary care centre in South East Asia region : Time for a new era | Manasa Alla | Received |
1200-FRI | Management and Care of Patients with HDV Differs Across Specialties | Faisal Abaalkhail | Received |
1201-FRI | Duration of nucleos(t)ide analogue (NA) treatments in patients with chronic hepatitis B (CHB) virus infection in the United States (US) | Jennifer Bevan | Received |
1202-FRI | Stimulating STING pathway leads to inhibition of HBV replication: insights into kupffer cell | Mingyuan Zhang | Received |
1204-FRI | Non-Linear Association Between Liver Fibrosis Scores and Viral Load in Patients with Chronic Hepatitis B | Gi-Ae Kim | Received |
1205-FRI | Post-transplant HBV vaccine compliance and seroprotection in thoracic organ transplant recipients | Chia-Yu Chiu | Received |
1206-FRI | Optimizing Hepatitis B Virus Seroprotection in Thoracic Organ Transplantation: The Role of Heplisav-B Vaccination Schedule | Chia-Yu Chiu | Received |
1208-FRI | The proportion of serum HBsAg-negative patients in hepatitis B virus-associated glomerulonephritis was as high as 70%--A retrospective cohort study from China | Tongtong Ji | Received |
1209-FRI | Serum total cholesterol is a predictor of end-stage renal disease in patients with hepatitis B virus-associated glomerulonephritis: a retrospective cohort study from China | Tongtong Ji | Received |
1210-FRI | Safety of Tenofovir Alafenamide in the Context of Hyperlipidemia and Cardiovascular Diseases: A Nationwide Analysis | Jeong-Ju Yoo | Received |
1211-FRI | Gender-Specific Disparities in Receiving Antiviral Therapy Among Treatment-Eligible Adults with Chronic Hepatitis B Infection Across Three Safety-Net Health Systems in the United States | Robert Wong | Received |
1212-FRI | Gaps in Hepatitis B Laboratory Monitoring Among an Ethnically Diverse Cohort of Adults with Treatment-Naïve Chronic Hepatitis B Infection in the United States | Robert Wong | Received |
1214-FRI | The efficacy and safety analysis of TDF for preventing mother-to-child transmission of hepatitis B virus in different gestational weeks | Xiaohong Gao | Received |
1215-FRI | Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: Liver-related Clinical Outcomes and Subgroup Analysis by Liver Cirrhosis Status | Soon Sun Kim | Received |
1216-FRI | Hepatitis B virus subviral particle biogenesis relies on functional ubiquitin and proteasome pathways | Sisi Yang | Received |
1217-FRI | HBeAg-positive pregnant mothers with higher HBV DNA decline rate from mid-pregnancy to delivery are more likely to achieve HBeAg seroconversion after delivery without postpartum cessation of nucleos(t)ide analogs therapy | Wenting Zhong | Received |
1218-FRI | High functional cure rate induced by Peg IFN alpha-2b in HBV postpartum women with HBeAg negative: an explorational study | Wenting Zhong | Received |
1219-FRI | DISMANTLING BARRIERS TO HEPATITIS B AND DELTA SCREENING, PREVENTION, AND LINKAGE TO CARE AMONG THE PWUD COMMUNITY IN PHILADELPHIA | Beatrice Zovich | Received |
1220-FRI | Serum HBsAg Rather Than HBV DNA Reflects Liver HBV Transcript Levels of Hepatitis B Patients Treated by Nucleoside Analogues | Wenhua Zhang | Received |
1222-FRI | Anti-HBs immune complex levels: A novel biomarker of hepatitis flare in patients with HBeAg-negative chronic hepatitis B who stop nucleos(t)ide analogue therapy | Simon Hume | Received |
1223-FRI | The impact of Tenofovir Amibufenamide (TMF) on blood lipids during the process of anti-hepatitis B virus treatment - A real world prospective study | Yang Ling | Received |
1225-FRI | Role of healthcare providers in recruitment of minority populations living with hepatitis B in clinical trials | Chari Cohen | Received |
1227-FRI | HBV induces liver fibrosis through the generation of ROS in a pyruvate-PPARα-dependent pathway | Xiaoqiong Duan | Received |
1228-FRI | Outcomes of nucleos(t)ide analogue discontinuation in chronic hepatitis B participants treated with xalnesiran with and without an immunomodulator: 48 weeks of follow-up results from the phase 2, randomized, controlled, adaptive, open-label platform study | HBV Program Roche | Received |
1229-FRI | Stratification of HBeAg-negative chronic hepatitis B patients through longitudinal monitoring of HBV DNA levels | Hae Lim Lee | Received |
1230-FRI | High-throughput screening for Antiviral Compounds using a Recombinant Hepatitis B Virus revealed the potent entry inhibitor, Skimmianine | Masaya Funaki | Received |
1232-FRI | Therapeutic evaluation of Tenofovir Alafenamide in the treatment of chronic hepatitis B patients with normal alanine transaminase and positive hepatitis B virus DNA: a 48-week multicenter retrospective study from China | Yida Yang | Received |
1233-FRI | Risk factors associated with hepatocellular carcinoma occurrence in chronic hepatitis B patients on long-term nucleos(t)ide analogues | Kazuhiro Murai | Received |
1234-FRI | Prevalence of hepatitis delta virus infection among hepatitis B positive individuals in Georgia: findings from the national seroprevalence survey, 2021 | Nazibrola Chitadze | Received |
1237-FRI | A Comparative Analysis of Adverse Event Incidence Rates between Intermittent and Continuous Regimen of Peginterferon alpha-2b Based on Exposure-Response Analysis | Weizhe Jian | Received |
1238-FRI | HBV promotes hepatocyte binucleated polyploid formation through down-regulation of HDAC6 to maintain the stability of the cccDNA pool and promote viral replication | Lili Wu | Received |
1239-FRI | Safety and Efficacy Assessment of Tenofovir Alafenamide (TAF) Antiviral Therapy Commenced Preconception or During Early/Mid-Trimester of Pregnancy in Hepatitis B Virus (HBV) Infection | Keshu Shen | Received |
1240-FRI | Short-term efficacy and safety after switching from entecavir to tenofovir alaferamide for chronic hepatitis B patients with suboptimal response or intolerant to entecavir | Fei Kong | Received |
1241-FRI | Factors associated with MASLD and liver fibrosis in foreign-born Asian-Americans with chronic hepatitis B seen in two non-academic hepatology clinics in Southern California: impact of metabolic features, MASLD and time spent living in the US | Michelle Gunawan | Received |
1242-FRI | Imatinib promotes HBV reactivation through oxidative stress-induced blockage of autophagic flux | Weixiu Li | Received |
1243-FRI | Nucleotide analogs reduced 3-year recurrence rate after curative radiofrequency ablation therapy in HBV-related HCC patients | Jing Liang | Received |
1244-FRI | The efficacy and safety of prophylactic tenofovir alafenamide to prevent HBsAg-positive cancer patients undergoing chemotherapy from HBV reactivation- An interim report of a prospective trial | Po-Yueh Chen | Received |
1245-FRI | Immunological correlates of rapid HBsAg decline in chronic HBV hepatitis patients undergoing Tenofovir Amibufenamide treatment | Shue Xiong | Received |
1246-FRI | Comparative Analysis of Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated with Tenofovir Alafenamide (TAF), Tenofovir Disoproxil Fumarate (TDF), and Entecavir (ETV): A Systematic Review and Meta-Analysis with GRADE Assessment | Natchaya Polpichai | Received |
1247-FRI | Longitudinal profile of serum HBV RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues | Lung Yi Mak | Received |
1248-FRI | Longitudinal profile of HBsAg isoforms and HBsAg-antibody immune complex in natural history of chronic hepatitis B infection | Lung Yi Mak | Received |
1249-FRI | Customized screening strategy for Hepatocellular Carcinoma demonstrates good cost-effectiveness in patients with HBsAg-positive in China. | Xin Hao | Received |
1250-FRI | Current management and treatment indications of baseline grey-zone (GZ) patients with HBeAg-negative chronic hepatitis B virus infection (CHBVe-) in Greece | George Papatheodoridis | Received |
1251-FRI | Long-term outcomes of baseline grey-zone (GZ) patients with HBeAg-negative chronic hepatitis B virus infection (CHBVe-) in Greece | George Papatheodoridis | Received |
1252-FRI | Effectiveness and Safety of Tenofovir Alafenamide in Chronic Hepatitis B Patients with Suboptimal Response to Antiviral Therapy | Wen Xie | Received |
1253-FRI | The Impact of Superimposed Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD) on Clinical and Patient-Reported Outcomes (PROs) Profile of Patients with Chronic Hepatitis B (CHB) and C (CHC) | Zobair Younossi | Received |
1255-FRI | HIV coinfection accelerates HBV-induced liver fibrogenesis through an exosome and miR-103a-3p dependent pathway | Min Xu | Received |
1256-FRI | Efficacy and safety of tenofovir amibufenamide in chronic hepatitis B virus infection patients with normal alanine aminotransferase: a multicenter, open-label, randomized controlled trial | Qing Xie | Received |
1258-FRI | Metabolic dysfunction-associated fatty liver disease improves response to peginterferon alpha-2b therapy in patients with chronic hepatitis B | Ying Zhu | Received |
1259-FRI | Effectiveness of adoptive cell transfer of antigen-specific T cells in mouse models of HBV infection | Toshikatsu Tamai | Received |
1261-FRI | Effects of different antiviral treatments on liver inflammation and fibrosis in patients with chronic hepatitis B | Huiqing Liang | Received |
1262-FRI | All-cause and cause-specific mortality in non-steatotic chronic hepatitis B patients with cardiometabolic risk factors | Shang-Chin Huang | Received |
1263-FRI | ´BeNEG-DO´: A Study of Clinical Outcomes, Immunologic Correlates and Genetic Predictors after NUC Treatment Withdrawal in e-Antigen Negative Chronic Hepatitis B | Jiajing Li | Received |
1264-FRI | Efficacy and Safety of PD-L1 Antibody ASC22 (Envafolimab) in Patients with Low Baseline HBsAg Levels: a randomized Phase IIb Expansion Cohort | Jinzi Jason Wu | Received |
1265-FRI | Efficacy of Prophylactic Antiviral Therapy in Preventing Hepatitis B Reactivation in Patients with Anti-HBc Antibody Undergoing Daratumumab Treatment | Jaejun Lee | Received |
1266-FRI | Capsid Assembly Modulators Such as ALG-001075 Induce Profound HBV DNA Knockdown and Directly Target HBeAg In Vitro | Cheng Liu | Received |
1267-FRI | FDA approved drug library screening to identify compounds that reduce HBs antigen | Akiyoshi Shimoda | Received |
1269-FRI | A simple model for predicting HBsAg loss using baseline HBsAg in chronic hepatitis B patients who received PEG-IFNα-2b therapy | fei yan | Received |
1270-FRI | Pharmacokinetics, Safety, and Tolerability of the siRNA TQA3038 in Healthy Chinese Volunteers | Dong Liu | Received |
1271-FRI | The relationship between reproductive history and clinical characteristics in HBeAg-negative chronic HBV-infected women of childbearing age | Shimin Yin | Received |
1272-FRI | Management and outcome of baseline grey-zone (GZ) patients among the French HEPATHER cohort: is it different from HBeAg negative chronic hepatitis B infection (CHBVe-) or HBeAg negative chronic hepatitis (CHBVHe-)? | Lucia Parlati | Received |
1274-FRI | First-In-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of an oral Toll-like Receptor 8 Agonist in Healthy Subjects | Bei Cao | Received |
1275-FRI | The role of steatosis and fibrosis parameters in predicting hepatocellular carcinoma recurrence in chronic hepatitis B patients | Ke Yin | Received |
1276-FRI | The Impact of hepatitis b virus infection on assisted reproductive technology outcomes a systematic review and meta-analysis. | Wei Xue | Received |
1277-FRI | Long-term follow up identifies a higher incidence of functional cure following nucleos(t)ide analogue discontinuation in HBeAg-negative Chronic Hepatitis B | Simon Hume | Received |
1279-FRI | Performance of hepatocellular carcinoma predictive scores in an Australian cohort with chronic hepatitis B infection | Thisuri Jayawardena | Received |
1281-FRI | Peginterferon alpha-2b based antiviral therapy as an effective treatment option for functional cure in inactive hepatitis B surface antigen carriers: A prospective, multicenter, randomized controlled trial | Shan Ren | Received |
1282-FRI | Higher Circulating CCR7loPD-1hi Follicular Helper T Cells and Lower HBcrAg Indicate durable clinical cure after PegIFNα-2b-based therapy in patients with CHB | Shan Ren | Received |
1284-FRI | Functional cure and prediction analysis of pegylated interferon alpha-2b in HBeAg negative chronic hepatitis B patients with normal ALT (Ice-breaking Project in China): an interim analysis update | Chong Zhang | Received |
1285-FRI | Assessment of clinical outcomes in HBsAg positive individuals compared to patients who achieved HBsAg loss as determined by conventional or ultrasensitive testing for HBsAg | Golasa Samadi Kochaksaraei | Received |
1286-FRI | Early off-treatment HBcrAg and anti-HBc levels identify patients at high risk of severe ALT flares after nucleos(t)ide analogue withdrawal - A pooled analysis of two prospective studies | Edo Dongelmans | Received |
1287-FRI | Plasma Hepcidin and Haptoglobin concentration predicts pegylated interferon a-2b treatment response in HBeAg-negative chronic hepatitis B patients | Jing Liang | Received |
1288-FRI | Pharmacokinetic/pharmacodynamic modelling of RG6084 effects on hepatitis B surface antigen and alanine transaminase to inform Phase 2 dosing regimen selection | Sijie Lu | Received |
1289-FRI | Core biomarkers for early detection of primary liver cancer | Hien Thi Thu Nguyen | Received |
1290-FRI | Combination therapy with TLR7 agonist TQ-A3334 and anti-PD-L1 TQ-B2450 enhance HBsAg decline in virally-suppressed patients with chronic hepatitis B: OCEANcure05 study | Ting Wu | Received |
1291-FRI | Relationship between the clinical efficacy and lymphocyte subsets in the clinical cure advanage population of chronic hepatitis B with pegylated interferon alpha | Dan Duan | Received |
1293-FRI | Impact and cost-effectiveness of a hospital-based hepatitis B screening and management program in China: a mathematical modelling prediction | Jia Chen | Received |
1294-FRI | HBV antigen-guided switching strategy from nucleos(t)ide analogue to interferon: avoid virologic breakthrough and improve functional cure | Da Huang | Received |
1295-FRI | Semi-mechanistic PK/PD modeling and simulation of sequential siRNA and bepirovirsen treatment predicts added benefit in HBsAg response in support of Phase 2b dose selection | Nadia Noormohamed | Received |
1296-FRI | NK cells function dvdftrecreases, What is the cause of LLV occurrence? | Guo Liying | Received |
1299-FRI | Tenofovir alafenamide to prevent hepatitis B virus reactivation in patients with ´resolved´ infection receiving rituximab-based chemotherapy: A randomized controlled trial | Grishma Hirode | Received |
1300-FRI | Residual hepatitis B viremia detected by a high-sensitivity droplet digital-PCR assay predicts hepatocellular carcinoma risk and prognosis in patients on antiviral therapy | Rex Wan-Hin Hui | Received |
1302-FRI | ALTERNATIVE HBV VACCINATION STRATEGIES FOR BOTH COMPENSATED AND DECOMPENSATED CIRRHOTICS | Brian Pearlman | Received |
1303-FRI | Patients with chronic HBV infection exhibiting significant inflammation and fibrosis should pay particular attention to the status of MASLD during antiviral therapy. | Qi Wang | Received |
1305-FRI | CLB-405 and CLB-505 combined with a saponin based adjuvant TQL-1055 exhibits a strong antiviral and enhanced immune responses in a mouse model of persistent Hepatitis B infection | Aditi Deshpande | Received |
1307-FRI | Sequential administration of siRNA with CLB-405 and CLB-505 HBsAg variants encoding clearance profile epitopes, combined with a novel adjuvant TQL-1055 exhibits significant anti-viral and T cell activity in an AAV/HBV mouse model | Aditi Deshpande | Received |
1308-FRI | Tolerability and immunogenicity of HBsAg variants, CLB-405 and CLB-505, combined with a novel semi-synthetic saponin adjuvant TQL-1055, in New Zealand white rabbits | Aditi Deshpande | Received |
1309-FRI | Lower Alanine Aminotransferase Normalization During Antiviral Treatment Is Associated with lower risk of Hepatocellular Carcinoma in Chronic Hepatitis B | Hyunjun Park | Received |
1310-FRI | Comparison of denosumab and bisphosphonates for tenofovir-induced osteoporosis in patients with chronic hepatitis B | Yunmi Ko | Received |
1313-FRI | Virologic outcome of peginterferon for HBeAg-positive chronic hepatitis B - a 20-year follow-up, entecavir-matched study | Che To Jimmy Lai | Received |
1314-FRI | HLA genotype regulates hepatitis B virus mutations associated with hepatocellular carcinoma. | Masaya Sugiyama | Received |
1315-FRI | Renal function comparison between entecavir and tenofovir alafenamide in treatment-naïve chronic hepatitis B | Wang Liang | Received |
1316-FRI | New Transient Elastography (TE) Device Hepatus? Shows Superior Efficiency and Strong Comparable to a Conventional TE Device in Liver Stiffness Measurement for CHB and NAFLD Patients | Shuyan Chen | Received |
1317-FRI | Long-Term Efficacy of the Hepatitis B Vaccine: A 24-Year Follow-Up Study of 6,645 Vaccinated Individuals | Saad Alghamdi | Received |
1318-FRI | Kinetics and Prediction of HBsAg Seroclearance during Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B | Yim Sun Young | Received |
1319-FRI | Significant increase in risk of hepatic further decompensation from excessive alcohol use in patients with chronic hepatitis B-related decompensated cirrhosis | Vicki Wing-Ki Hui | Received |
1322-FRI | Effect of age and development of liver and other organ cancers on HBs antigen loss in hepatitis B patients | Takashi Honda | Received |
1324-FRI | Final results of GATE study: a program to narrow Gap between in Accordance with guidelines and consent to Treat CHB population in East of China | Shaoqiu Zhang | Received |
1326-FRI | Complete determination of hepatitis B virus genotype in all participants with chronic HBV infection receiving nucleos(t)ide analog therapy using multi-method analysis to better understand clinical outcomes: Phase 2b B-Clear study | Jerome Bouquet | Received |
1327-FRI | Impact of hepatitis B surface antigen levels on regulatory T lymphocyte frequency: pooled analysis from single cell RNA sequencing datasets | Fengge Zhu | Received |
1329-FRI | Accurate HBsAg Testing is Associated with HBsAg Seroreversion Outcomes | Na Gao | Received |
1331-FRI | Evaluation of PAGE-B Score and Machine Learning Enhanced Prediction of Hepatocellular Carcinoma Development in Chronic Hepatitis B patients using Conditional Survival Forest: a multicenter study | Athanasios Angelakis | Received |
1333-FRI | Detection and Monitoring of Infant Drug Exposure: A Study on TFV Concentration in TDF and TAF | Chengjing Tao | Received |
1335-FRI | FACTORS ASSOCIATED WITH HIGH TITER RESPONSE to HBV VACCINE IN PRIOR VACCINE NON-RESPONDERS WITH HIV: The BEeHIVe TRIAL | Kenneth Sherman | Received |
1336-FRI | Role of air pollution in the development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues | Chia-Yen Dai | Received |
1338-FRI | Presence of metabolic comorbidities increases the risk of hepatocellular carcinoma in sub-Saharan African individuals living with chronic hepatitis B | Lesley Patmore | Received |
1340-FRI | Pharmacokinetics and Safety of a Single Dose of Elebsiran (VIR-2218, siRNA) Subcutaneously Administered in Adult Participants with Moderate Renal Impairment | Li Wang | Received |
1341-FRI | Imaging follow-up for HBV patients with advanced fibrosis and/or Page -B score >10 for HCC screening in the HEPATHER French Cohort; is the job well done? | Lucia Parlati | Received |
1342-FRI | Implementation of the Hepatitis B ´Triple Panel´ in the Obstetric Care Setting: Prevalence and Predictors of Testing, Exposure, and Vaccine Immunity | Natalia Schmidt | Received |
1343-FRI | Hepatitis B virus reactivation in cancer patients receiving Janus kinase inhibitors | Khalis Mustafayev | Received |
1345-FRI | Hepatitis B treatment outcomes and factors associated with HBV treatment success: a population-based study in Rwanda. | Jean Damascene Makuza | Received |
1347-FRI | Tenofovir Alafenamide Fumarate in Treatment-naïve Chronic Hepatitis B Patients with Liver Fibrosis: a preliminary non-invasive results of 96 weeks | Jialing Zhou | Received |
1348-FRI | Late diagnosis of chronic hepatitis B is associated with increased liver-related complications - A population-based, retrospective cohort study | Michael Le | Received |
1350-FRI | Outcomes of Nucleos(t)ide Analog Discontinuation in HBeAg-Positive Chronic Hepatitis B Patients Without Achieving HBeAg Loss | CHIEN-WEI PENG | Received |
1351-FRI | Male sex, high γ-GTP, high AFP, high GDF15 and high FIB-4 index were high risk factors for the occurrence of primary HCC in CHB patients under NUC treatment. | Kazuhiro Murai | Received |
1352-FRI | Tracking B cell immunity during perturbation of hepatitis B infection induced by treatment withdrawalWithdrawal of prolonged nucleos(t)ide analogue (NA) treatment can result in HBsAg loss in some subjects with chronic hepatitis B (CHB), potentially reveal | Sabela Lens | Received |
1353-FRI | Circular RNA circSMAD2 inhibits autophagy via targeting miR-629/PDCD4 axis in Hepatitis B virus infection | Md Ismail | Received |
1354-FRI | Impact of Concurrent Fatty Liver (FL) and Chronic Hepatitis B (CHB) on Virologic (VR), Biochemical (BR), and Complete Response (CR) Among Patients Treated with Nucleos(t)ide Analogs (NA): A REAL-B Study | Angela Chau | Received |
1355-FRI | Development of a low-cost diagnostics platform for the identification of HBV DNA using CRISPR/Cas13a system | Teja Naveen Sata | Received |
1356-FRI | A twenty years tailored treatment history of an italian cohort patients with HBV/HDV chronic hepatitis: from multiple pegylated interferon-alpha (Peg-IFN) cycles through entecavir/tenofovir to bulevirtide treatment. | Aldo Marrone | Received |
1357-FRI | The impact of HIV infection on all-cause mortality among individuals treated for HBV in Rwanda: A population-based cohort study. | Jean Damascene Makuza | Received |
1358-FRI | Eliminating viral hepatitis one island at a time - the Hainan experience | Min Liao | Received |
1359-FRI | 32.2% of Inactive HBsAg Carriers Achieved Clinical Cure at 48 Weeks with Pegylated Interferon Alpha-2b Therapy: A Multicenter Real-World Study (STARHB Project in China) - 2-Year Data Update | Jing ZHAO | Received |
1360-FRI | The effect of tenofovir alafenamide on the risk of hepatocellular carcinoma in different risk groups defined by mPAGE-B score | Lilian Yan Liang | Received |
1362-FRI | Factors and prediction model of HBsAg relapse after achieving clinical cure in CHB patients with PEG IFNα-2b | Jing Chen | Received |
1363-FRI | Revelation of unknown confounding factors in functional HBV cure: a systemic review and meta-analysis | George Lau | Received |
1364-FRI | Single cell RNA sequencing reveals exhausted adaptive immunity in utero to HBV exposed neonates born to mothers with high HBsAg titres persisting despite vaccination | Prabhjyoti Pahwa | Received |
1365-FRI | Comparable Outcomes Between Besifovir and Other Antiviral Therapies in Hepatocellular Carcinoma Development Among Patients with Chronic Hepatitis B | Jae Seung Lee | Received |
1366-FRI | Functional Analysis of Fumarylacetoacetate Hydrolase as a Hepatocyte Host Factor Gene Regulating Hepatitis B Virus Replication and Hepatocarcinogenesis | Shouichi Namikawa | Received |
1367-FRI | Apply HBV RNA and HBcrAg to Follow-up of Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogs | Xiaoyin Wang | Received |
1368-FRI | Treatment eligibility of patients with chronic hepatitis B in the indeterminate phase | Jian Wang | Received |
1372-FRI | Novel therapeutic hepatitis B virus vaccine using plasmid-launched live attenuated flavivirus vector immunization generates robust CD8 T cell responses that correlate with efficacy in a chronic hepatitis B model | Frederik Pauwels | Received |
1373-FRI | Serum ESPL1 Protein as an Early Warning Biomarker for the Initial Occurrence and Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma | Bobin Hu | Received |
1377-FRI | The rapid reduction rate was significantly lower in grey zone HBeAg-negative patients who started antiviral therapy compared to those with active hepatitis | Yen-Chun Liu | Received |
1378-FRI | CCR2 of CD4+CD8+CXCR5+ T cell regulated IL-21 and TNF-α secretion in CHB patients | Qi Gu | Received |
1379-FRI | Superior Diagnostic Efficacy of PRO-C3 and GP73 Compared with FIB-4, FAST, Agile 3+, and LSM for Detection of Fibrosis in Chronic Hepatitis B | Qianqian Chen | Received |
1381-FRI | Leveraging in silico clinical trials of the Everest study to obtain mechanistic insights into determinants of functional cure with standard-of-care therapies in chronically infected hepatitis B patients | Rajat Desikan | Received |
1382-FRI | Risks of discontinuation and benefits of continuation of TDF after interruption of mother-to-child transmission in immunotolerant pregnant women | Huan Liang | Received |
1384-FRI | The Impact of Concurrent Chronic Hepatitis B Infection on the Diagnostic Accuracy of FIB-4 in Individuals with Metabolic-Associated Steatotic Liver Disease (MASLD) | Fajuan Rui | Received |
1385-FRI | Characterization of HDV RNA and HBsAg during pegylated interferon-alpha and ritonavir-boosted lonafarnib combination therapy: The D-LIVR study | Leeor Hershkovich | Received |
1386-FRI | Higher Sustained Response rate and Partial cure in NUC Experienced Pegylated Interferon-Treated Patients Compared to NUC Naïve Pegylated Interferon Monotherapy Patients | Rachel Wen-Juei Jeng | Received |
1387-FRI | Evaluation of Hepatitis B Vaccination Uptake and Awareness of Liver Cancer Risk Factors Among State Fair-goers in Minnesota: A Cross-Sectional Study | Amir Sultan Seid | Received |
1388-FRI | Effectiveness and Safety of 48-Week Tenofovir Amibufenamide vs Tenofovir Alafenamide Fumarate for Patients with Chronic Hepatitis B: A Retrospective Real-World Study | Qing-Lei Zeng | Received |
1389-FRI | Innate immunity plays an important role in the inactive chronic HBV carriers with positive HBeAg and high HBV DNA during TAF treatment | Qiumin Luo | Received |
1390-FRI | Second line treatment with bulevirtide in HDV patients from the ANRS-MIE French multicentre real-life cohort ANRS HD EP01 BULEDELTA | Miroslava Subic Levrero | Received |
1392-FRI | Impact of metabolic disease on treatment response in chronic hepatitis B patients with nucleos(t)ide analogues therapy: a multicenter REAL-B study | Rui Huang | Received |
1394-FRI | Temporal changes in demographics and complications/comorbidities of patient with chronic hepatitis B: Results of a real-world U.S. cohort | Mindie Nguyen | Received |
1395-FRI | Prevalence of delta hepatitis identified with hepatitis B infection through emergency department blood-borne virus screening | Shivaali Karelia | Received |
1396-FRI | Hepatocellular Carcinoma in Western Kenya: Risk Factors, Diagnosis & Surgical Management | Mercy Karoney | Received |
1397-FRI | Immune Checkpoint Inhibitor (ICI) Treatment and Immune-related Adverse Events (IrAEs): Lessons Learned from Oncology for its Potential Use for Chronic Hepatitis B (CHB) Patients | Mitchell Leus | Received |
1398-FRI | The current burden of hepatitis B in the United States: a state, territorial, and county analysis -the impact of immigration, 2021 | Devin Razavi-Shearer | Received |
1399-FRI | Investigation of the reference value of ALT for the initiation of nucleic acid analogs for chronic hepatitis B. | Taisei Keitoku | Received |
1400-FRI | Immuno-metabolic driven hepatitis B surface antigen seroconversion in mild and severe hepatitis B reactivation | Jayesh Kumar Sevak | Received |
1404-FRI | Single cell sequencing reveals rise in intrahepatic CXCL8, CCL4, and SELL expression with increased fibrosis in naive chronic hepatitis B patients with low HBsAg levels | Ravinder Singh | Received |
1405-FRI | Characterization of intrahepatic immune microenvironment in liver biopsies across different phases of untreated HBeAg-negative patients | Maria Stella Franzè | Received |
1406-FRI | Uptake and T Cell Stimulation by BJT-778-HBsAg Immune Complexes: Insights into Anti-HBs Monoclonal Antibody Function. | Loghman Salimzadeh | Received |
1407-FRI | Preclinical Pharmacokinetics of EDP-514, an Oral, Once-Daily Antiviral Treatment for Hepatitis B Virus | Meng Huang | Received |
1408-FRI | Increasing Risk of Metabolic Comorbidities in Patients with HBV Monoinfection, HBV/HCV Coinfection, and HBV/HIV Coinfection: A Nationwide Population-based Study | Jae Yoon Jeong | Received |
1409-FRI | Dose-Dependent Effects of Neutralizing Anti-HBs Monoclonal Antibody VIR-3434 on Hepatitis B Surface Antigen Composition | Maria Pfefferkorn | Received |
1410-FRI | Global prevalence and outcome of CHB patients with indeterminate phase: A Systematic Review and Meta-analysis of 35 studies and 27,529 patients | Jie Li | Received |
1411-FRI | Predictors of HBsAg loss in HIV-HBV coinfected patients receiving antiretroviral therapy: a systematic review | Mansoor Rahman | Received |
1412-FRI | Distribution of circulating T follicular helper 17 cell subsets altered in CHB patients | Shengxia Yin | Received |
1413-FRI | Differential HBV replicative markers and covalently closed circular DNA transcription in immune-active chronic hepatitis B with and without HBeAg | Hye Seon Kim | Received |
1414-FRI | Pre-clinical Characterization of Cavrotolimod, a TLR9 Agonist for the Treatment of Chronic Hepatitis B | Hilario Ramos | Received |
1416-FRI | Treatment Response of IFN and Nuc in CHB Patients with Severe Liver Fibrosis or Cirrhosis (OASIS Subgroup Analysis) | Ruirui You | Received |
1417-FRI | Antiviral efficacy of tenofovir alafenamide versus entecavir in treatment-naïve chronic hepatitis B: A Multicenter Longitudinal Study | Mindie Nguyen | Received |
1418-FRI | Risk of Cirrhosis and HCC in CHB Patients during IFN or Nuc Treatment (OASIS Subgroup Analysis) | Ruirui You | Received |
1419-FRI | Surveillance of Hepatocellular Carcinoma is Cost-Effective in Chronic Viral Hepatitis Patients in Korea | Young Youn Cho | Received |
1420-FRI | Association of Proton Pump Inhibitors and the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B patients: A Korean Nationwide Cohort Study | Young Youn Cho | Received |
1421-FRI | Behaviour, Aspirations and Treatment needs of people living with hepatitis B (BEAT-B): a mixed methods study in hepatitis B patients from five countries in South Asia | Manya Prasad | Received |
1422-FRI | Long-term clinical outcomes after HCV elimination by direct-acting antivirals in patients with chronic hepatitis C: A large-scale, multicenter cohort study | Eiichi Ogawa | Received |
1423-FRI | High GGT levels is a risk factor for HCC development having potential to reflect mitochondrial dysfunction after HCV eradication | Mina Nakagawa | Received |
1424-FRI | Scanvir: an ideal concept for eliminating hepatitis C | Marilyne DEBETTE-GRATIEN | Received |
1426-FRI | Histological improvement of fibrosis in patients with hepatitis C who exhibit for 5 years a sustained virological response to antiviral treatment with direct-acting antivirals | Takayuki Iwamoto | Received |
1427-FRI | Sustained virologic response and posttreatment liver function are associated with 5-year survival after direct-acting antiviral treatment in decompensated cirrhotic patients with hepatitis C virus: A long-term follow up study of Japanese clinical trial co | Yuki Tahata | Received |
1428-FRI | HCV Ab titer and ALT mark occult hepatitis C virus infection in treatment-naïve HCV Ab-positive and -negative patients, respectively: A 3-year prospective cohort study | Ming-Ling Chang | Received |
1430-FRI | Hepatic steatosis in chronic hepatitis C affects the risk of hepatocellular carcinoma mainly in women | Shiho Miyase | Received |
1431-FRI | Fatigue in Chronic Hepatitis B (CHB) and C (CHC) is Associated with Impairment of Patient-Reported Outcomes (PROs) and Work Productivity | Yusuf Yilmaz | Received |
1432-FRI | Close partnership with NGOs increases attendance and DAA treatment uptake in people who previously injected drugs (ex-PWID) with chronic hepatitis C | Grace Lai-Hung Wong | Received |
1433-FRI | Service Evaluation of Children with HCV and neurodevelopment delay; Incidental finding of high rates of learning and behavioural difficulties in UK children living with HCV | Carla Lloyd | Received |
1435-FRI | Factors associated with the aggravation of gastroesophageal varix in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy | Yuki Tahata | Received |
1436-FRI | Closing The Gap: Implementing Hepatitis C Reflex Testing Within UNM Health System | Colleen Chávez | Received |
1437-FRI | Alterations in The Tryptophan Pathway During Hepatitis C Virus Infection Demonstrates a Shift Towards a Pro-inflammatory State | Jenna Oringher | Received |
1438-FRI | Incidence of liver disease progression in patients with hepatitis C virus genotype 3 after SVR following DAA therapy | Dachuan Cai | Received |
1440-FRI | Changes in Hepatitis C Virus Screening and Treatment Rates in Pregnant Individuals Before and After Implementation of Universal Screening Guidelines | Chandler Shapiro | Received |
1441-FRI | Impact of sustained virological response on long-term outcomes after curative resection in patients with of hepatitis-C-virus-related hepatocellular carcinoma in the era of direct-acting antiviral therapy | Hayato Abe | Received |
1442-FRI | Telehealth to increase healthcare access; perspectives of people who use drugs | Zoi Papalamprakopoulou | Received |
1443-FRI | Stability of capillary whole blood (CWB) in microtainer, and Limit of Detection (LoD) for Hepatitis C Virus (HCV) (genotypes 1-6) in CWB versus Venous WB (VWB) using Cepheid Xpert HCV RUO System. | Anuradha Rao | Received |
1444-FRI | Comparing baseline FIB-4 versus post-SVR12 FIB-4 to predict HCC occurrence following direct-acting antiviral attained SVR12 | Mustafa Al-Karaghouli | Received |
1445-FRI | Three for Two or One for Three: Evaluating HCV Treatment Regimens, Compliance, and Subpopulations | Fadi Abu Baker | Received |
1446-FRI | Sex and Race Disparities in Liver Listings and Transplants for Hepatocellular Carcinoma in the United States | Abdellatif Ismail | Received |
1447-FRI | Long-term glycemic control in patients achieving sustained virologic response with direct-acting antivirals for hepatitis C virus infection | Chen-Hua Liu | Received |
1448-FRI | Sustained Virologic Response (SVR) in HCV-infected Patients with Hepatocellular Carcinoma (HCC): Real-world Outcomes and Predictors of Success | David Twitchell | Received |
1449-FRI | Avoiding phlebotomy entirely: Validation of a point-of-care measure of APRI & FIB4 from finger-prick blood | David Smookler | Received |
1450-FRI | Sofosbuvir/Velpatasvir Effectiveness in Treating Chronic Hepatitis C Genotype 3: A Real-World Study in Xinjiang, China. | WEI SUN | Received |
1451-FRI | Implementation of Glecaprevir-Pibrentasvir treatment for children aged 3-12 years with chronic Hepatitis C: Multicenter real-world data | Yaniv Faingelernt | Received |
1452-FRI | Multistep Hepatocarcinogenesis in Preneoplastic Nodules on EOB-MRI after Long-Term Sustained Virologic Response in Patients with Chronic Hepatitis C | Tomoko Tanaka | Received |
1454-FRI | Analysis of influence factors on antiviral efficacy in patients with chronic hepatitis C virus infection in Tianjin area | Peng Chen | Received |
1455-FRI | The SVR10K study: A Real-World Data with Pangenotypic Direct-Acting Antivirals Across Multiple Diverse Regions | Grace Lai-Hung Wong | Received |
1457-FRI | Prevalence and risk factors for hepatocellular carcinoma (HCC) among patients with current and prior hepatitis C virus (HCV) infection in a real-world cohort in the post-DAA era. | Mai Sedki | Received |
1458-FRI | Trends in Care Utilization in Two Large Nationally Representative Datasets Reveal Important Disparities in Hepatitis C Access to Screening and Treatment | Brian McSteen | Received |
1459-FRI | Glecaprevir/pibrentasvir in chronic HCV: An integrated analysis of patients on multiple concomitant medications | Shweta Raina | Received |
1460-FRI | Methionine Sulfoxide, Methionine, and Ornithine as Biomarkers for Predicting Development of Hepatocellular Carcinoma after Hepatitis C Virus Elimination | Takeshi Chida | Received |
1461-FRI | Directly observed DAA therapy comprising extended dispensation intervals as a unique approach to streamlined HCV microelimination for PWID | Caroline Schwarz | Received |
1462-FRI | Including underserved populations in the global efforts against viral hepatitis - an Austrian approach to HCV elimination among homeless people without health insurance | Caroline Schwarz | Received |
1464-FRI | Multi-collaboration contributes to HCV DBU Relink in Guangdong,China (First report) | Yue Wu | Received |
1465-FRI | A review of phase 1 & 2 of the Joint United Kingdom Health Security Agency (UKHSA) & National Hepatitis C Paediatric Multi-Disciplinary Operational Delivery Network (pMDT ODN) National Hepatitis C Paediatric tracking project | Carla Lloyd | Received |
1466-FRI | Bemnifosbuvir does not alter cardiac repolarization in healthy participants: results from a thorough QT study | Patrick Scoble | Received |
1467-FRI | Multiscale modeling of lead-in results from a Phase 2 study of an 8-week combination regimen of Bemnifosbuvir and Ruzasvir in patients with chronic hepatitis C virus infection | Patrick Scoble | Received |
1469-FRI | Epidemiological Insights into Hepatitis B and C through Blood Samples from the Korea National Health and Nutrition Examination Survey | Chang Hun Lee | Received |
1470-FRI | A multicenter real world study of sofosbuvir/velpatasvir for HIV/HCV coinfected patients | Jing Chen | Received |
1471-FRI | Examination of factors predicting hepatic decompensation after elimination of HCV in patients with liver cirrhosis | Ryo Sasaki | Received |
1472-FRI | Metabolic dysfunction-associated steatotic liver disease is associated with liver fibrosis in hepatitis C | Wesal Elgretli | Received |
1473-FRI | The power of the Community Pop-up Clinic: Cascade of Care and HCV Treatment among Vancouver´s inner-city Populations as a path towards elimination | Shana Yi | Received |
1474-FRI | A Comparison of Sofosbuvir/Velpatasvir (S/V) and Glecaprevir/Pibrentasvir (G/P) for the Treatment of HCV infection Among HCV-Infected People Who Use Drugs (PWUDs) | Shana Yi | Received |
1477-FRI | Transient Elastography in the ED Enhances Triage of Hepatitis C Virus Patients Compared to FIB-4 | Morgan Stacey | Received |
1478-FRI | Costs and outcomes of a one-step hepatitis C virus RNA point-of-care diagnostic strategy among people who inject drugs in the U.S. | Emily Kahn | Received |
1479-FRI | Trends in HCV Screening, Follow-up Testing, and Treatment in Pregnant People and Infants in a Tertiary Care Center | Randeep Kaur | Received |
1480-FRI | Successful Performance of the Xpert HCV test for Point of Care Detection of HCV RNA in a CLIA-Waived Setting | Lesley Miller | Received |
1483-FRI | Long Term Outcome Following HCV Treatment With Glecaprevir/Pibrentasvir In People Who Use Drugs | Shana Yi | Received |
1484-FRI | Virologic effect and hepatotoxicity of BCR-ABL tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: a prospective study | Khalis Mustafayev | Received |
1485-FRI | Attempt to Predict Outcomes in DAA-Treated Patients Using Machine Learning with Hepatitis C Virus and Human Genetic Information | Hiroaki Haga | Received |
1487-FRI | Default Hepatitis C Screening and Proactive Linkage To Care Among Hospitalized Adults | Lina Yagan | Received |
1488-FRI | Engaging community pharmacies within hepatitis C (HCV) test and treat networks to enhance access to care for key populations living with HCV: experience from Alberta, Canada. | Jenny Godley | Received |
1489-FRI | Current Status of Hepatitis C Virus Infection and Treatment in Hemodialysis centers in Sichuan Province, China | Xiaoxia Geng | Received |
1490-FRI | A government-leading multi-organization collaborative model for HCV elimination in Chengmai County, Hainan Province | Xiaoyang Yang | Received |
1491-FRI | Validation of an artificial intelligence model for prediction of hepatocellular carcinoma risk after oral antiviral therapy in patients with chronic hepatitis C | Yu Rim Lee | Received |
1493-FRI | Seizing the moment: Opportunistic screening impact on viral hepatitis prevalence in the Emergency Department over four years | Juan Carlos Ruiz Cobo | Received |
1494-FRI | Exploration of influencing factors and predictive models for the decrease of non-invasive liver fibrosis indicators in patients with HCV infection treated with DAA | Xiaoxia Geng | Received |
1496-FRI | Tailoring HCC risk stratification in chronic hepatitis C patients following viral eradication: a simple algorithm utilizing alpha-fetoprotein | Yen-Chun Liu | Received |
1497-FRI | POSITIVE ANTI-HBC IGG IS AN INDEPENDENT RISK FACTOR FOR HEPATOCELLULAR CARCINOMA IN A COHORT OF CHRONIC HEPATITIS C PATIENTS | Mario Pessoa | Received |
1498-FRI | HCV Promotes Aging in HIV-Infected Individuals: Evaluating Immune Senescence using Telomere Length and DNA Methylation | Jacob Ciricillo | Received |
1499-FRI | Prevalence of HBV and HIV infection in anti-HCV positive individuals with a history of drug use | CHARIKLEIA KRANIDIOTI | Received |
1501-FRI | Bemnifosbuvir Poses High Barrier for Resistance in both Preclinical and Phase 1b Monotherapy Studies | Patrick Scoble | Received |
1503-FRI | HCV Reinfection Among People Who Use Drugs (PWUD) Treated For HCV Infection: A Long-Term View | Shana Yi | Received |
1505-FRI | Direct acting antiviral therapy is associated with increased one-year overall survival in patients with Hepatitis C related Hepatocellular carcinoma | Sarah Huang | Received |
1508-FRI | SEX DISPARITIES IN THE RATE OF DELAYED HEPATITIS C DIAGNOSIS IN PATIENTS WITH A LIVER COMPLICATION-RESULTS OF A POPULATION-BASED ANALYSIS | Charles Levesley | Received |
1509-FRI | Automated Screening Outcomes for Hepatitis B and C in the Preanesthesia Unit: A Hospital-Based Study | Carlos Alventosa-Mateu | Received |
1510-FRI | The Impact of Homelessness on the Outcomes of Patients with Hepatitis C: An Analysis of a National Database | David Lee | Received |
1512-FRI | Access to a primary care provider (PCP) both reduces the risk of untreated viremia and of incomplete diagnosis among patients with hepatitis C virus (HCV) | Mai Sedki | Received |
1513-FRI | A descriptive analysis of injection-related infections among people living with hepatitis C for direct acting antiviral (DAA) treatment received and naiive individuals across pre- and post-treatment phases. | Ji Hyun Choi | Received |
1514-FRI | The Impact of Pre-Transplant Portal Vein Thrombosis on Post-Transplant Patient Survival | Nazli Begum Ozturk | Received |
1515-FRI | Presentation and malformations associated with extrahepatic congenital portosystemic shunts | Valerie McLin | Received |
1517-FRI | Ursodeoxycholic acid improves liver enzymes in patients with obliterative portal venopathy - a pilot study | Gene Im | Received |
1518-FRI | Porto-sinusoidal vascular disorder and sinusoidal obstructive syndrome in patients treated with thiopurines: a systematic analysis | Erica Nicola Lynch | Received |
1520-FRI | Hepatic congestion promotes liver pathogenesis through the activation of Integrin αV-YAP/TAZ-CTGF axis in LSECs | Seiya Kato | Received |
1521-FRI | Liver Nodules including Hepatocellular Cancer Rather than Impaired Liver Function are the Primary Clinical Challenge in Management of Patients with Fontan Associated Liver Disease | Aliya Gulamhusein | Received |
1522-FRI | Thromboembolic Event Risk Factors in Patients with Liver Abscesses: Development of a Predictive Nomogram | Jaejun Lee | Received |
1523-FRI | Porto-sinusoidal vascular disease:A new nomenclature different from Idiopathic non-cirrhotic portal hypertension | Jie Liu | Received |
1524-FRI | Machine Learning of CT Images for Noninvasive Discrimination of Porto-sinusoidal Vascular Disease from Cirrhosis in Patients with Portal Hypertension | Yanna Liu | Received |
1528-FRI | Safety and outcomes of an on-demand transfusion strategy versus prophylactic transfusion of platelets in patients with liver cirrhosis and severe thrombocytopenia undergoing high-risk invasive procedures | Sagnik Biswas | Received |
1529-FRI | The liver and spleen stiffness measure by transient elastograghy a promising tool for the clinical management of patients after Fontan-type surgery circulation | Barbara Coco | Received |
1530-FRI | S100A8/9 is Upregulated in Platelets and Platelet-Derived Microparticles in Alcohol-Associated Hepatitis and Can Mediate Endothelial Inflammation | Fallyn Kirlin | Received |
1531-FRI | Reliability of splenic stiffness in prediction of variceal bleeding and high-risk varices in non-cirrhotic portal fibrosis (NCPF) | Akash Shukla | Received |
1532-FRI | Galectin-3 Binding Protein May Act Via Platelet-Derived Microparticles to Promote Hepatic Stellate Cell-Monocyte Crosstalk Leading to Disease Progression in Alcohol-Associated Cirrhosis | Ainsley Baker | Received |
1533-FRI | Preprocedural Thromboelastography Decreases Need For Blood Product Transfusion Prior to Endoscopy for Upper Gastrointestinal Bleeding in Cirrhotics: A Retrospective Review | Adam Vinall | Received |
1534-FRI | Portal vein thrombosis in cirrhosis, etiological spectrum, risk profile, and outcome. | Babu Lal Meena | Received |
1536-FRI | DNA methylome analysis reveals epigenetic alteration of complement genes in advanced MASLD | Won Kim | Received |
1537-FRI | Effects of various genetic polymorphisms in f metabolic dysfunction-associated steatotic liver disease in Japan and their appropriate use in risk assessment of liver-related events | yuya seko | Received |
1538-FRI | NAFLD does not affect the effectiveness of tenofovir alafenamide in patients with chronic HBV infection after expanding the antiviral indications: A real-world multicenter, retrospective cohort study from Eastern and Central China | Yang Ling | Received |
1539-FRI | Impact of Glucagon-Like Peptide-1 Receptor Agonists on Metabolic Health in Liver Transplant Recipients | Idris Yakubu | Received |
1540-FRI | Deep learning model to predict steatotic liver disease diagnosis and staging in pregnant individuals | Jeanette Rios | Received |
1541-FRI | Serum Noninvasive Testing Scores and Modeling to Predict Intermediate or High Risk for Advanced Fibrosis due to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Type 2 Diabetes (T2D) Population Cohort. | Gretchen Arndt | Received |
1542-FRI | Safety and Efficacy of Endoscopic Sleeve Gastroplasty after Orthotopic Liver Transplantation | Benjamin Richter | Received |
1543-FRI | Hepatocellular carcinoma and lifestyle: How do dietary patterns differ in those with metabolic and non-metabolic dysfunction associated steatotic liver disease? | Nikil Vootukuru | Received |
1544-FRI | Degree of Metabolic Dysfunction is linked to Steatohepatitis (MASH), Fibrosis, and Higher Cardiovascular Risk in Patients with Metabolic Dysfunction-Associated Steatotic liver disease (MASLD) | David Kim | Received |
1545-FRI | Using Panel Management to Identify Adult Patients With High Risk MASLD/MASH Fibrosis in a Primary Care Clinic: A Pilot Study | Sarah Householder | Received |
1547-FRI | MASLD is a night-time disease driven by nocturnal hepatic, adipose, and skeletal muscle insulin resistance | Thomas Marjot | Received |
1548-FRI | Lean Non-Alcoholic Fatty Liver Disease Is Not A Distinct Pathophysiological Entity | Prajna Anirvan | Received |
1549-FRI | Biomarker response in metabolic dysfunction-associated steatohepatitis (MASH) patients with high-risk baseline FAST scores: Observations from the ENLIVEN Phase2b trial with pegozafermin. | Cynthia Hartsfield | Received |
1550-FRI | THE INTERPLAY BETWEEN COAGULATION IMBALANCE AND PNPLA3 MUTATION IN MASLD DIABETIC PATIENTS: IMPACT ON HEPATIC AND VASCULAR COMPLICATIONS | Rosa Lombardi | Received |
1551-FRI | Analysis Of Cardiovascular Risk Factors During The Treatment Of Metabolic Dysfunction Associated Fatty Liver Disease With A Low Carbohydrate Diet | Kwan Kit Cheung | Received |
1552-FRI | Plasma immune profile associated with MASLD in persons with HIV | Kara Wegermann | Received |
1554-FRI | Improving Screening of Metabolic-Dysfunction Associated Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus: A Quality Improvement Initiative | MARAM ALENZI | Received |
1560-FRI | Spatial transcriptomics maps the metabolic zonation of hepatocytes in MASLD I148M-PNPLA3 carriers | Erika Paolini | Received |
1561-FRI | Application of artificial intelligence algorithm as a vascular evaluation tool for intra-stage assessment in the cirrhotic patients with metabolic dysfunction-associated steatotic liver disease | Zhengxin Li | Received |
1562-FRI | Lower Prevalence of MASLD in Non-Hispanic Black Patients Is Not Explained by Higher Hepatic Fat Oxidation | Fernando Bril | Received |
1563-FRI | Pegozafermin reduced progression to cirrhosis: A post-hoc analysis from the Phase 2b ENLIVEN study | Cynthia Hartsfield | Received |
1567-FRI | The combination of fatty acids desaturase 2 rs174583 and PNPLA3 rs738409 polymorphisms is a risk factor in advanced fibrosis in metabolic dysfunction-associated steatotic liver disease | Shunsuke Ikejima | Received |
1570-FRI | Steatotic liver disease in people living with hepatitis C virus following viral eradication with direct-acting antiviral therapy | Mohamed Shengir | Received |
1571-FRI | Lipidomic and eicosanoid profiles in individuals with steatotic liver disease in pregnancy, gestational hypertension, and preeclampsia. | Jeanette Rios | Received |
1572-FRI | Exploring an Unlikely Association: Outcomes of MASLD Patients Hospitalized with Upper Gastrointestinal Bleeding | Binyamin Abramowitz | Received |
1573-FRI | VLDL lipidomics capture signatures of MASLD-associated genetics and disease progression through a novel acyl chain distribution analysis | David GUARDAMINO OJEDA | Received |
1575-FRI | The Prognostic Implications of Dietary Vitamin D Intake Among Patients with Metabolic Dysfunction-associated Steatotic Liver Disease: An Analysis of the NHANES Database | David Lee | Received |
1576-FRI | The long-term prognostic effects of caffeine intake in patients with metabolic dysfunction-associated steatotic liver disease: An analysis of the NHANES Database | David Lee | Received |
1577-FRI | National Trends in the Costs Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Admissions Stratified by Patient Demographics: An Analysis of US Hospitals | David Lee | Received |
1580-FRI | Unveiling the Hidden Connection: Exploring the Interplay Between Pericarditis and Metabolic dysfunction-associated steatohepatitis (MASH) | Lisnaldy Ramirez | Received |
1583-FRI | Dissecting liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure | Xia Yu | Received |
1585-FRI | Shifting of PBMC Transcriptomic Landscape from Acute Decompensation to Acute-on-Chronic Liver Failure | Jiyang Chen | Received |
1586-FRI | Monocyte/macrophages-derived RESISTIN is a potential therapeutic target for acute-on-chronic liver failure | Xianbin Xu | Received |
1587-FRI | A new prognostic method for acute-on-chronic liver failure: a machine learning prognostic model based on elastography | Jieyang Jin | Received |
1590-FRI | Development and patterns of acute-on-chronic liver failure in cirrhotic patients with acute kidney injury: implications for prognosis and therapeutic approaches | Susan Fischer | Received |
1591-FRI | Single-cell multimodal analysis reveals the dynamic immunopathogenesis of HBV-ACLF progression | Jun Li | Received |
1592-FRI | SEMA6B accelerates acute-on-chronic liver failure by triggering systemic inflammation and hepatocyte apoptosis | Jun Li | Received |
1593-FRI | Comparative analysis of Liver cirrhosis and Acute Coronary Syndrome (STEMI and NSTEMI) and their outcomes: Case Control Study of an In-patient analysis | Anwar Uddin | Received |
1594-FRI | HIV patients with Low CD4 counts and the development of Acute Liver Injury and Cirrhosis: An In Patient Analysis Study from 2016-2020 | Anwar Uddin | Received |
1596-FRI | Integrating prior decompensation in ACLF definitions for simplified clinical management | Jun Li | Received |
1597-FRI | Intravenous administration with the ASK1 inhibitor SRT-015 alleviates liver injury and systemic inflammation in disease models of liver failure | Vanessa Legry | Received |
1599-FRI | Natural killer cell-derived extracellular vesicles alleviate CD8+ T cell exhaustion in acute-on-chronic liver failure via TGF-β/Smad pathway | Zhouhan Wang | Received |
1600-FRI | A Nation-wide Retrospective Cohort study of the Outcomes, Prevalence and Comparative analysis of Liver Cirrhosis and Pulmonary Hypertension | Anwar Uddin | Received |
1601-FRI | Predicting Mortality and Cirrhosis-Related Complications with MELD3.0: An Analysis of a Multicenter Cohort | JIHYE LIM | Received |
1602-FRI | The Etiology of Chronic Liver Disease is an Independent Prognostic Factor in Patients with Acutely Decompensated Chronic Liver Disease. | Do Seon Song | Received |
1607-FRI | AARC Liver failure score based on registry of 10,994 patients is a better prognostic model for ACLF patients justifying global application and expansion of AARC database | Ashok Kumar Choudhury | Received |
1609-FRI | Resource utilization following liver transplantation for acute on chronic liver failure in alcohol associated liver disease. | Nehna Abdul Majeed | Received |
1610-FRI | Evolving role and outcome of liver transplantation for acute-on-chronic liver failure: a 20-year single-center experience. | William Bernal | Received |
1612-FRI | Designation of Acute-on-Chronic Liver Failure in Patients with Severe Alcoholic Hepatitis | Kevin Houston | Received |
1613-FRI | Hepatic irradiated pigs develop radiation induced veno-occlusive liver disease with ferroptosis | Zhen Sun | Received |
1614-FRI | Use of continuous renal replacement therapy in critically ill patients with cirrhosis/acute-on-chronic liver failure: the Multicentre CRRTnet substudy | Constantine Karvellas | Received |
1615-FRI | Cirrhotic Cardiomyopathy Independently Increases Post-Transplant Mortality in Patients Transplanted For Acute on Chronic Liver Failure: The MODEL Consortium Experience | Thuraya Al-Sayegh | Received |
1616-FRI | The Echocardiographic Markers of Cirrhotic Cardiomyopathy Can Independently Predict Circulatory Failure and Posttransplant Death in Patients with Acute on Chronic Liver Failure: 15 Centers Experience | Thuraya Al-Sayegh | Received |
1617-FRI | Albumin Reprograms the B cell Transcriptional Landscape and Rescues Neutrophil Dysfunction in Immunocompromised Patients with Advanced Cirrhosis | Joan Claria | Received |
1618-FRI | Deep Learning Model for Prediction of Prognosis in Patients with Acute-on-Chronic Liver Failure | Seong Hee Kang | Received |
1621-FRI | Pharmacokinetics and Safety of Tenofovir Alafenamide in Chinese Patients with Acute-on-Chronic Liver Failure | Taotao Yan | Received |
1622-FRI | Hemoadsorption with continuous renal replacement therapy reduces catecholamine requirements and hypercytokinemia in ACLF patients with septic shock and stage 3 AKI- A prospective cohort study. | Rakhi Maiwall | Received |
1625-FRI | Evaluating the Impact of Pre-Liver Transplant Acute-on-Chronic Liver Failure on Post-Liver Transplant Prognosis in Patients with Alcohol-Associated Liver Disease | David Lee | Received |
1626-FRI | How Does the Presence of Pre-Transplant Acute-on-Chronic Liver Failure Affect Post-Liver Transplant Outcomes Among Patients with Metabolic Dysfunction-associated Steatotic Liver Disease | David Lee | Received |
1628-FRI | The Influence of Geographical Differences and COVID-19 on Hepatic-Failure Related Mortality Rates | Qasim Chohdry | Received |
1629-FRI | How Important is Acute-on-Chronic Liver Failure Grade for Post-Liver Transplant Outcomes? A Single-Center Analysis | Constance Mobley | Received |
2001-SAT | Risk factors associated with decreased bone mineral density in patients with metabolic dysfunction-associated steatotic liver disease: a cross-sectional study at a health examination center | Shinya Yokoyama | Received |
2002-SAT | Enhancing prediction of moderate fibrosis or higher in MASLD patients for Resmetirom treatment via machine learning | Winston Dunn | Received |
2003-SAT | Deep Learning Predicts Hepatocellular Carcinoma Development in Steatotic Liver Disease Using Digital Pathology | Takuma Nakatsuka | Received |
2004-SAT | A novel steatosis liver disease (SLD) index with easy-to-use clinical parameters in primary care settings for steatotic liver disease | Dae Won Jun | Received |
2005-SAT | Allyl nonanoate, a bile metabolite, activated hepatic stellate cells through GPR 119 signaling in metabolic dysfunction associated steatosis disease (MASLD). | Dae Won Jun | Received |
2007-SAT | Screening for Advanced Fibrosis among Alaska Native peoples with Metabolic Dysfunction-Associated Steatotic Liver Disease | Janet Johnston | Received |
2008-SAT | Quantitative Analysis and Integration of Machine Learning for Biomarker Assessments and their Association with Treatment Response: Insights from the ENLIVEN Phase 2b Trial of Pegozafermin | Oliver Mansbach | Received |
2011-SAT | Multiple DP/AI quantification approaches are complimentary in identifying histology features: Cross sectional study in a Japanese cohort. Vandana Gupta1, Ruixue Hou1, Hiroaki Yashiro1, Shuling Zhang1, David Cordover1, Simon Kim1, Mark Chen1, Erin Smith1, | Vandana Gupta | Received |
2012-SAT | Comparative evaluation of zonal fibrosis patterns in pediatric and adult metabolic dysfunction-associated steatohepatitis biopsies using Second Harmonic Generation/Two Photon Excitation-based qFibrosis analysis | Naim Alkhouri | Received |
2013-SAT | Fibro-Scope: an artificial intelligence/neural network system is useful in predicting liver related events, cardiovascular events, and prognosis in Japanese patients with metabolic-dysfunction associated steatotic liver disease | yuya seko | Received |
2014-SAT | Diagnostic Potential of FAST and AGILE3+ Scores for F2/F3 Fibrosis: An Analysis of the Phase 2 ENLIVEN Study | Naim Alkhouri | Received |
2015-SAT | Clinical management of discrepancies between FIB-4 and liver stiffness measurement in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) | Joseph Rabbat | Received |
2018-SAT | Thrombospondin 2: A Key Player in Fibrogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease Uncovered by Multi-Omics Analysis | Takefumi Kimura | Received |
2019-SAT | Machine Learning-Facilitated Predictive Model for Liver-related Events in Type 2 Diabetes Mellitus | Sherlot Juan Song | Received |
2021-SAT | The associations between circulating metabolic biomarkers on the risk of hepatocellular carcinoma development in the USA | Rikita Hatia | Received |
2022-SAT | Factors associated with obtaining lower IQR-CAP values in the detection of hepatic steatosis by transient elastography | Iván López-Méndez | Received |
2023-SAT | Framingham Fibrosis Index for Metabolic Dysfunction Associated Steatotic Liver Disease: Validation in Large Nationwide Cohort | Krisyah Clemons | Received |
2024-SAT | Automated digital analysis of Shh-injured area correlates with conventional and digital pathologies in MASLD and MASH patients | Amon Asgharpour | Received |
2025-SAT | VALIDATION OF THE DIAGNOSTIC ENRICHMENT UTILITY OF NIS2+ FOR VARYING PHENOTYPES OF METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE | Amon Asgharpour | Received |
2026-SAT | PERFORMANCE METRICS OF SPLEEN STIFFNESS MEASUREMENT (SSM) OBTAINED BY TRANSIENT ELASTOGRAPHY IN PATIENTS WITH METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) | Amon Asgharpour | Received |
2027-SAT | Resmetirom Therapy of MASH-Associated Child Pugh A Cirrhosis Reduces Estimated Risk for Clinical Outcome Based on HepQuant RISK ACE Model | Gregory Everson | Received |
2028-SAT | The Oral Cholate Challenge Test Identifies the MASH Patients with >=F3 Fibrosis with Greatest Hepatic Impairment Who Show the Most Benefit from Short-term Rencofilstat Therapy | Gregory Everson | Received |
2030-SAT | An automatic tissue folding detection algorithm to aid AI segmentation models. | Kezia Hobson | Received |
2031-SAT | An automatic out of focus detection model for enabling the assessment of liver biopsies. | Kezia Hobson | Received |
2032-SAT | Histological diagnostic tool for detecting and characterising portal tracts in liver disease using Artificial Intelligence. | Dylan Windell | Received |
2033-SAT | The use of AI-assisted digital pathology in determining the inflammatory burden in liver disease. | Dylan Windell | Received |
2035-SAT | VALIDATION OF THE AGA AND AASLD CARE PATHWAYS FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN A PROSPECTIVE COHORT OF OVERWEIGHT AND OBESE INDIVIDUALS | Veeral Ajmera | Received |
2036-SAT | The Oral Cholate Challenge Test Defines Likelihood of Large Esophageal Varices in an Overweight and Obese US Population | Michael McRae | Received |
2037-SAT | Maintenance Therapy with GLP-1 Receptor Agonists Does Not Impact the? Clearance of Orally Administered Isotopes of Unconjugated Cholate | Michael McRae | Received |
2038-SAT | Multiple genetic polymorphisms are associated with the risk of metabolic syndrome, fatty liver, and airflow limitation: A Taiwan Biobank Study | Ying-Ying Yang | Received |
2039-SAT | Enhancing Traditional Fibrosis Prediction Models with Machine Learning in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | David Kim | Received |
2040-SAT | Prevalence and Characteristics of High-Risk FIB-4 among Primary Care Patients with Pre-Diabetes (PreDM): Potential to Improve the Current State of Disease Under-Recognition | Max Goldman | Received |
2041-SAT | Performance of Noninvasive Tests in Identifying Appropriate Patients for Resmetirom Treatment: Real World Data from Four Tertiary Care Centers | Eda Kaya | Received |
2042-SAT | The diagnostic ability for hepatic steatosis using attenuation imaging and controlled attenuation parameter; a prospective multicenter study in Japan | Takashi Nishimura | Received |
2043-SAT | A Single-center, Observational Study to Evaluate the Utility of Ferritin as a Noninvasive Biomarker in Patients with MASLD | Keerthi Thallapureddy | Received |
2044-SAT | Misclassification and Discordance with Magnetic Resonance Elastography using FIB-4-based Stratification for at-risk MASLD | Akash Roy | Received |
2045-SAT | Identifying Candidates for Liver Biopsy in Metabolic-Associated Steatotic Liver Disease: Machine Learning-Based Predictive Models | Dong Yun Kim | Received |
2046-SAT | Clinical utility and diagnostic accuracy of phosphatidylethanol for detecting and differentiating MetALD from MASLD: A prospective study | Federica Tavaglione | Received |
2047-SAT | Evaluation of the consistency and heterogeneity of fibrosis assessment in adjacent virtual liver needle biopsies using AI-based qFibrosis | Yayun Ren | Received |
2049-SAT | Characterization of Intracellular Organelle Abnormalities in MAFLD | Hidenori Kido | Received |
2050-SAT | Diagnostic performance of FibroScan´s controlled attenuation parameter (CAP) and Continuous CAP in MASLD with PDFF as the reference: a multicenter study. | Asako Nogami | Received |
2052-SAT | Validation of FibroTest-T2D as a serum biomarker of early bridging fibrosis according to biopsy length, and sex-specific differences in large populations at risk of MASLD. | Thierry Poynard | Received |
2054-SAT | A Real World, Large Scale Application of the AGA MASLD Pathway. Pitfalls, Challenges and Success Story | Pratishtha Singh | Received |
2055-SAT | Liver virtual biopsy using CSE-MRI in patients with chronic liver disease: a comparative work with elastography and blood test. | Juliette FOUCHER | Received |
2057-SAT | A Machine Learning Approach Identifies Patients at Risk of Metabolic Dysfunction-associated Steatotic Liver Disease-related Complications at the Population-level | Jaideep Behari | Received |
2058-SAT | Developing a Brief Evaluation Index to Diagnosis Metabolic Dysfunction-Associated Steatotic Liver Disease | Xinyuan He | Received |
2059-SAT | The correlation between measurements obtained by the iLivTouch and FibroScan a multicenter randomized study in the US. | Calvin Pan | Received |
2060-SAT | Deep-learning-aided quantification of steatohepatitis-associated pathological findings in liver specimens | Reiichiro Kondo | Received |
2061-SAT | Comparison of liver fibrosis between MASLD in PLHIV and Non-PLHIV | Krishnadas Devadas | Received |
2062-SAT | NIS2+, an effective monitoring tool for tracking disease evolution in patients with fibrotic MASH | Arun Sanyal | Received |
2063-SAT | NIS2+, an effective tool for monitoring MASH resolution and fibrosis improvement in patients with at-risk MASH | Arun Sanyal | Received |
2064-SAT | Evaluation of Two Non-invasive Approaches to Assessing at-risk MASH in Clinical Practice: MASEF and FAST scores | Naim Alkhouri | Received |
2065-SAT | INDEPENDENT VALIDATION OF SECOND HARMONIC GENERATION/TWO PHOTON EXCITATION IMAGING AND ARTIFICIAL INTELLIGENCE-BASED SNOF INDEX FOR METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS CIRRHOSIS ASSESSMENT | Kutbuddin Akbary | Received |
2066-SAT | Identification of new exosomal microRNA markers for metabolic dysfunction-associated steatotic liver disease using artificial intelligence approach | Michinori Kohara | Received |
2067-SAT | Detecting MASH resolution and fibrosis improvement with NIS2+ in patients with at-risk MASH | Vlad Ratziu | Received |
2068-SAT | Plasma proteome signatures associated with steatohepatitis in morbidly obese patients | MELISSA MARIA MILITO | Received |
2069-SAT | Pathological Significance of Intranuclear Lipid Droplets and Glycogenated Nuclei in Liver Biopsy | Norihiro Imai | Received |
2070-SAT | T1-mapping in the liver: The need for standardization | Irdina Nadziruddin | Received |
2071-SAT | A combined imaging and proteomic approach identifies inflammatory response proteins upregulated in MASH: results from the UK Biobank | Alessandro Fichera | Received |
2072-SAT | Anthropometric Factors and Their Association with Fibrosis and MASH in Patients with MASLD in Japan and the United States | Ryuki Hashida | Received |
2074-SAT | Evaluation of the Performance of MASEF score in Patients with Metabolic Dysfunction Associated Steatohepatitis (MASH) under a Lipid-Lowering Medication | Ibon Martinez-Arranz | Received |
2075-SAT | Improved diagnostic accuracy of Vibration-Controlled Transient Elastography based tests in Identifying Metabolic Dysfunction-Associated Steatohepatitis (MASH) and at-risk MASH in obese and lean individuals with Metabolic Dysfunction-Associated Steatotic L | Joo Wei Ethan Quek | Received |
2076-SAT | Corrected T1 Mapping (cT1) outperforms in evaluating clinically significant and advanced fibrosis in non-obese Individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Findings from a multi-ethnic Asian cohort with histologically | Joo Wei Ethan Quek | Received |
2079-SAT | Simple noninvasive tests have poor diagnostic accuracy for MASLD F2-3 in a real world Canadian cohort | Nashla Hamdan | Received |
2080-SAT | Stain-free digital pathology imaging provides microarchitecturally-resolved insights into scar evolution and histological injury allowing direct clinical outcome prediction in metabolic dysfunction-associated steatotic liver disease | Timothy Kendall | Received |
2081-SAT | Usefulness of serum microRNAs as biomarkers for pediatric metabolic dysfunction-associated steatotic liver disease (MASLD) | Caroline Blakley | Received |
2082-SAT | Machine Learning based Predictive Modeling using Proteomic Signatures in Extracellular Vesicles as Diagnostic Indicators of Metabolic Dysfunction-Associated Steatohepatitis. | Ola Leszczynska | Received |
2083-SAT | Development of a Machine Learning Model to Predict Progression of Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease | Jamie Yang | Received |
2084-SAT | DISPARITIES IN NON-INVASIVE TESTING-BASED RISK STRATIFICATION AMONG HISPANIC COMPARED TO NON-HISPANIC INDIVIDUALS AT-RISK FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: ANALYSIS OF A PROSPECTIVE COHORT OF 358 OVERWEIGHT AND OBESE INDIVIDUA | Monica Tincopa | Received |
2085-SAT | Explainable Artificial Intelligence on Proteomics for the diagnosis of advanced liver fibrosis on MASLD patients using open data | Eleni Myrto Trifylli | Received |
2086-SAT | An Effective, Inexpensive, and Simple Alternative to Current AGA Guidelines for Risk-Stratifying Liver Fibrosis: MASHFIB-10 Machine Learning Model | Devon Chang | Received |
2087-SAT | Agile 3+ and Agile 4 Scores Predict Cardiovascular Events in a Large General Population Cohort | Madeleine Chang | Received |
2088-SAT | Prevalence of Cardiovascular Events in MASLD, MetALD, and ALD Patients in a Large General Population Cohort | Madeleine Chang | Received |
2089-SAT | Noninvasive assessment of steatotic liver disease in individuals with class 2 and class 3 obesity | Michael Thornton | Received |
2090-SAT | PLIN2 expression is a reliable biomarker of MASH that is specifically associated with inflammation and ballooning rather than steatosis | Giulia Angelini | Received |
2091-SAT | Artificial Intelligence (AI) in Metabolic dysfunction-associated steatotic liver disease (MASLD): a dual approach for innovating genomic analysis and development of risk prediction models | Miriam Longo | Received |
2092-SAT | PLIN2 is a specific marker for MASH and is not a marker for cardiovascular disease or diabetes | Giulia Angelini | Received |
2093-SAT | Clinical comparison of the HeparDx™ diagnostic blood test with MyLab™ elastography of significant fibrosis in patients with non-cirrhotic MASH | Giulia Angelini | Received |
2094-SAT | Exploring the impact of mitochondrial biomarkers on HCC risk according to etiologic drivers: a multicenter study | Miriam Longo | Received |
2095-SAT | Single-cell RNA Sequencing Reveals the Heterogeneity of Monocyte-derived Macrophages in Metabolic Dysfunction-associated Steatotic Liver Disease | Haozhe Xu | Received |
2096-SAT | Clinically Significant Portal Hypertension by Non-Invasive Tests in Compensated Advanced Chronic Liver Disease due to Metabolic dysfunction-Associated SteatoHepatitis (MASH) with Obesity and Overweight. | Denise Vezozzo | Received |
2099-SAT | MetaSight´s Metabolic Dysfunction-Associated Steatohepatitis (MASH)-fibrosis score: A blood test enabling patient monitoring of liver fibrosis | Shira Shaham-Niv | Received |
2100-SAT | Comparisons of diagnostic performance according to the scoring systems using magnetic resonance elastography and transient elastography for discriminating patients with metabolic-associated steatohepatitis and significant fibrosis | Min Joo Yoon | Received |
2101-SAT | Screening for advanced liver fibrosis due to MASLD with VCTE alongside retina scanning in patients with type 2 diabetes: A cross-sectional study of 1005 patients | Andrea Lindfors | Received |
2102-SAT | AGILE3+ encompasses the two-step approach needed to enhance diagnostic accuracy of advanced fibrosis in patients with suspected MASLD | Savvoula Savvidou | Received |
2103-SAT | Differentiation of steatotic liver disease from advanced liver fibrosis/cirrhosis by breath volatile organic compound analysis | Vaclav Smid | Received |
2105-SAT | The Diagnostic Performance of Agile 3+ Score for Detecting Advanced Fibrosis in Individuals with Chronic Hepatitis B and Concurrent MASLD: A Multicenter Study | Fajuan Rui | Received |
2106-SAT | PLIN2 and RAB14 are potentially useful biomarkers for monitoring treatment response post bariatric surgery | Giulia Angelini | Received |
2108-SAT | NF-TE Score: A Novel predictor for liver fibrosis in Metabolic dysfunction Associated Steatotic Liver Disease | Krishnadas Devadas | Received |
2114-SAT | EVALUATING IMPACT OF WEIGHT CHANGES ON HISTOLOGICAL PATTERNS OF LIVER FIBROSIS IN MASH: IMPLICATIONS FOR SPATIAL INTERROGATION | Nicholas Syn | Received |
2115-SAT | Model for Advanced fibrosis in MASLD-Informed by Inflammation (MAM-I): A Novel Model To Predict Adavanced Fibrosis in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | David Kim | Received |
2116-SAT | Differential patterns of liver and spleen stiffness in chronic viral hepatitis and metabolic associated steatotic liver disease | Giovanni Petralli | Received |
2119-SAT | Retrospective cross sectional evaluation of the LIVERFASt Test for staging liver fibrosis in MASLD patients in NIDDK studies´ populations using liver biopsy | Mona Munteanu | Received |
2120-SAT | Comparison of transient elastography and magnetic resonance elastography for assessment of MASLD/MASH: a retrospective review | Anandita Mathur | Received |
2121-SAT | Prognostic significance of ELF test compared to liver biopsy in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) | Antonio Liguori | Received |
2123-SAT | FIB-4 based referral pathways to identify liver fibrosis and incident advanced liver disease have poor clinical utility in two independent General population cohorts | Laurens van Kleef | Received |
2131-SAT | Retrospective Analysis of a Cohort of Patients with Various Liver Diseases Followed At An Urban Clinic Who Underwent a Liver Biopsy Over The Past 25 Years. Pattern of Liver Biopsy Utilization and Pitfalls. | Magdy Elkhashab | Received |
2132-SAT | Further exploration of differences between lean and non-lean metabolic dysfunction-associated steatotic liver disease (MASLD) in Latino subjects: PNPLA3 frequency and lipidomic profiles | Marco Arrese | Received |
2135-SAT | Validation of the 2023 Diagnostic Criteria for Metabolic Dysfunction-associated Steatotic Liver Disease and the Role of PNPLA3 I148M Variant in Latin America | Luis Antonio Diaz | Received |
2136-SAT | Rapid identification of resmetirom-eligible patients in a large healthcare system using database programming and natural language processing | Marc Sherman | Received |
2138-SAT | Ethnic Differences in ELF scores in a suburban MASH population | Kinnari Modi | Received |
2140-SAT | High Mortality at Safety-Net Hospitals for Patients with Cirrhosis | Sachin Shah | Received |
2141-SAT | Shifting Burdens: Gender Disparities and Evolving Trends in Liver Cirrhosis Across Low SDI Countries | Gautam Maddineni | Received |
2143-SAT | Analysis of the distribution and severity of liver fibrosis stages among the local population within the Rio Grande Valley: identification of risk factors and accuracy of non-invasive diagnostic tools. | Dimple Desai | Received |
2144-SAT | Real-world experience with FibroScan in a tribal specialty liver clinic | Janet Johnston | Received |
2145-SAT | Significant Racial/Ethnic Disparities in Liver Transplant Waitlist Outcomes Among U.S. Adults with End-Stage Liver Disease Due to Steatotic Liver Disease | Shyam Patel | Received |
2146-SAT | A nationwide retrospective study: the association of race with clinical outcomes in hospitalized patients with hepatorenal syndrome | Shahana Prakash | Received |
2147-SAT | Racial/Ethnic Disparities in Liver Transplant Outcome | Tomoki Sempokuya | Received |
2148-SAT | Racial/Ethnic Disparities in Liver Transplantation: The Unintended Consequence of Disparate Alcohol-Associated Liver Disease | Tomoki Sempokuya | Received |
2149-SAT | HEALTH LITERACY AND EDUCATION LEVEL ARE DETERMINANTS OF DISEASE SEVERITY IN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE | Alana Saddic | Received |
2150-SAT | Evaluating Gaps and Disparities in Hepatitis B Treatment among US Adults: A Real-World Analysis using a Nationwide Electronic Health Records Database | Robert Wong | Received |
2151-SAT | Disparities in Primary Biliary Cholangitis: A retrospective study using real-world data from a single hepatology clinic in the greater Los Angeles area | Sabrina Alff | Received |
2155-SAT | HOSPITALIZED PATIENTS WITH CIRRHOSIS, ESPECIALLY THOSE NOT IN HIGH INCOMECOUNTRIES CONTINUE TO HAVE WORSE OUTCOMES REGARDLESS OF WHETHEROUTCOMES WERE STUDIED DURING AND AFTER THE COVID PANDEMIC | Ashok Kumar Choudhury | Received |
2156-SAT | Racial/Ethnic Disparities in Risks of Cirrhosis Among Veterans with Metabolic Dysfunction Associated Steatotic Liver Disease in the United States | Robert Wong | Received |
2157-SAT | Gaps and Disparities in Hepatocellular Carcinoma Surveillance Among a Multi-Center Safety-Net Cohort of Adults with Cirrhosis | Robert Wong | Received |
2158-SAT | Disparities and Barriers in Improving Oral Health in Cirrhosis: The ORACLE (Oral Health In Cirrhosis of the Liver) study | Mette Munk Lauridsen | Received |
2159-SAT | A Cross-Sectional Analysis of Disparities for Acute Liver Failure-Related Mortality in the United States | Nazli Begum Ozturk | Received |
2160-SAT | Social Vulnerability (SV) is Associated with Higher Premature Mortality from Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in the United States (US) | James Paik | Received |
2161-SAT | The Association Between Food Environment and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Socioeconomically Developed (SED) Countries: A Global Study of the United Nations and the Global Burden of Disease (GBD) Data | Zobair Younossi | Received |
2162-SAT | Trends in Alcohol-Associated Cirrhosis: Incidence and Mortality Disparities Between Men and Women, and Young and Older Individuals in a Central Canadian Province (2010-2020) | Nabiha Faisal | Received |
2163-SAT | Social Drivers of Health Prevalence and Screening Acceptability Among Patients with Chronic Liver Disease | Rebecca Kim | Received |
2164-SAT | Disparities and Outcomes of Physical Restraint Use in Hepatic Encephalopathy: A National Inpatient Assessment | Yasmin Ali | Received |
2165-SAT | Sex Differences in Disease Severity at Diagnosis of Cirrhosis in a National Cohort | Mary White | Received |
2166-SAT | Outcomes in a Multidisciplinary MASLD Clinic Are Affected by Race | Malcolm Chapman | Received |
2170-SAT | Palliative Care Consultation Can Improve End of Life Care for Patients with Cirrhosis Removed from the Liver Transplant List Compared to Patients with Pancreatic Adenocarcinoma | Katherine Cooper | Received |
2172-SAT | Elevated Rates of Liver and Intrahepatic Duct Cancer in Native American and Alaskan Native Females Versus Males When Compared to Their White Counterparts: A 5-Year Regional Analysis | Tulika Saggar | Received |
2173-SAT | The Wall Within: Understanding Racial Disparities in Liver Transplant Outcomes in the US Southwestern Region Centre | Anandalakshmi Ponnaluri | Received |
2175-SAT | Racial and ethnic disparities in liver cancer risk by birth cohort: An electronic health record (EHR)-based epidemiologic cohort study | Chanda Ho | Received |
2176-SAT | Safety and Efficacy of Contraceptive Agents After Liver Transplantation | Grace Zhang | Received |
2177-SAT | Disparities in Alcohol-associated Liver Disease: Trends in Liver Transplantation and Listing to Death Ratio | Alexander Zhao | Received |
2178-SAT | The Impact of Housing Insecurity on Hospitalized Patients with Diagnosis of Cirrhosis: A Comparative Analysis Using Data from the National Inpatient Sample (2016-2019) | Joseph Akambase | Received |
2179-SAT | The Effect of Socioeconomic Factors on Outcomes of Variceal Hemorrhage | Cerise Kleb | Received |
2181-SAT | Navigating behavioral change: The lived experience of Mexican and Central American patients with MASLD | Maya Balakrishnan | Received |
2182-SAT | High Prevalence and Low Awareness of Markers of Chronic Liver Disease Among Men Who Have Sex with Men in Los Angeles | Grace Yi | Received |
2183-SAT | Community Resilience Estimates (CRE) can predict patient outcomes related to end-stage liver disease and liver transplantation in the United State | Kenji Okumura | Received |
2185-SAT | THE BURDEN OF STEATOTIC LIVER DISEASE IN CROATIAN VETERANS THREE DECADES AFTER THE WAR | Tatjana Reic | Received |
2187-SAT | Bridging Gaps in Vibration Controlled Transient Elastography (VCTE) Usage for Metabolic Dysfunction-Associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH) Patients: Insights on Sociodemographic Influences and Care Connections | Taranika Sarkar Das | Received |
2189-SAT | GLOBAL DISPARITIES IN LIVER DISEASES RESEARCH FUNDING: A ROOT CAUSE OF HEALTH DISPARITIES | Daniel Huynh | Received |
2190-SAT | Disparities in Waitlist Outcomes for Hepatocellular Carcinoma: Insurance Status and Access to Locoregional Therapies | Soobin Lee | Received |
2191-SAT | Equity in Liver Transplant Access for Critically Ill Patients | Alaina Miller | Received |
2193-SAT | Liver Transplantation Disparities in Listing to Death Ratio and Mortality from 1999-2021 | Alexander Zhao | Received |
2194-SAT | Subgroup disparities in patients with cirrhosis that received palliative/hospice care and discussion: Findings from a large, single-center study | Annie Fung | Received |
2198-SAT | Racial Differences in Progression through Living Donor Liver Transplant Donor Candidacy Evaluation | Melanie Zheng | Received |
2199-SAT | Health Disparities in Autoimmune Hepatitis | Irina Dan Adao | Received |
2202-SAT | Exploring multilevel risk factors for metabolic-dysfunction-associated steatotic liver disease (MASLD) in a racially, ethnically, and socioeconomically diverse cohort | Janet Chu | Received |
2203-SAT | Alcohol Relapse After Liver Transplantation Among Patients with Alcohol-Associated Liver Disease in the Mountain West | Rebecca Kim | Received |
2206-SAT | Characterizing Non-Medical Referral and Evaluation Drop-offs in Adult Liver Transplantation: A California Liver Network Study | Shayana Seneviratne | Received |
2208-SAT | Hepatic osteodystrophy in cirrhosis, etiological spectrum, and outcome. | Babu Lal Meena | Received |
2213-SAT | Socioeconomic deprivation is an independent risk factor for liver fibrosis in fatty liver disease: a community-based propensity-score matched case-control study | Manya Prasad | Received |
2214-SAT | Evaluation of Pharmaceutical Care Service (PCS) for Liver Cirrhosis Patients in Acute Tertiary Hospital in Singapore | Mei-Ling Yee | Received |
2215-SAT | Transplanting Hepatitis C NAT positive solid organs into HCV negative recipients; an Advanced Practice Provider (APP) led clinic, 4-year real world outcomes | Ariana Peguero | Received |
2217-SAT | The PNPLA3 I148M variant aggravates inflammation in macrophages through impaired nuclear receptors (LXR alpha, PPAR gamma, and GR alpha) signalling | Emmanuel Dixon | Received |
2219-SAT | Monocyte transcriptomic landscape and inter-organ crosstalk between the liver, brain and bone marrow in a model of alcohol misuse in aging | Marti Ortega-Ribera | Received |
2220-SAT | CD73 enhances the immunoregulatory functions of hepatic Tregs through enzymatic and nonenzymatic pathways in MAFLD development | Xinjie Zhong | Received |
2221-SAT | A Pilot Study of the Combination of Sorafenib plus Nivolumab in Unresectable Hepatocellular Carcinoma (HCC): Safety, Efficacy, and Immune Cell Profiling in Child Pugh A and B Cohorts | Bridget Keenan | Received |
2224-SAT | Interplay between CD40 and Integrin α5β1 Enhances Tumor Cell Survival in Poorly Differentiated Hepatocellular Carcinoma | Le Thuy | Received |
2230-SAT | The effect of high-salt diet in the immunology and development of hepatocellular carcinoma | Amalia Tzoumpa | Received |
2231-SAT | The impact of PD-1+innate-like CD8+ T cells on the HBsAg reduction in active chronic hepatitis B patients receiving nucleos(t)ide analogue therapy | Rachel Wen-Juei Jeng | Received |
2234-SAT | NLRP3 activation in monocytes drives murine liver inflammation and fibrogenesis | Christian Stoess | Received |
2239-SAT | A large-scale metabolomics screen to define pathways for microbiome-derived small molecules | Kazuma Sekiba | Received |
2243-SAT | INTESTINAL COLONIZATION BY A GUT PATHOBIONT ACCELERATES METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE: IMPLICATIONS OF THE GUT IMMUNE RESPONSE IN SHAPING THE LIVER CELLULAR LANDSCAPE | Erika Prando Munhoz | Received |
2248-SAT | Gut commensal bacteria exert anti-inflammatory and anti-fibrotic effects by regulating macrophage polarization through secondary bile acids | Hongyan Xiang | Received |
2250-SAT | Gut Microbe-Produced Indole-3-Propionic Acid Alleviates Hepatitis B-Related Fibrosis by Regulating Th17 Cell Differentiation through Glucose Metabolism Reprogramming | Fangyuan Chen | Received |
2251-SAT | Analysis for gut microbial profile changes by Japanese diet identified specific species that reflect MASLD progression | Yoshimi Yukawa-Muto | Received |
2252-SAT | Prevalence, risk factors, and outcomes of Clostridioides difficile infection in liver transplant recipients | Kelly Thomas | Received |
2263-SAT | Association between the gut microbiota and primary biliary cholangitis: A two-sample Mendelian randomization study | Hongqin Xu | Received |
2264-SAT | Salivary Microbiome is Independently Associated with Hospitalizations in a Multi-Center Prospective Cohort of Outpatients with Cirrhosis: NACSELD3 Experience. | Jasmohan Bajaj | Received |
2265-SAT | Dietary intervention improves intestinal permeability and reduces colon fibro-inflammation in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH? | Susanne Pors | Received |
2266-SAT | Acyl-CoA thioesterase 12-mediated PPARγ activation preserves gut barrier integrity by suppressing intestinal epithelial cell necroptosis: Protective role in metabolic dysfunction-associated steatohepatitis | Akiko Sugiyama | Received |
2267-SAT | Reduced Bacteroides Thetaiotaomicron Contributes to the Disordered Metabolism of Bile Acids in MASLD Patients | Jian Wu | Received |
2270-SAT | Clostridium spp. cocktail alleviates hepatocellular carcinoma progression by modulating HIF1a-derived lipid profiling. | seol hee Song | Received |
2273-SAT | Cryptogenic Pyogenic Liver Abscess: A Sentinel Marker for Colorectal Cancer? | Guneet Sidhu | Received |
2274-SAT | Lactulose is associated with increased risk of disseminated infection from intestinal pathogens | Aaron Hecht | Received |
2275-SAT | Intra-Tumoral Microbiome Promote Hepatocellular Carcinoma Cell Proliferation and Is Associated with Prognosis | Ming-Lun Yeh | Received |
2278-SAT | Acute alcohol binges alter colonic mucosal architecture to cause transient changes in defecation | Scott Minchenberg | Received |
2280-SAT | Western diet contributes to MASH by remodeling gut microbiota and metabolite 2-OG | Ming Yang | Received |
2283-SAT | ´From Abscess to Tumor: Tracking the Prevalence of Colon Cancer Among Pyogenic Liver Abscess Patients (2016-2020)´ | Khalid Home | Received |
2284-SAT | Utilizing FIB-4 and transient elastography to diagnose steatotic liver disease in patients with type 2 diabetes: Quality improvement project at a Veterans Affairs resident clinic | Nimmy Thomas | Received |
2285-SAT | Risk of incident extrahepatic cancers among Medicare patients with non-alcoholic steatohepatitis (NASH) | Jesse Fishman | Received |
2286-SAT | Risk of all-cause mortality and adverse outcomes from steatotic liver disease and its subgroups in the general population | Maurice Michel | Received |
2287-SAT | Racial Differences and Comparative Clinical Outcomes among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Hospitalized for COVID-19: Insights from the National Inpatient Sample Database. | Fnu Vikash | Received |
2288-SAT | Prognostic value of the FIB-4 index for all-cause mortality in heart failure with steatotic liver disease: Results from the MyoVasc study | Joost Boeckmans | Received |
2289-SAT | Pruritus is Common and Persistent in Patients with MASLD | Nasir Hussain | Received |
2290-SAT | Structural equation modelling identifies sex-specific classes to characterize subtypes of metabolic dysfunction-associated steatotic liver disease | Carlos Pirola | Received |
2291-SAT | Clinical outcomes of steatotic liver disease in Japan | Tomomi Kogiso | Received |
2292-SAT | Gender Disparities in Metabolic Dysfunction Associated Steatotic Liver Disease: Transcriptomic results from the BARIA longitudinal cohort study | Mijra Koning | Received |
2294-SAT | Analysis of the distribution and severity of liver fibrosis stages among the local population within the Rio Grande Valley: identification of risk factors and accuracy of non-invasive diagnostic tools. | Dimple Desai | Received |
2295-SAT | The Effect of Diet Composition Exposome on the Natural History of Metabolic-Associated Steatotic Liver Disease in the Million Veteran Program Cohort | Lauren Callans | Received |
2296-SAT | Metabolic-Associated Steatotic Liver Disease in Relation to Food Behaviors in the Million Veteran Program Cohort: Eat Your Broccoli | Lauren Callans | Received |
2297-SAT | Lifestyle habits significantly mitigate MASLD risk: Results from a prospective multi-center study | Gediz Dogay Us | Received |
2298-SAT | Risk difference for long-term clinical outcomes in steatotic liver disease (MASLD, MetALD and ALD) | Nobuharu Tamaki | Received |
2299-SAT | Evolution of MASLD/MASH Patient Experiences: Insights from ´The State of Steatotic (Fatty) Liver Care in America´ Surveys 2022-2024 | Neeraj Mistry | Received |
2300-SAT | Associations between Metabolic Dysfunction-Associated Steatotic Liver Disease and Abdominal Pain: A Single-Center Retrospective Study | George Waldenmaier | Received |
2301-SAT | Synergistic Impact of Low Body Mass Index and Metabolic Dysfunction-Associated Steatotic Liver Disease on Incident Alzheimer´s Disease Risk: A Nationwide Cohort Study | Tae Seop Lim | Received |
2303-SAT | Neighborhood-level social determinants of health are associated with MASLD burden, complications, and mortality | Claire Faulkner | Received |
2304-SAT | Economic Cost of Inaction for Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Germany, Japan, and the United States | Zobair Younossi | Received |
2305-SAT | Understanding Metabolic Dysfunction-Associated Steatohepatitis: Differences in Clinical and Demographic Characteristics Across Racial and Ethnic Groups | Michelle Jajko | Received |
2306-SAT | Validation and epidemiologic definition of the novel steatotic liver disease nomenclature in a national cohort with cirrhosis | Catherine Mezzacappa | Received |
2307-SAT | Thyroid Disorders (hypothyrodism and hyperthyrodism) and their associations with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: A Study on Inpatient Outcomes, Incidence and Prevalence | Anwar Uddin | Received |
2310-SAT | Characteristics and clinical outcomes in patients with cirrhosis due to metabolic dysfunction-associated steatotic liver disease (MASLD) in Sweden | Ying Shang | Received |
2311-SAT | Clinical features of MetALD: database analysis of 108,446 subjects | Hideki Fujii | Received |
2312-SAT | Differences in prevalence of MASLD with clinically significant fibrosis by sex/menopause status in a large prospective US cohort of persons with HIV | Kara Wegermann | Received |
2313-SAT | The Cumulative Impact of Concurrent Diabetes Mellitus and Obesity on Long-term Risks of Cirrhosis Among a National Cohort of U.S. Veterans with MASLD or MetALD | Robert Wong | Received |
2314-SAT | Longitudinal Risk of Cirrhosis Across the Spectrum of Steatotic Liver Disease Among a National Cohort of Veterans in the United States | Robert Wong | Received |
2315-SAT | Sexual Dimorphism in Metabolic Dysfunction-Associated Steatotic Liver Disease Among 1,472 People with HIV | Sahar Saeed | Received |
2316-SAT | Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Severe Fibrosis have Worse Executive Function Performance | Ali Weinstein | Received |
2317-SAT | Significant sex/gender disparities in the prevalence, cardiometabolic risk profiles and management of MASLD: Results from a cohort of 24,888 Canadians | Jessica Burnside | Received |
2318-SAT | Investigation of factors contributing to liver fibrosis in MASLD through serial MR elastography and MRI-PDFF | Takashi Kobayashi | Received |
2319-SAT | Metabolic-associated Steatotic Liver Disease and Infections: A Systematic Review and Meta-analysis | Spyridon Peppas | Received |
2320-SAT | Prognosis of lean and non-lean MASLD in a large-scale Asian population study | Shun-Ichi Wakabayashi | Received |
2322-SAT | Changes in Hemoglobin A1c and Body Weight are Strongly Associated with Changes in Liver Stiffness in Adults with Biopsy-Proven MASLD | Matthew Dukewich | Received |
2324-SAT | The Global Profile of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Clinical Presentation, Histologic Stage, Non-invasive Tests and Mortality from the Global NAFLD/MASLD Registry | Zobair Younossi | Received |
2326-SAT | Real-world experience of a multidisciplinary MASLD clinic | Joshua Fricker | Received |
2328-SAT | Epigenetic age acceleration is associated with steatotic liver disease in adolescence and early adulthood: A 10 year cohort study. | Phillip Melton | Received |
2329-SAT | Current multi-dimensional view of non-alcoholic steatohepatitis (NASH)/ metabolic dysfunction-associated steatohepatitis (MASH) global epidemiological rates | Gauri Saal | Received |
2330-SAT | Liver-related events and mortality in patients with Metabolic Dysfunction Associated Steatotic Liver Disease varies with the type of Cardiometabolic Risk Factor | . Shalimar | Received |
2331-SAT | Comparing Rates of Decompensation, Hepatocellular carcinoma, Overall and Liver-related death between MASLD, MetALD and ALD in a National Cohort | Binu John | Received |
2332-SAT | Independent risk factors for chronic kidney disease: The impact of SLD and obesity in a large-scale health checkup cohort | Michihiro Iwaki | Received |
2334-SAT | A prospective assessment of the impact of decompensation of cirrhosis on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease | Ian O´Connor | Received |
2336-SAT | Impact of hemoglobin A1c (HbA1c) trajectory on the risk of liver-related complications in patients with type 2 diabetes mellitus (T2DM): A territory-wide cohort study | Terry Cheuk-Fung Yip | Received |
2337-SAT | Predicting hepatic decompensation in patients with metabolic dysfunction-associated steatotic liver disease-related cirrhosis: The ABID-LSM model. | Luis Bertot | Received |
2339-SAT | CORONASH study: prospective study of prevalence and severity of metabolic dysfunction - associated steatotic liver disease (MASLD) in patients undergoing coronary angiography | Raluca Pais | Received |
2340-SAT | Low Anti-Mullerian Hormone in Reproductive-Aged Women is Associated with MASLD in Midlife: Data from the Longitudinal CARDIA Cohort | Katherine Cooper | Received |
2341-SAT | Stability of the NASH-CHECK patient-reported outcome measure over time in patients with metabolic dysfunction-associated steatotic liver disease and stable clinical status | Ian O´Connor | Received |
2342-SAT | Steatotic Liver Disease with Metabolic Dysfunction and Modest Alcohol Consumption Cumulatively Impact Survival in the Younger Populations. | Jesse Pustjens | Received |
2343-SAT | Increasing liver fibrosis in MASLD is associated with higher risk of hip fractures in males | Elena Gibson | Received |
2344-SAT | Incidence of cirrhosis and extrahepatic manifestations among lean and non-lean individuals with Metabolic Dysfunction-associated Steatotic Liver Disease | Majd Aboona | Received |
2348-SAT | Obesogenic Medication Use is Associated with Increased Risk of MASLD and Liver Fibrosis | Ian Jaffe | Received |
2349-SAT | Predictive Models for Hepatocellular Carcinoma (HCC) development in Cirrhotic and Non-Cirrhotic Metabolic Dysfunction-Associated Steatotic Liver Disease patients | Prerana Sruthi Vatsavayi | Received |
2350-SAT | Balancing the Booze: How Light to Moderate Drinking Affects Liver and Cardiovascular outcomes in Steatotic Liver Disease | Felice Cinque | Received |
2351-SAT | Association of BMI trajectory with Mortality Among Non-alcoholic fatty liver disease Individuals: a prospective cohort study | Junping Shi | Received |
2352-SAT | Association between use of anti-hypertensive drugs and risk of hepatocellular carcinoma (HCC) in metabolic dysfunction-associated steatotic liver disease (MASLD) patients with cirrhosis | Ahmed Elhariri | Received |
2353-SAT | Real-world outcomes of patients with metabolic dysfunction-associated steatohepatitis (MASH) compensated cirrhosis at a large academic referral center | Shadera Slatter | Received |
2354-SAT | PNPLA3 rs738409 is significantly and independently associated with histological progression and regression in MASLD: A large paired and prospective liver biopsy study. | Eduardo Vilar-Gomez | Received |
2355-SAT | Evaluating acute healthcare utilization post implementation of a primary care metabolic-associated steatotic liver disease risk stratification pathway: A large Canadian cohort study | Elizabeth Baguley | Received |
2356-SAT | Characteristics of adult MASH patients and factors associated with MASH-relevant clinical endpoints in a real-world US cohort | Philip Newsome | Received |
2357-SAT | Time to Disease Progression and All-Cause Mortality in Adult MASH Patients in a Real- World US Cohort | Alfred Barritt IV | Received |
2358-SAT | Quantitation of Plasma Cells, Cytotoxic T cells, and Kupffer cells/Macrophages with Hepatic Fibrosis Stage in Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Michael Estep | Received |
2359-SAT | Association of Steatotic Liver Disease (SLD) with Adverse Pregnancy Outcomes: Results from the Prospective Fatty Liver in Pregnancy (FLIP) Cohort. | Tatyana Kushner | Received |
2360-SAT | Artificial Intelligence for Early MASLD Identification in the Electronic Medical Record | Ariana Stuart | Received |
2361-SAT | Clinical characteristics and FIB-4 risk stratification of primary care patients with obesity, diabetes, or both: real-world implications for adopting a FIB-4 referral algorithm to detect metabolic dysfunction-association steatotic liver disease (MASLD) wi | Janet Chu | Received |
2362-SAT | Three gradient boosting machine-learning models in Indeterminate FIB-4 Score Are Superior to Noninvasive Tests in Predicting Cirrhosis: A National and VA Analysis | Sebastian Niezen | Received |
2363-SAT | Smoking and Progression to Cirrhosis | Samantha Wray | Received |
2364-SAT | The Effects of Visceral Adipose Tissue on Survival in MASLD | James Lee | Received |
2365-SAT | Disparities in the Association between Metabolic Associated Steatotic Liver Disease and Visceral Adipose Dysfunction Across Sexes, Races, and Diabetes Status: A Cross-Sectional Study of US Adults. | Bhargav Vemulapalli | Received |
2366-SAT | Prevalence of Metabolic dysfunction-associated fatty liver disease (MAFLD) in patients with Diabetes Mellitus: A Clinical Investigation of Patients in Puerto Rico West area. | Milaris Sanchez-Cordero | Received |
2367-SAT | Sex differences in clinical outcomes of patients with metabolic dysfunction-associated steatotic liver disease -results of a nationwide real-world U.S. cohort | Taotao Yan | Received |
2368-SAT | CAUSE-SPECIFIC MORTALITY AMONG AUSTRALIANS WITH CIRRHOSIS DIFFERS BY CIRRHOSIS ETIOLOGY AND DECOMPENSATION STATUS | Vikas Bhasker | Received |
2369-SAT | Patterns of Dietary Supplement Use among Patients with Steatotic Liver Disease in the United States: Vitamins, Minerals and Botanicals | Gabrielle Jutras | Received |
2370-SAT | Discordance of FIB-4 and SAFE scores for the prediction of advanced fibrosis in primary care patients with obesity, diabetes, or both | Janet Chu | Received |
2371-SAT | Differential Prognosis and Impacts of Cardiometabolic Risk Factors and Alcohol Intake in MASLD and MetALD Patients | Young Chang | Received |
2375-SAT | Association between metabolic dysfunction-associated steatotic liver disease and mortality: A nationwide cohort study | Gi-Ae Kim | Received |
2377-SAT | MASLD and metALD: the amount of liver fat and number of cardiometabolic risk factors in relation to the risk of type 2 diabetes and cardiovascular disease | Gabrielle Alblas | Received |
2378-SAT | Minimal or Moderate Alcohol Use before Liver Transplantation for MASLD is not associated with Steatosis Recurrence or Survival | Ashish Bibireddy | Received |
2379-SAT | Long-Term Vascular Outcomes and Mortality After Bariatric Surgery Among Patients with Obesity, Type 2 Diabetes, and Metabolic Dysfunction-Associated Steatotic Liver Disease | Arunkumar Krishnan | Received |
2381-SAT | Cause-specific mortality in patients with metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study | Axel Wester | Received |
2383-SAT | Change in nomenclature and definition from NAFLD to MASLD maintains the disease severity determining association between type 2 DM and MASLD - The results of multi-centre Indian Consortium on MASLD (ICOM-D). | Ajay Duseja | Received |
2385-SAT | Cumulative Dose and Duration of Statin use are associated with a reduced risk of liver cancer after adjusting for age, FIB-4 score, and prior cirrhosis diagnosis in MASLD patients; a 10-year cohort study | Georgia Sofia Karachaliou | Received |
2386-SAT | Health Goal Coaching is Associated with Higher Health Goal Motivation and Satisfaction in Participants at Risk for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) | Jillian Price | Received |
2387-SAT | HEALTHCARE PROVIDERS´ PERSPECTIVES ON NEW METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) NOMENCLATURE | Somaya Albhaisi | Received |
2388-SAT | Sodium-Glucose Cotransporter-2 Inhibitors and the Risk of Hepatocellular Carcinoma Among Patients with Type 2 Diabetes, Metabolic Dysfunction-Associated Steatotic Liver Disease, and Obesity: A Large Population-Based Cohort Study | Arunkumar Krishnan | Received |
2389-SAT | Primary Care Based Implementation of Electronic Clinical Decision Support for Metabolic Dysfunction Associated Steatotic Liver Disease Improves Care Delivery Independent of Patient Demographics and Clinical Factors: A Prospective Implementation Study | Ashley Spann | Received |
2390-SAT | All-cause mortality differs between steatotic liver disease subtypes: Results from a prospective cohort of 16,560 Adults in Canada | Jessica Burnside | Received |
2391-SAT | Statin Use with Cardiovascular Disease and All-Cause Mortality in Patients with Hypertension, Metabolic Dysfunction-Associated Liver Disease, and Obesity: A Population-Based Cohort Study | Arunkumar Krishnan | Received |
2392-SAT | Fibrosis risk stratification in metabolic dysfunction-associated steatotic liver disease patients with diabetes in Taiwan- A multi-center cohort study | Jee-Fu Huang | Received |
2393-SAT | Hepatic Fibrosis But Not Steatosis is Associated with Early-Stage/Sub-clinical Markers of Heart Failure in Metabolic Dysfunction-Associated Steatotic Liver Disease | Rabab Ali | Received |
2396-SAT | Forecasted changes in tumor characteristics and survival of patients with nonviral hepatocellular carcinoma in the United States: a modeling study based on the SEER-Medicare database | Joanne Liu | Received |
2397-SAT | Sex differences in long-term overall, liver and nonliver-related mortality of patients with metabolic dysfunction-associated steatotic liver disease: a real-world longitudinal cohort study | Taotao Yan | Received |
2398-SAT | Suboptimal diagnosis rate and peri-complication diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) in the U.S.: A population-based study | Vy Nguyen | Received |
2399-SAT | Cost utility of bariatric surgery among obese patients with chronic liver disease | Shalini Bansal | Received |
2400-SAT | Use of a Computerized Clinical Decision Support (cCDS) Tool in Primary Care Increases Rates of Confirmatory Testing in patients with Metabolic Associated Steatotic Liver Disease (MASLD) at Risk for Advanced Liver Fibrosis: A Pilot Study | James Miller | Received |
2401-SAT | Increasing metabolic dysfunction-associated steatotic liver disease-related mortality rates in the United States from 2006 to 2023 and future forecast to 2040 | Xinrong Zhang | Received |
2402-SAT | Global epidemiology and characteristics of MASLD in type 1 diabetes: an updated systematic review and meta-analysis | Matheus Souza | Received |
2403-SAT | Identifying social determinants of health and environmental factors associated with significant fibrosis in MASH patients enrolled in the Mount Sinai MASH Center of Excellence Registry and Biobank | Alejandra Paredes-Marin | Received |
2404-SAT | Clinical, Psychosocial and Social Determinants of Health Factors Associated with Degree of Hepatic Steatosis and Liver Stiffness Among Overweight and Obese Adults at Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease | Monica Tincopa | Received |
2405-SAT | Representation of sex, race and ethnicity in MASH trials: a systematic review and meta-analysis | Matheus Souza | Received |
2410-SAT | The best cutoff for transient elastography as a predictor of liver outcomes in metabolic-associated steatotic liver dysfunction (MASLD) patients | Gil Salles | Received |
2411-SAT | Association of NAFLD with and without Advanced Fibrosis with Fatal, Non-Fatal, and Combined Cardiovascular Events: A Systematic Review and Meta-Analysis | Mannat Kaur Bhatia | Received |
2412-SAT | Magnesium depletion score and mortality in individuals with metabolic dysfunction-associated steatotic liver disease over a median follow-up of 14 years | Lei Fan | Received |
2413-SAT | Examining the prevalence of hepatic steatosis and advanced fibrosis using multiple non-invasive measures in Canada: A national estimate using the Canadian Health Measures Survey (CHMS) from 2009-2019 | Jacob Romano | Received |
2417-SAT | Investigating the prevalence of MetALD in comparison to MASLD in patients previously diagnosed with NAFLD | Yousef Almahanna | Received |
2419-SAT | Relationship between Alcohol Consumption and All-cause Mortality in patients with Steatotic liver disease: Findings from NHANES III | Jie Li | Received |
2420-SAT | Assessing the prevalence of cardiometabolic risk factors in patients referred to a Steatotic Liver Disease clinic | Yousef Almahanna | Received |
2421-SAT | Diabetic Microvascular Complications are Associated with Mortality in Individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Type 2 Diabetes Mellitus: A Nationwide Study | Yee Hui Yeo | Received |
2422-SAT | Frequent misclassification of MetALD results in underestimation of its prevalence and long-term prognosis | Dae Won Jun | Received |
2423-SAT | High adherence to the Mediterranean diet is associated with lower Liver Risk Scores - Analysis of the NHANES 2017-2018 Cohort | TSUBASA TSUTSUMI | Received |
2424-SAT | Olanzapine-Induced Liver Injury: A Case Report | Karen Young | Received |
2425-SAT | Lipofuscinosis as a novel discriminating feature for drug-induced liver injury vs. autoimmune hepatitis | Sabine Weber | Received |
2427-SAT | Unveiling Preventable Liver Damage: Exploring LAAT and Hallas Tools in Hospitalized Patients Assessed with Updated RUCAM Scale | Hussam Almasri | Received |
2428-SAT | Single-cell investigation of mercaptopurine-associated liver injury | Keito Hoshitsuki | Received |
2429-SAT | Deep learning-based diagnostic model of pyrrolizidine alkaloid-related hepatic sinusoidal obstruction syndrome based on CT: development and validation study | Hong Gao | Received |
2430-SAT | ´Shrooms´ and Severe Hepatitis - A Unique Entity | Lakshmi Chirumamilla | Received |
2431-SAT | Induction of Cyp2e1 contributes to asparaginase-induced hepatocyte sensitization to lipotoxicity. | Yin Zhu | Received |
2432-SAT | The Impact of COVID-19 and COVID-19 Vaccination on Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury Occurring During Clinical Trials: Consensus Recommendations from the IQ DILI Consortium | Melissa Palmer | Received |
2433-SAT | Nuclear factor erythroid 2-related factor 2 (NRF2) activation aggravates liver injury by causing mitochondrial dysfunction | Alejandro H. Gutierrez | Received |
2434-SAT | KEAP1 deletion rescues cell death associated with GPX4 knockdown in hepatocytes in acute models of liver injurydelta | Leticia Colyn | Received |
2435-SAT | Hepatic Sinusoidal Congestion Associated with Inotuzumab in Patients with B-cell Acute Lymphoblastic Leukemia: A Case Series Report | Derek Tai | Received |
2436-SAT | Variability in Reference Ranges of Hepatic Biochemical Tests in Pediatric Populations: Implications for Monitoring and Assessment of Drug Induced Liver Injury | Arie Regev | Received |
2437-SAT | Early Bile Drainage Saves Beagles from Amanita Subjunquillea-Induced Acute Liver Failure | Xiuying Ma | Received |
2438-SAT | Drug-Induced Liver Injury due to Medications for Alcohol Use Disorder: Insights from the DILIN Prospective Study | Harish Gopalakrishna | Received |
2439-SAT | Liver Injury in Clinical Trials of Biologic Agents Has a Lower Rate of Attribution to Drug-Induced Liver Injury (DILI) Compared to Non-Biologic Agents | Jasmine Amirzadegan | Received |
2440-SAT | Impact of lipophilicity and daily dose on drug-induced liver injury in the Japanese cohort | Kota Tsuruya | Received |
2442-SAT | Intrathecal Methotrexate is Associated with Acute Transient Hepatocellular Liver Injury | Harish Gopalakrishna | Received |
2444-SAT | Drug induced liver injury: A unusual case of cholestatic hepatitis caused by highly active anti-retroviral therapy (HAART) | haniya waseem | Received |
2445-SAT | Evolving Patterns of Potentially Hepatotoxic Botanical use in the United States: Results from NHANES 2003 - 2018 Surveys. | Alisa Likhitsup | Received |
2447-SAT | Improving the Diagnostic Accuracy of the RECAM in North American Patients with Suspected Idiosyncratic Drug-Induced Liver Injury | Jacob Ciricillo | Received |
2449-SAT | The MetaHeps technology for drug causality assessment in patients diagnosed with idiosyncratic drug-induced liver injury (DILI) | Michele Visentin | Received |
2450-SAT | Sequential analysis of serum levels of ten intestinal permeability and inflammation markers in patients with drug-induced liver injury and other forms of acute liver injury | Daniel Di Zeo-Sánchez | Received |
2451-SAT | The Ongoing Problem of Mislabeling of Herbal and Dietary Supplements Implicated in Hepatotoxicity | Victor Navarro | Received |
2453-SAT | Dual-mode action of scalable, high-quality engineered stem cell-derived SIRPα extracellular vesicles for treating acute liver failure | Seohyun Kim | Received |
2454-SAT | A Novel Machine Learning Model for Distinguishing Drug-Induced Liver Injury from Autoimmune Hepatitis: Development and Validation | Yu Wang | Received |
2455-SAT | Higher pre-treatment ALT level and pre-existing liver disease are associated with increased risks of fluconazole related liver toxicity. | Pinghsin Hsieh | Received |
2456-SAT | Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis | Yu Su | Received |
2457-SAT | IDENTIFICATION OF RISK PROFILES FOR LIVER INJURY IN ADULTS WITH MULTIPLE SCLEROSIS USING ARTIFICIAL INTELLIGENCE METHOD | Dominique Larrey | Received |
2458-SAT | TransDILI: a deep transfer learning based prediction for drug-induced liver injury through leveraging molecular structure images | Yue Li | Received |
2459-SAT | Clinical Outcomes of Idiosyncratic DILI are Improving in the United States: Results from the DILIN Prospective Study, 2004 to 2024 | Robert Fontana | Received |
2460-SAT | Muscle steatosis significantly increases the risk of death in patients with cirrhosis - a retrospective cohort study | Hong Yu | Received |
2462-SAT | Co-administration of Alcohol, Ritonavir and Lopinavir Affects Expression of the SET Cheperone Protein in Hepatocytes and Monocytes and HIV-1 Infectivity In Vitro | Liting Chen | Received |
2463-SAT | The pivotal role of ABCB11 on genetic susceptibility to drug-induced liver injury from anabolic steroids | Paola Nicoletti | Received |
2464-SAT | Exploring the Impact of Acetaminophen Overdose on Patients with Acute Alcoholic Liver Failure | Nisha Sanghani | Received |
2465-SAT | CXXC-type zinc finger protein 5 deficiency in mice ameliorates acetaminophen-induced liver injury via the STAT1 signaling pathway | Hyuneui Jeong | Received |
2466-SAT | Exposure to cigarette smoke aggravates hepatic damage in mice induced by ethanol or acetaminophen | Hyuneui Jeong | Received |
2468-SAT | Correlation between decreased type 3 innate lymphocyte and deterioration of liver function in cholestatic drug induced liver injury | Rongtao Lai | Received |
2469-SAT | Characterization of liver injury induced by CDK 4/6 inhibitors induced liver injury | LUCY MEUNIER | Received |
2470-SAT | The burden of anti-cancer drugs in drug-induced liver injury in the French-speaking hepatotoxicity network | LUCY MEUNIER | Received |
2475-SAT | Efficacy of UDCA as first-line treatment for cholestatic checkpoint inhibitor-induced liver injury | LUCY MEUNIER | Received |
2476-SAT | Trends and Outcomes of Acetaminophen-induced Hepatotoxicity: A 2016 to 2021 Analysis Using the National Inpatient Sample Dataset | Chineye (Brenda) Amuchi | Received |
2477-SAT | The role of 2´-5´-oligoadenylate synthase-like protein (OASL1) in cholestatic- and hepatotoxin-mediated liver fibrosis | Daram Yang | Received |
2478-SAT | Maternal smoking exacerbates subsequent liver damage in offspring mice | Daram Yang | Received |
2479-SAT | Decoding Acetaminophen Risks: A U.S. Inpatient Data Comparison of Acetaminophen toxicity in patients with Alcoholic and without Alcoholic Liver Disease | Raj Patel | Received |
2481-SAT | Aging promotes liver injury: Studies on C57Bl/6 mice | Sathish kumar Perumal | Received |
2482-SAT | Nilotinib Induced Hepatotoxicity with Decade Long Latency and Newly Discovered Pancreatic Head Mass | Jason John | Received |
2483-SAT | Frontal EEG Monitoring Reduces Anesthesia Requirement During Liver Transplantation | Gabriel Rice | Received |
2484-SAT | Comprehensive deep learning-based assessment of living liver donor CT angiography: from vascular segmentation to volumetric analysis | Jinsoo Rhu | Received |
2485-SAT | The Impact of Arrhythmias: Outcomes of Patients with Liver Transplantation and Atrial Fibrillation | Jason John | Received |
2486-SAT | The classification of portal vein thrombosis and a tactical algorithm based on it | Boris Yaremin | Received |
2487-SAT | Risk Factors and Survival in Patients with De Novo Malignancies Following Liver Transplantation Alone or Simultaneous Liver-Kidney Transplantation | Nazli Begum Ozturk | Received |
2488-SAT | Outcomes of Simultaneous Liver-Kidney Transplantation vs Liver Transplantation Alone in Patients with Cirrhosis Requiring Renal Replacement Therapy | Nazli Begum Ozturk | Received |
2489-SAT | Cystatin C vs. Creatinine: Who Wins in Cirrhosis? | Alexandra Fiedler | Received |
2490-SAT | Streamlining Nutritional Support for Inpatient Cirrhosis Management | Alexandra Fiedler | Received |
2491-SAT | Reprogramming of bile acid metabolism attenuates liver inflammation during ischemia/reperfusion injury | Kunpeng Huang | Received |
2492-SAT | Frailty is associated with multiple negative clinical outcomes in patients referred for liver transplantation. | Heidi Johnston | Received |
2493-SAT | Comparative Outcomes of Trans-arterial Chemoembolization and Radioembolization as Bridging Therapy for Hepatocellular Carcinoma in Liver Transplant Candidates. | Butros Fakhoury | Received |
2495-SAT | Characterization and Post-Transplant Outcomes of Machine Perfusion Organs for Liver Re-Transplantation | Roy Wang | Received |
2496-SAT | Operational Time and Severe Postoperative Complications: Their Impact on Long-term Survival in Liver Transplant Patients | Ayato Obana | Received |
2498-SAT | Center-level Variability in Utilizing Normothermic Machine Perfusion and the Association with Recipient Insurance | Chawin Lopimpisuth | Received |
2499-SAT | Tracking Long-Term Outcomes in ALPPS Procedure: A Follow-Up Study Analyzing Extended Survival | Mohammad AbuAssi | Received |
2500-SAT | Clinical outcomes of TACE in patients listed for liver transplantation at a single center from 2018-2022 | Elizaveta Makarova | Received |
2502-SAT | Etiology-specific trends of delisting for liver disease improvement and re-compensation among candidates on liver transplant list in the US | Mohamed Elfeki | Received |
2505-SAT | The impact of tacrolimus level and its intrapatient variability on the development of chronic kidney disease following liver transplantation | Soon Kyu Lee | Received |
2506-SAT | Enhanced recovery of warm ischemic damaged rat liver graft using normothermic machine perfusion (NMP) by supplementing perfusate with bone morphogenetic protein-7 (BMP-7) mimetic TBD 184 | Anil Kharga | Received |
2507-SAT | Application of Hemopure based oxygenated solution during pig to baboon liver xenotransplantation to minimize duration of ischemia during back benching: Bioenergetic metabolites analysis | Anil Kharga | Received |
2509-SAT | Analysis of the impact of female sex and sarcopenia on serum creatinine and waitlist priority for liver transplantation | Shivangi Gupta | Received |
2513-SAT | Sleep Disturbance is Associated with Frailty, Impaired Physical Function, Fatigue, Anxiety, and Depression in Liver Transplant Recipients: Results from the LivCog Cohort Study | Minjee Kim | Received |
2514-SAT | Stress-Induced Cardiomyopathy in Liver Transplant Recipients: A Systematic Review | Mohammad AbuAssi | Received |
2515-SAT | High-Throughput Proteomics Analysis Identifies Changes in Circulating Proteome Signatures Across Different Stages of Liver Transplantation Surgery | Xing Li | Received |
2516-SAT | Evaluating effects of two oxygenated solutions for flushing by simulating liver transplantation on pump: Hemopure combined with William´s E culture media or University of Wisconsin (UW) solution | Anil Kharga | Received |
2517-SAT | Establishment and observation of a long-term viable allogenic murine liver transplantation model | Keiko Iwaisako | Received |
2520-SAT | Serum and Urinary Metabolomics are Associated with the Development of De Novo Metabolic Syndrome after Liver Transplant: A Multi-center Longitudinal study. | Jasmohan Bajaj | Received |
2521-SAT | ASSESSING LIVER TRANSPLANT REJECTION USING PAIRED BLOOD AND BIOPSY SAMPLES | Katelynn Madill-Thomsen | Received |
2524-SAT | Incidence and outcome of rejection in hyperimmunized liver transplant recipients receiving an induction therapy | Faouzi Saliba | Received |
2525-SAT | VIBRATION-CONTROLLED TRANSIENT ELASTOGRAPHY AS A NON-INVASIVE TOOL TO EXCLUDE HEPATIC STEATOSIS IN LIVING LIVER DONOR EVALUATION | Sarita Ratana-Amornpin | Received |
2526-SAT | The Impact of Recipient Body Mass Index and Cold Ischemic Time on Post-Liver Transplant Biliary Strictures | Ebehiwele Ebhohon | Received |
2528-SAT | Calibrating Exception Points for Continuous Distribution: Why Matching HCC to Non-HCC Waitlist Dropout Falls Short | Joshua Norman | Received |
2529-SAT | Atrial Fibrillation Pre-Liver Transplant Associated with Increased All-Cause and Cardiovascular Mortality Post-Transplant | John Barnes | Received |
2530-SAT | Living Donor Liver Transplantation: The Role of Transplant Kinship on rejection rates and allograft survival, using genetic related vs unrelated live donors. | Maisa Elbadawi | Received |
2533-SAT | Liver Transplantation for MASH Cirrhosis Has Better Post-Transplant Outcomes Than Non-MASH Cirrhosis | Waqas Rasheed | Received |
2534-SAT | Exercise stress echocardiography is a feasible alternative to pharmacologic stress echocardiography for cardiac risk evaluation in patients with cirrhosis prior to liver transplantation | Madeleine Gill | Received |
2535-SAT | National Trends of Bridging Locoregional Therapy in Liver Transplant Candidates with Hepatocellular Carcinoma. | Butros Fakhoury | Received |
2536-SAT | Sex and Race Disparities in Liver Listings and Transplants for Non-Hepatocellular Carcinoma Indications in the United States | Abdellatif Ismail | Received |
2538-SAT | Anxiety and depression are significantly associated with worse health-related quality of life in liver transplant survivors | Alexander Scherer | Received |
2539-SAT | Early Extubation: A Promising Strategy to Mitigate Post-Liver Transplant Complications and Enhance Recovery | Justin Lin | Received |
2540-SAT | Recognizing the Need for Statin Use in Liver Transplant Recipients: How Effective are Providers at Adhering to Primary and Secondary Prevention Guidelines? | Jacob Ciricillo | Received |
2541-SAT | Favorable outcome in Patients Over 65 Years with Hepatocellular Carcinoma Undergoing Liver Transplantation | Saad Alghamdi | Received |
2543-SAT | CHOLESTEROL CONTENT AND EXPRESSION OF SREBF-2 AND HMGCR PREDICT EARLY ALLOGRAFT DYSFUNCTION AND THE OUTCOME OF HUMAN LIVER TRANSPLANTATION | Sandra Torres | Received |
2544-SAT | Risk Factors and Outcomes of Rejection in Liver Transplant Recipients with Autoimmune Liver Diseases: A Comprehensive Analysis | Ahmad Yanis | Received |
2546-SAT | Worse tumor biology, and not tumor size, is associated with lower post-liver transplant survival in recipients with hepatocellular carcinoma | Behnam Saberi | Received |
2547-SAT | Relapse of alcohol use in liver transplant recipients before and during the COVID-19 pandemic. | Abla Alj | Received |
2548-SAT | The Difference in Liver Transplant Outcomes between Normothermic and Hypothermic Machine Perfused Livers | Ahmad Anouti | Received |
2549-SAT | Predicting Liver Graft Discard Criteria: A Machine Learning Approach to Key Donor Characteristics | Ahmad Anouti | Received |
2551-SAT | The Impact of Machine Perfusion on Transplanted Liver Grafts with Macro-Steatosis | Ahmad Anouti | Received |
2552-SAT | The Role of Smoking in Post-Transplant Cancer Development: Insights from a Two-Decade Cohort Study | Carmen Alonso Martín | Received |
2553-SAT | The Risks Associated with Thymoglobulin Use in Patients with Liver Transplant Rejection: A National Database Analysis | Jordan Carty | Received |
2554-SAT | A SYSTEMATIC REVIEW OF TREATMENT AND OUTCOMES FOR LATE CELLULAR REJECTION, CHRONIC DUCTOPENIC REJECTION, AND ANTIBODY MEDIATED REJECTION AFTER LIVER TRANSPLANTATION | Yianni Protopapadakis | Received |
2557-SAT | Impact of Post-Transplant Body Mass Index Trajectory on Liver Transplant Outcomes | Roy Wang | Received |
2558-SAT | Comparative Analysis of Liver Biopsy Complications across the United States: A Propensity Matched Study of Patients with Normal and Reduced Platelet Counts Using Inpatient Data | Raj Patel | Received |
2559-SAT | Hepatocellular carcinoma recurrence after liver transplant: an Australian single-centre study | Matthew Garas | Received |
2560-SAT | MRI-serum based score accurately identifies liver transplant patients without rejection avoiding need for liver biopsy: a multisite European study | Jelte Schaapman | Received |
2561-SAT | Acupuncture in the pre and post liver transplantation setting is safe, well accepted and improves quality of life. | Giada Pietrosi | Received |
2562-SAT | Research Trends in Liver Transplantation for Hepatocellular Carcinoma and Related Tumors: A Comprehensive Bibliometric Review (2000-2022) | Mohammad AbuAssi | Received |
2563-SAT | Tenofovir Alafenamide Monotherapy Is Effective in Suppressing Hepatitis B Virus After Liver Transplantation | Ying-hong Shi | Received |
2564-SAT | Coronary Artery Disease Liver Transplantation (CAD-LT) score can accurately identify patients requiring invasive Coronary Angiography | Nandhakumar Rajadurai | Received |
2566-SAT | Social Determinants of Health Measured by SDI and ADI do not Impact Liver Transplant Outcomes | Hiba Khan | Received |
2567-SAT | Human versus artificial intelligence: Head-to-head comparison of predictive performance of MELD 3.0 and latest machine learning models | Vivek Charu | Received |
2568-SAT | LONG-TERM OUTCOMES OF PATIENTS TRASPLANTED FOR ACUTE LIVER FAILURE IN THE UNITED STATES: AN ANALYSIS OF THE UNOS DATABASE | Ana Marenco-Flores | Received |
2569-SAT | Outcome of utilizing MELD 3.0 from a Canadian perspective: a retrospective study in a single tertiary-care transplant centre | Crystal Liu | Received |
2570-SAT | Liver transplant immunosuppression education in the US: a survey of transplant hepatology fellowship program directors | Jinxuan Hao | Received |
2571-SAT | Albumin Infusions can Lead to Clinically Significant Changes in MELD 3.0 scores for Patients Waitlisted for Liver Transplantation | Priyata Dutta | Received |
2572-SAT | The Patient And Kidney Graft Outcomes of Safety Net Kidney Transplants Are Similar to Kidney Transplant Recipients Without A Previous Liver Transplant: A Retrospective UNOS database Analysis | Mohanad Awadalla | Received |
2573-SAT | Post-liver transplantation renal dysfunction primarily driven by older age and MELD at listing rather than liver disease etiology type | Niki Wadhwa | Received |
2574-SAT | Post-Transplant Predictors and Outcomes of Persistent Cholestasis after Liver Transplantation | Aaroh Patel | Received |
2575-SAT | Liver Transplantation for Short Telomere Syndrome: outcomes, and detailed histopathologic evaluation of explants. | Ashwin Akki | Received |
2577-SAT | Psychological Burden of the Liver Transplant Process | Christina Tsai | Received |
2578-SAT | Human Immune Organoids to Model Liver Transplant Rejection | Elsa Solà | Received |
2579-SAT | Palliative Medicine Utilization for Older Adults with End-Stage Liver Disease Referred for Liver Transplantation | Gavisha Waidyaratne | Received |
2580-SAT | Improved Self-Efficacy in Post-Liver Transplant Patients in Management of Post-Transplant Metabolic Syndrome Through Behavioral Resources and Intervention Through Digital Group Education (BRIDGE): A Share Medical Appointment Program | Asal Bastani | Received |
2581-SAT | Post liver transplant resource utilization in early versus standard liver transplant in alcohol associated liver disease. | Nehna Abdul Majeed | Received |
2582-SAT | Survival Outcomes for Living versus Deceased Donor Liver Transplantation for PSC: A 2 decade multicenter experience | Omar Mousa | Received |
2583-SAT | Liver Transplantation for Wilson disease: A Spectrum from Acute Liver Failure to Neuro-Wilson | Saad Alghamdi | Received |
2584-SAT | Metabolic Dysfunction-Associated Steatohepatitis Emerges as the Leading Cause for Adult Liver Transplantation in Saudi Arabia: A single-center study | Saleh Alqahtani | Received |
2585-SAT | Features of a very long-term survival after liver transplantation in Italy: a preliminary single center experience | Maria Donato | Received |
2586-SAT | Neurocognitive impairment in liver transplant (LT) recipients: comprehensive cognitive evaluation | Kacey Berry | Received |
2587-SAT | Impact of Early mTOR Inhibitor Immunosuppressive Therapy following Liver Transplantation: Enhancement of Glomerular Filtration Rate | Sidart Pradeep | Received |
2589-SAT | EXTENDED CRITERIA DONORS IN DONATION AFTER CIRCULATORY DEATH: CAN ABDOMINAL NORMOTHERMIC REGIONAL PERFUSION SAFELY EXPAND THE DECEASED DONOR POOL? | Philippe Paci | Received |
2591-SAT | Geographic distribution of US donor recovery facilities in relationship to liver transplant centers: Should we rethink the origin of donor allocation? | Anji Wall | Received |
2593-SAT | AH and MetALD have higher overall survival after liver transplantation for SLD compared to ALD and MASLD | Smruti Rath | Received |
2594-SAT | Pre-Transplant Oral Midodrine Exposure Does Not Affect Mortality Among Liver Transplant Recipients | Sudharshan Achalu | Received |
2597-SAT | The safety and tolerability of QEL-001, an autologous Chimeric Antigen Receptor (CAR) T regulatory (Treg) cell therapy, in liver transplantation - A safety cohort in the LIBERATE study | Alberto Sanchez-Fueyo, | Received |
2601-SAT | Is Pre-Liver Transplant Cannabis Use Actually Risky? Association with Survival, Rejection, and Fungal Infections | Sudha Kodali | Received |
2602-SAT | One-third of liver donors for recipients of severe alcoholic hepatitis experience psychological distress. | Chinmay Hegde | Received |
2606-SAT | Pediatric liver transplant trends and outcomes in 2011-2023: A single-center study | Saleh Alqahtani | Received |
2607-SAT | Longer Cold Ischemia Time Predicts Increased Transfusion Requirements During Liver Transplantation | Maham Ghani | Received |
2608-SAT | Worse Metabolic Outcomes in Black Females Who Receive a Liver Transplantation | Hiba Khan | Received |
2609-SAT | Impact of Sarcopenia, Frailty, and Muscle Fat Infiltration on Mortality in Patients Undergoing Liver Transplant Evaluation | Maham Ghani | Received |
2610-SAT | The Impact of Acute Pancreatitis in Patients with Liver Failure in a Single Tertiary ICU | Terra Pearson | Received |
2611-SAT | Lipoprotein-Insulin Resistance (LP-IR) Score Predict Future Risk of Atherogenic Events in Liver Transplant Recipients: A Prospective Study | Madison Nguyen | Received |
2612-SAT | Assessing the Prognostic Impact of Acute-on-Chronic Liver Failure Severity on Post-Liver Transplant Outcomes | David Lee | Received |
2613-SAT | The Prognostic Relationship Between Varying Degrees of Acute-on-Chronic Liver Failure on the Post-Transplant Prognosis of Patients with Autoimmune Liver Diseases Undergoing Liver Transplantation | David Lee | Received |
2614-SAT | Mental Health Needs Of Patients Seeking Support Through Transplant Receipients´ International Organization (TRIO) | Lorrinda Gray-Davis | Received |
2615-SAT | The Prognostic Correlation Between Pre-Liver Transplant Acute-on-Chronic Liver Failure and Post-Transplant Outcomes Among Patients with Hepatitis C | David Lee | Received |
2616-SAT | SURVIVAL OUTCOMES OF PATIENTS WITH AUTOIMMUNE LIVER DISEASE AND ACUTE-ON-CHRONIC LIVER FAILURE AWAITING LIVER TRANSPLANT: A 20-YEAR PERSPECTIVE | Romelia Barba | Received |
2617-SAT | Racial and Ethnic Disparities in Post-Liver Transplant Outcomes for Patients with Acute-on-Chronic Liver Failure: An Analysis of the UNOS Database | David Lee | Received |
2618-SAT | The Effects of Recipient Body Mass Index on the Prognostic Outcomes of Patients with Acute-on-Chronic Liver Failure Undergoing Liver Transplantation | David Lee | Received |
2619-SAT | Association of Cirrhotic Cardiomyopathy and its Echocardiographic Markers with Intraoperative and Perioperative Cardiac Outcomes in Two Large Liver Transplant Centers | Alex Liu | Received |
2620-SAT | Value of Educational Components of a Peer-to-Peer Mentoring Program: A Transplant Recipients´ International Organization (TRIO) Study | Lorrinda Gray-Davis | Received |
2621-SAT | The Impact of Functional Status on the Post-Transplant Outcomes of Patients with Acute-On-Chronic Liver Failure Undergoing Liver Transplantation | David Lee | Received |
2622-SAT | Determinants of Caregiving Burden; Interim Results from the Multi-Center LivCog Cohort Study | Marina Serper | Received |
2627-SAT | Neoadjuvant Immunotherapy in Patients Undergoing Liver Transplantation for Primary Liver Cancer at a Single Center | Sudha Kodali | Received |
2628-SAT | Effects of a structured, modified Mediterranean dietary intervention after liver transplantation (MEDDIET): Interim analysis of a randomized, controlled trial | Mohammad Qasim Khan | Received |
2630-SAT | Pre-Transplant Phosphatidylethanol Levels are Predictive of Post-Transplant Relapse Risk in Short-Term Abstainers: A Single-Center Study | Ethan Berman | Received |
2631-SAT | A Path to Better Patient Selection: A Risk Score to Predict Post-Transplant Survival Among Patients with Hepatocellular Carcinoma | Kali Zhou | Received |
2632-SAT | Evaluating the prognostic value of Right Ventricular dilation in Liver Transplantation | Chathur Acharya | Received |
2636-SAT | Frailty and Sarcopenia predict peri-operative outcomes in patients undergoing liver transplantation: Analysis of National Inpatient Sample 2016-2020. | Aalam Sohal | Received |
2637-SAT | Advancing Diagnosis, Management, Treatment, and Transplantation of Liver Disease in Telomere Biology Disorders: Publication and Dissemination of Guidelines | Heidi Carson | Received |
3001-SUN | Evolving Trends and Outcomes for Alcohol-Associated Hepatitis Patients with severely High MELD Scores on the US Liver Transplant Waitlist | Tomohiro Tanaka | Received |
3002-SUN | In-hospital Outcomes for Acute Alcohol Associated Cirrhosis and Major Cardiac Arrhythmias | Anwar Uddin | Received |
3003-SUN | Mortality From Alcohol-associated Liver Disease and Alcohol Use Disorder is Decreasing Globally yet Increasing in the United States | Pojsakorn Danpanichkul | Received |
3004-SUN | Vitamin D deficiency exacerbates alcohol-associated liver disease via gut barrier dysfunction and hepatic overload of endotoxin in mice | KOSUKE KAJI | Received |
3006-SUN | Administration of polyethylene glycol ameliorates inflammation of liver and gut, and hangovers against acute alcohol consumption | Tom Ryu | Received |
3007-SUN | Cognitive Interviewing of Experts and Patients to Develop an Alcohol Insight Scale for Patients with Alcohol-Associated Liver Disease | Victoria Gill | Received |
3008-SUN | ATP-Binding Pocket Inhibitor for Mixed Lineage Kinase Domain-like Protein (MLKL) Attenuated Alcoholic Liver Disease via Necroptosis-independent Pathway | Dae Won Jun | Received |
3009-SUN | Comprehensive profiling of infiltrated circulating immune cell types and their subset responsible for alcoholic steatohepatitis by scRNAseq analysis | Dae Won Jun | Received |
3011-SUN | Trends in Hospitalizations for Alcohol Related Hepatitis in the Pre-COVID, COVID, and Post-COVID Era: A National Database Study | Regis Lee | Received |
3012-SUN | Impacts of smoking on alcoholic liver disease: A nationwide cohort study | Jeong-Ju Yoo | Received |
3013-SUN | Prevalence and impact of cardiometabolic risk factors in alcohol-related liver disease and MetALD | Wesley Dixon | Received |
3015-SUN | Targeted Breath Biopsy profiling of induced biomarkers unveils a metabolic adaptation in cirrhosis toward alcohol production | Giuseppe Ferrandino | Received |
3016-SUN | The impact of integrated care on clinical outcomes in patients with alcohol-associated liver disease: early outcomes from a multidisciplinary clinic. | Shreya Sengupta | Received |
3017-SUN | Autophagy deficiency induces the expression of interferon-stimulated genes in mouse livers | Shengmin Yan | Received |
3018-SUN | Sympathetic nervous system-beta 3 adrenergic receptor-mediated lipolysis in binge drinking-induced fatty liver disease | Lin Jia | Received |
3019-SUN | Beer Consumption is Associated with Low Dietary Quality Among Alcohol Users | Madeline Novack | Received |
3020-SUN | Cardiolipin Treatment in hepatocyte specific Ptpmt1-/- mice is Hepatoprotective in an Animal Model of Alcohol-associated Hepatitis | Josiah Hardesty | Received |
3021-SUN | Patients Receiving Liver Transplantation for Acute on Chronic Liver Failure and Known Alcohol Related Liver Disease have Equivalent Relapse Risk Compared to those Transplanted for First Presentation of Severe Alcohol Related Hepatitis | Stephanie Zanowski | Received |
3022-SUN | Effect of diabetes on mortality and liver transplantation in alcoholic liver cirrhotic patients with acute decompensation | Sung-Eun Kim | Received |
3023-SUN | Body mass index influences liver-related mortality after the first decompensation event in patients with alcohol-related liver disease | Noriyo Yamashiki | Received |
3024-SUN | POTENTIAL USE OF iPSC-DERIVED HEPATOCYTE-LIKE CELLS TO DEVELOP PRECISION MEDICINE FOR ASH | Samantha Hoey | Received |
3025-SUN | The role of C/EBPβ-SAA1/2 axis in alcohol-associated liver disease resolution. | Irina Tikhanovich | Received |
3026-SUN | Prevalence of Infection in Alcohol-Associated Hepatitis and Impact on Mortality | Regis Lee | Received |
3027-SUN | Clinical impact of harm reduction in patients with chronic liver disease and alcohol use disorder by brief intervention in a hepatology outpatient unit | Nagisa Hara | Received |
3028-SUN | Cardiometabolic Comorbidities are Associated with Lower Rates of Recompensation and Transplant Free Survival in Patients with Acute Alcohol Associated Liver Disease | Kelly Torosian | Received |
3029-SUN | Early pharmacologic treatment of alcohol use disorder and psychiatry consultation are associated with improved overall survival in severe alcohol-associated hepatitis | Claire Durkin | Received |
3030-SUN | TREATMENT OF ALCOHOL USE DISORDER WITH MEDICATIONS AND WITH INTEGRATED CARE MODEL BENEFIT PATIENTS WITH ALCOHOL-ASSOCIATED LIVER DISEASE | Prabha Bhandari | Received |
3031-SUN | Survival benefit from corticosteroids in severe alcohol-associated hepatitis attributed to clinical and treatment differences in a large multicenter cohort | Claire Durkin | Received |
3032-SUN | Prognostic significance of skeletal muscle mass in patients with alcoholic cirrhosis | Tadashi Namisaki | Received |
3033-SUN | Screening of compensated alcohol-related liver disease: efficacy of a holistic approach (hepatology visit, brief intervention, and non-invasive test) on alcohol abstinence and relapses | Ares Villagrasa | Received |
3034-SUN | Obesity and acute alcohol-associated hepatitis: adding insult to injury | Yun-Cheng Hsieh | Received |
3036-SUN | Influence of the COVID-19 pandemic and alcohol on hospitalizations for decompensated liver disease | Erika Dorff | Received |
3038-SUN | Incidence and Predictors of Long-Term Risks of Cirrhosis Among Veterans with Alcohol-Associated Liver Disease | Robert Wong | Received |
3040-SUN | A Balancing Act: The Life-Saving Potential and Dilemma of Liver Transplantation as an Endpoint in Alcohol-Associated Hepatitis Trials | Aparna Goel | Received |
3041-SUN | Combination of high-fat diet with chronic ethanol consumption in mice results in early-stage alcohol-associated liver disease. | Marta Szydlowska | Received |
3042-SUN | A NOVEL ROLE OF STARD10 IN ERBB2-MEDIATED LIPOGENESIS IN ALCOHOL-ASSOCIATED LIVER DISEASE | Manisha Dagar | Received |
3043-SUN | A NOVEL ROLE OF PHOSPHORYLATED UBIQUITIN CONJUGATING ENZYME 9 ON LIPOGENESIS IN ALCOHOL-ASSOCIATED LIVER DISEASE | Swati Chandla | Received |
3045-SUN | Trends in Alcohol-Associated Hepatitis Among U.S. Veterans: Exploring Alternative Definitions Beyond Solely Using ICD-9/10 Codes to Improve Accurate Estimates of Disease Burden | Zeyuan Yang | Received |
3046-SUN | UBC9 PHOSPHORYLATION REGULATES CYTOKINE SECRETORY SIGNALING IN ALCOHOLIC ASSOCIATED LIVER DISEASE | Youngyi Lim | Received |
3047-SUN | Engagement with addiction medicine post-liver transplant increases treatment for alcohol use disorder | Mounica Konjeti | Received |
3048-SUN | The Histologic Features of Severe Alcohol-Associated Hepatitis Undergoing Liver Transplantation: An Explant Study | Chad Spencer | Received |
3052-SUN | Naltrexone Use in Patients with Combined Metabolic and Alcohol-associated Liver Disease (MetALD), Propensity Score Matched Study | Amir Hossein Gougol | Received |
3053-SUN | Predictors of survival and hepatic recompensation in patients with ALD referred for early liver transplantation | Nicholas Lim | Received |
3054-SUN | Brewing Bias: Alcohol biomarker testing trends for patients on the liver transplantation waitlist | Hamza Sadhra | Received |
3055-SUN | Using a human liver-on-a-chip model to study alcohol-associated liver disease by targeting LSECs and ALDH2 | Takashi Tsuchiya | Received |
3056-SUN | Population Based Screening For Alcohol Associated Liver Disease Using the Electronic Health Record | Kristina Folta | Received |
3057-SUN | Cirrhosis is Associated With Worse Outcomes in Hospitalizations for Alcohol Withdrawal | Yasmin Ali | Received |
3058-SUN | SUBCUTANEOUS INJECTION OF GALANIN ATTENUATES ALCOHOLIC HEPATITIS AND ABDOMINAL ADIPOSE TISSUE INFLAMMATION INDUCED BY ETHANOL BINGE IN OB/OB MICE | Yuanwen Chen | Received |
3059-SUN | Statin therapy may protect against variceal bleeding in patients with alcohol-associated liver disease | Nariman Hossein-Javaheri | Received |
3060-SUN | Real-world Evidence of Emerging Health Disparities in Severe Alcoholic Hepatitis Incidence in the Post-COVID Era | Jiangqiong Li | Received |
3061-SUN | What is the correlation between AUDIT score and phosphatidylethanol level both taken on admission to a tertiary liver unit? A cirrhosis registry studySkladany L1,2, Ciefova J1, Adamcova Selcanova S1, Zilincanova D1, Havaj D1, Sulejová KK1, Gazda J2 | Lubomir Skladaný | Received |
3062-SUN | Short-term Costs of Alcohol-associated Hepatitis Care in Different Clinical Settings | Chi Mai Nguyen | Received |
3063-SUN | Impact of Steroids and Infection on Mortality in Alcohol-related Hepatitis | Joseph Alukal | Received |
3066-SUN | Gene isoform transcript usage is associated with higher alcohol-associated hepatitis susceptibility in females than males | Alastair Kilpatrick | Received |
3067-SUN | Prognostic Utility of Systemic Inflammatory Response Syndrome Criteria in Acute Alcoholic Hepatitis | Joseph Spengler | Received |
3071-SUN | Cholesterol toxicity and PON-1 levels in alcohol-associated hepatitis correlate with severity and survival | Praveena Narayanan | Received |
3073-SUN | Longitudinal Outcomes And Recovery In Patients With Decompensated Alcohol Associated Liver Disease | Weiyu Wu | Received |
3074-SUN | Biased agonism of FPR1 signaling in neutrophils mitigates alcohol-associated liver disease | Yong He | Received |
3075-SUN | Alcohol binge drinking impairs lipid metabolism in healthy hamsters and aggravates liver lesions in diet-induced obese MASH hamsters | Francois Briand | Received |
3076-SUN | Deciphering the impact of myeloid cell-derived osteopontin in alcohol-associated liver disease | Nithyananthan Subramaniyam | Received |
3079-SUN | The Impact of Type 2 Diabetes (T2D) on the Outcomes of Liver Transplantation (LT) Among Patients with Alcohol-associated Liver Disease (ALD) In the United States | Maria Stepanova | Received |
3080-SUN | Prior Diagnosis of Decompensated Alcohol-Associated Liver Disease Does Not Increase Risk of Alcohol Relapse During Transplant Evaluation and May Increase Risk of Post-Transplant Alcohol Relaps | Sasha Deutsch-Link | Received |
3085-SUN | Non-enzymatic Targeting of Metabolic-Alcohol-Associated Liver Disease and Cancer associated with ALDH2 deficiency and altered TGF-beta Signaling | Xiaochun Yang | Received |
3086-SUN | Formoterol promotes mitochondrial biogenesis and decreases liver injury after chronic-binge ethanol (CBE) treatment in mice | Devadoss Samuvel | Received |
3087-SUN | Post-liver transplant PETH monitoring: Potential as an early Biomarker for Rejection and Graft Failure | Muhammad Ali Butt | Received |
3091-SUN | Plasma cell-free mtDNA is released in alcohol-related liver disease and correlates with liver injury | MARAM ALENZI | Received |
3092-SUN | Sex differences in characteristics and outcomes of Veterans with alcohol-associated hepatitis | Anahita Rabiee | Received |
3094-SUN | Identification of Alcohol-associated Hepatitis Using Electronic Medical Records | Rachel Thompson | Received |
3095-SUN | GLP-1 RECEPTOR AGONISM REDUCES INJURY, HEPATIC CYP2E1 ACTIVITY AND INCREASES ANTIOXIDANT ACTIVITY IN A MOUSE MODEL OF ALCOHOL-INDUCED ACUTE HEPATITIS | frhaan zahrawi | Received |
3096-SUN | Prevalence, Risk Factors, and Outcomes of Fungal Infections in Patients with Severe Alcohol-Associated Hepatitis | Filippa Trikantzopoulou | Received |
3098-SUN | Impact of Social Determinants of Health on Transplant Candidacy for Alcohol-Associated Liver Disease | Avni Malik | Received |
3100-SUN | Alcohol Use Disorder Treatment During Evaluation in Patients with ALD Referred for Early Liver Transplant | Kevin Wang | Received |
3101-SUN | Demographic Disparities in The Outcomes of Patients Admitted with Alcohol-Associated Hepatitis: A Cross-Sectional Study | Nehna Abdul Majeed | Received |
3102-SUN | Development of Alcohol-associated Liver Disease in Young Indian Adults: An Observational Study of Clinical and Socio-Demographic Correlates and opportunities for early intervention | Mohit Varshney | Received |
3103-SUN | Impact of COVID-19 on Alcoholic-Related Hepatitis Admissions at a Midwest Tertiary Care Hospital | Padmavathi Mali | Received |
3104-SUN | Cardiometabolic Comorbidities Influence Early Mortality in Patients with Alcohol-associated Hepatitis (AH) | Christina Tran | Received |
3105-SUN | Initiation of naltrexone is associated with lower rates of SBP and mortality than acamprosate in patients with decompensated alcohol-associated cirrhosis | Vinay Jahagirdar | Received |
3106-SUN | Performance of urine rapid Ethyl glucuronide testing to characterize recent and unhealthy alcohol use at HIV clinics in Zambia | Michael Vinikoor | Received |
3107-SUN | Therapeutic inhibition of Bruton´s tyrosine kinase (BTK) acts on both immune cells and hepatocytes to attenuate immune cell activation and steatosis in a mouse model of alcohol-associated hepatitis | Prashanth Thevkar Nagesh | Received |
3109-SUN | Single-cell RNA sequencing analysis reveals specific cell subpopulations in alcohol-associated hepatitis characterized by inflammatory, angiogenic and fibrogenic profile | Elisa Pose | Received |
3113-SUN | Liver-related Complications are Associated with Worse Outcomes in Patients with Severe Alcohol-Associated Hepatitis | Filippa Trikantzopoulou | Received |
3116-SUN | Impact of area-level income and residence on in-hospital mortality and intensive care unit admissions among patients with cirrhosis and alcohol-related hepatitis hospitalizations: A population-based study. | Liam Swain | Received |
3117-SUN | The effect of area-level material and social deprivation on cirrhosis and alcohol-related hepatitis hospitalization rates during the COVID-19 pandemic: A population-based study. | Liam Swain | Received |
3118-SUN | Engineered Human Liver Co-cultures to Model Hepatic Dysfunctions in MetALD | Owen Lally | Received |
3119-SUN | Impact of Pre-Transplant Steroid Therapy on Early Post-Transplant Infections in Alcohol-Associated Hepatitis Patients Undergoing Liver Transplantation | Alex Chang | Received |
3120-SUN | Rising Trends of Concurrent Mood Disorders in Hospitalized Patients with Alcohol-Associated Liver Disease Between 2014 and 2023: A Nationwide Study of Insured and Uninsured Populations | Emily Shu-Yen Chan | Received |
3121-SUN | Post-Transplantation Outcomes in Alcohol-Related Liver Disease: Higher Relapse Rates Associated with Alcohol-Associated Hepatitis | Alex Chang | Received |
3123-SUN | Risk Reduction is Possible in Patients with High-Risk SIPAT Scores Undergoing Liver Transplantation for Alcohol-Related Liver Disease | Alex Chang | Received |
3124-SUN | Trends in Post-Discharge Pharmacological Alcohol Cessation Therapy and Psychiatric Referrals for Hospitalized Patients with Alcohol-Associated Liver Disease (ALD) Between 2014 to 2023: A Nationwide Study | Emily Shu-Yen Chan | Received |
3130-SUN | Acute-on-Chronic Liver Failure (ACLF) criteria in Alcohol-associated Hepatitis: Implications for Liver Transplantation | Luis Antonio Diaz | Received |
3132-SUN | Inflammation during alcohol associated hepatitis is mediated by liver sinusoidal endothelial cell production of Galectin-9 and PD-L1 | Benjamin Swartzwelter | Received |
3133-SUN | Thirty-Day Readmissions Among Patients with Alcoholic Hepatitis, Risk factors, Impact on Mortality and Healthcare Resource Utilization: A Nationwide Analysis | Shahryar Khan | Received |
3134-SUN | Prevalence and outcome of Concomitant Hepatitis B or C infection in Alcohol associated Liver Disease | Akash Shukla | Received |
3137-SUN | Hepatic Methyltransferase Proteins Mediate PNPLA3-I148M-Driven Lipid Droplet Dynamics in Fatty Liver | Xinshou Ouyang | Received |
3138-SUN | Medications for AUD in Patients with Alcohol-associated Cirrhosis or Hepatitis: No hepatotoxicity, but side-effect risks and decompensation | Gene Im | Received |
3140-SUN | Drinking Behavior in the AHFIRM trial as measured by Phosphatidyl Ethanol | Steven Flamm | Received |
3145-SUN | The Development, Feasibility, and Usability of an Artificial Intelligence-Enabled Conversational Agent in Virtual Reality for Patients with Alcohol-Associated Cirrhosis | Yee Hui Yeo | Received |
3146-SUN | Sociodemographic disparities in access to liver transplantation waitlist in patients with Alcohol associated liver diseases: A single center study. | Islam Mohamed | Received |
3148-SUN | Abstinence triggers site-specific metabolomic changes in the resolution of Alcohol-related Liver Disease | NUPUR SHARMA | Received |
3149-SUN | The Clinical Significance of Homelessness on the Hospital Outcomes of Patients Admitted with Alcohol-associated Liver Disease | David Lee | Received |
3150-SUN | National Trends in the Costs of Patients Admitted with Alcohol-associated Liver Disease Stratified by Patient Demographics: Analysis of National Hospital Database | David Lee | Received |
3151-SUN | National trends in the Costs of Patients admitted with Alcohol Associated Liver Disease Stratified by Psychiatric Comorbidities and Substance Use: Analysis of National Hospital Database | David Lee | Received |
3152-SUN | Identifying Risk Factors for Return to Alcohol Use in Post-Liver Transplant: The Role of Sobriety Duration and Age | Natalia Rodriguez-Payan | Received |
3153-SUN | Integrated hepatology and addiction care for hospitalized patients with alcohol use disorder improves medical alcohol therapy engagament at discharge | Jay Luther | Received |
3155-SUN | Hepatocyte-specific deletion of betaine homocysteine methyltransferase promotes age-dependent progression of liver disease | Poonam Sagar | Received |
3156-SUN | Exploring the interplay of graded alcohol use and excess weight on atherogenic lipid profiles among Latinos with underlying chronic liver disease | Shyam Patel | Received |
3157-SUN | Differences in Alcohol Use Disorder Treatment and Return to Drinking According to Severity of Alcohol-Associated Hepatitis | Kamalpreet Hara | Received |
3161-SUN | Hepatocyte-specific deletion of betaine homocysteine methyltransferase promotes alcohol-induced liver injury | Ramachandran Rajamanickam | Received |
3162-SUN | Psychiatric Comorbidities and Risk of Return to Drinking Amongst Liver Transplant Recipients | Sienna Li | Received |
3165-SUN | LIVER TRANSPLANTATION IN ALCOHOLIC HEPATITIS AND ACLF: REDEFINING SELECTION AND SOBRIETY CRITERIA | Parvez Mantry | Received |
3166-SUN | Alcohol intervention after acute variceal bleeding: reduces alcohol consumption, but remains underutilized in real-world setting | YU JUN WONG | Received |
3167-SUN | SGLT2 Inhibitors Suppressed the Onset of Esophageal Varices and Extrahepatic Cancer Compared to DPP4 Inhibitors in Type 2 Diabetic Patients with MASLD: A Nationwide Medical Claims Database Study in Japan | Takumi Kawaguchi | Received |
3168-SUN | Identification of Candidates for MASLD Treatment with Indeterminate Vibration-Controlled Transient Elastography | David Marti-Aguado | Received |
3169-SUN | Effects of Luseogliflozin on MASLD in Patients with Type 2 Diabetes Mellitus: A Pooled Meta-analysis of Phase III Clinical Trials | Takumi Kawaguchi | Received |
3170-SUN | Changing Prescription Pattern of Anti-diabetic Medications and Improvement in Glycemic Control in Patients with T2DM, with and without Cirrhosis: a territory-wide cohort study in Hong Kong from 2000-2023 | Mary Yue Wang | Received |
3171-SUN | Evaluation of MASH drug efficacy using liver organoids based on drug target pathways | Yeonjoo An | Received |
3172-SUN | Long-term outcomes of GLP-1 analogues treatment in MASLD patients with type 2 diabetes | Takamasa Ohki | Received |
3174-SUN | The association between levothyroxine and its potential preventative effect on liver conditions, particularly in MASLD and MASH | Joel Joy | Received |
3175-SUN | Effects of Saroglitazar in Compensated MASLD Cirrhosis: A Magnetic Resonance Elastography-Based (MRE) Based Single Arm Prospective Study | Akash Roy | Received |
3176-SUN | Real-world Assessment of Glucagon-like Peptide 1 Receptor Agonist (GLP-1RA) in the Management of Patients with MASLD with Different Stages of Liver Fibrosis | Dalton Caviness | Received |
3177-SUN | A real-world evidence, phase 4, multicenter, open-label, single-arm study to evaluate the safety and efficacy of saroglitazar 4 mg in patients with non-alcoholic fatty liver disease with obesity, type 2 diabetes mellitus, dyslipidemia, or metabolic syndro | Deven Parmar | Received |
3178-SUN | The 5-Year Mortality Rate in MASLD Patients Undergoing Pharmacologic versus Bariatric Interventions | Leith Ghani | Received |
3179-SUN | A Phase I trial to determine lowest effective dose of betaine for improvement of ALT in metabolic dysfunction-associated steatotic liver disease | Andrew Lim | Received |
3180-SUN | Patterns of Practice for Screening and Management of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD). Report of a Global Survey. | Aysha Aslam | Received |
3181-SUN | Comparing Major Adverse Cardiovascular Event (MACE) incidence in MASLD patients undergoing pharmacologic versus bariatric interventions | Qumber Ali | Received |
3184-SUN | Validating pre-identified morphological baseline features for predicting fibrosis progression in MAESTRO-NASH | Jörn Schattenberg | Received |
3185-SUN | Resmetirom protects against diet-induced MASLD and reduces atherosclerosis development in obese Ldlr-/-.Leiden mice | Eveline Gart | Received |
3186-SUN | Accurate prediction of liver fat reductions across range of weight loss by quantitative systems pharmacology modeling | Scott Siler | Received |
3189-SUN | Pemafibrate improves liver function with alteration of bile acid composition in patients with steatotic liver disease | Kota Tsuruya | Received |
3191-SUN | Differential class effects of oral anti-diabetic drugs on cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease | Heejoon Jang | Received |
3192-SUN | Comparison of Bariatric Surgery vs. GLP-1 Receptor Agonists on Cardiovascular Outcomes and Mortality in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease, Diabetes, and Obesity: A Large Population-Based Cohort Study | Arunkumar Krishnan | Received |
3193-SUN | Saroglitazar is more effective than simvastatin in reducing steatosis in patients with Met-ALD. | Anand Kulkarni | Received |
3198-SUN | Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis | EN YING TAN | Received |
3200-SUN | CVI-2742, a novel THR-beta selective agonist, exhibits enhanced liver-targeting properties in non-human primates and potent anti-NASH activity in mouse NASH model | Jingwen Liu | Received |
3201-SUN | SkQ1, a mitochondria-targeted ferroptosis inhibitor, demonstrates efficacy against steatosis, ballooning and fibrosis in preclinical models of MASH | Anton Petrov | Received |
3203-SUN | DUAL SILENCING OF YAP1/WWTR1 AS A NOVEL THERAPEUTICAL APPROACH FOR LIVER FIBROSIS | Masayuki Sugimoto | Received |
3204-SUN | EFFICACY AND ADVERSE EVENTS OF RESMETIROM 80 MG IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): A SYSTEMATIC REVIEW AND META-ANALYSIS | Ankita Nekkanti | Received |
3207-SUN | Oral mannose supplementation dampens liver fibrosis in murine MASH model by reducing activated hepatic stellate cells | John Hong | Received |
3210-SUN | A small molecule inhibitor of fibroblast activation protein (FAP) blocks enzymatic activity and improves liver histopathology in cynomolgus monkeys with MASH and F1/F2 fibrosis | Xiao-Rong Peng | Received |
3211-SUN | TGF-β Signaling Targeting Peptide BTI615 Attenuated Liver Fibrosis by Modulating Fibrotic Niche in CCl4-induced Mouse-model | Qiu Jiang | Received |
3218-SUN | Evaluation of Efficacy of Berberine Ursodeoxycholate (HTD1801) Compared to Ongoing Use of GLP-1 Receptor Agonists in Patients with MASH and T2DM | Kjersti Swearingen | Received |
3219-SUN | Time Course of Onset, Incidence and Prevalence of Gastrointestinal Adverse Events with HTD1801 (Berberine Ursodeoxycholate) in Patients with MASH and T2DM | Kjersti Swearingen | Received |
3221-SUN | A Systematic Review on Resmetirom: Arresting MASH/MASLD Progression | Charmy Parikh | Received |
3222-SUN | Efficacy and Safety of Pegbelfermin in MASH Cirrhosis- A Meta-Analysis and Systematic Review of Randomized Controlled Trials | Muhammad Shahzil | Received |
3225-SUN | Sigma1 regulation of hepatic lipid metabolism in response to diet-induced obesity | Luis Martinez | Received |
3229-SUN | Real World Data Assessing the Impact of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease | Reeti Gulati | Received |
3233-SUN | MASH 2B TRIALS- A SYSTEMATIC REVIEW | Bipneet Singh | Received |
3234-SUN | Surge in incidence and prevalence of autoimmune hepatitis since the COVID-19 pandemic | Yuting Huang | Received |
3235-SUN | Quality Improvement for Vibration Controlled Transient Elastography Using a Novel Analysis Algorithm | Jeffrey Schwartz | Received |
3236-SUN | Timely post-discharge follow-up after a first diagnosis of cirrhosis is associated with reduced mortality and rehospitalization in a large national cohort | Max Schechter | Received |
3237-SUN | Patient Perceptions of Undergoing Routine Viral Hepatitis Screening and Receiving a Hepatitis C (HCV) Diagnosis While Incarcerated: A Qualitative Study | Harit Agroia | Received |
3238-SUN | Hope for the Best, Prepare for the Worst: Integrating Palliative Care with Liver Transplant Candidate Evaluation and Management | Jesslyn McMahon | Received |
3239-SUN | Rising Proportion of Hispanics and Women with Steatotic Liver Disease-related End-Stage Liver Disease and Hepatocellular Carcinoma Awaiting Liver Transplantation in the United States | Shyam Patel | Received |
3240-SUN | Poor Access to Anti-Obesity Medications in Metabolic Dysfunction-Associated Steatotic Liver Disease | Jane Giang | Received |
3241-SUN | Assessing transitions of care amongst inpatients with cirrhosis discharged from a diverse, urban liver transplant center: the importance of hepatology involvement and discharge destination | Max Schechter | Received |
3242-SUN | Early palliative care (PC) in end-stage liver disease (ESLD) patients significantly improves health-related quality of life (HRQoL) | Shirley Bong | Received |
3244-SUN | Activity Metrics Measured by Wearable Technology Correlates with Patient-Reported Wellbeing in Cirrhosis | Brian McSteen | Received |
3245-SUN | Psychometric Properties of a Novel Tool to Measure Goal Concordant Care (GCC) From Patients with End Stage Liver Disease, and their Caregivers. | Manisha Verma | Received |
3246-SUN | State-Level Variability and Disparities in Location of Death of Patients with End-Stage Liver Disease: A Retrospective Cross-Sectional Analysis | Julia Meguro | Received |
3247-SUN | Healthcare Contact Days Pre- and Post-Liver Transplant in Patients with Cirrhosis: A National Cohort Study | Gurmehr Brar | Received |
3248-SUN | A QUALITATIVE INQUIRY INTO THE EXPERIENCES OF PARTICIPANTS AND NURSES IN THE AUSTRALIAN LIVER FAILURE TRIAL | Jeyamani Ramachandran | Received |
3249-SUN | The perceived psychological benefits and harms of undergoing HCC screening among Cherokee Nation patients - a patient perspective | Nicole Kim | Received |
3250-SUN | Hepatology Clinician Perspectives on Addiction Stigma in the Care of Patients with Liver Disease and Addiction | Lamia Haque | Received |
3251-SUN | Patients with Non-alcoholic Fatty Liver Disease (NAFLD) and Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) have Similar Clinical, Non-invasive Tests (NITs) and Patient-Reported Outcomes (PROs) Profile | Zobair Younossi | Received |
3252-SUN | The long-term follow-up status of 3,643 patients achieving SVR after DAAs, managed by Specialists in hepatology; Nationwide survey | Masatsugu Ohara | Received |
3253-SUN | The Quality of Care Provided to Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease in the Department of Veterans Affairs | Kaitlyn Carlson | Received |
3254-SUN | Racial Differences in Perception of Healthcare Experiences Among Patients with Alcohol-Associated Liver Diseases: A Cross-Section Analysis of the All of Us Database | Nicole Ng | Received |
3255-SUN | Socioeconomic Factors Impact the Perception of Care in Patients with Cirrhosis: Findings from the All of Us Database | Nicole Ng | Received |
3256-SUN | Effectiveness of polyene phosphatidylcholinein improving liver function for patients with non-hepatitis B chronic liver disease: a real-world study | Ning Lin | Received |
3257-SUN | Impact of distance from liver transplant centre on outcomes following liver transplantation - an Australian single centre study | Ken Liu | Received |
3258-SUN | Mortality improvement in cirrhotic and hepatocellular carcinoma patients with major discrepancies according to etiology: a 10-year nationwide study | Claire DELACOTE | Received |
3260-SUN | Exploring the Impact of Weekend Admission and Rurality on Outcomes and Practices in Hospitalized Patients with Decompensated Cirrhosis: A Nationwide Cross-Sectional Study | Ahamed Khalyfa | Received |
3261-SUN | Compensated Advanced Chronic Liver Disease Management in Primary Care: Good Quality With the Right Model | Alvin Lee | Received |
3262-SUN | The Effect of Implementation Intervention (Gilead FOCUS program) on Linkage to Hepatitis C Care Time at a Community Health Center in Deep South | Adelero Adebajo | Received |
3263-SUN | Bisphosphonate effectiveness in patients with cirrhosis: an emulated clinical trial | Beanna Martinez | Received |
3265-SUN | Annual Out-of-Pocket Medical Costs and Financial Burden Among Transplant Recipients in the United States | Gabrielle Jutras | Received |
3266-SUN | Treatment persistence and discontinuation among chronic hepatitis B patients initiating antiviral treatment | Sarah Hague | Received |
3267-SUN | Early detection of liver fibrosis in patients with alcohol use disorder improves long-term abstinence | Amelia Orgill | Received |
3268-SUN | Liver Cancer Risk in Individuals Under 35 and PM2.5 Exposure: A Global Analysis of 179 Countries from 1990 to 2019, with Projections to 2035 | Wang Zixing | Received |
3269-SUN | Caregivers of Liver Transplantation Recipients Experience Significant Anxiety Pre-Transplant and Decreased Informational Support Post-Transplant | Meena Tadros | Received |
3270-SUN | Trends in Prescriber Characteristics of Oral Hepatitis B Medications in the United States | Xiaohan Ying | Received |
3271-SUN | Immunogenicity of SARS-CoV-2 Vaccine in Patients with Chronic Liver Disease | Asif Hitawala | Received |
3272-SUN | Creation of a New VA Transplant Center Increased Access and Reduced Wait Times for Liver Transplant | Jessica Davis | Received |
3273-SUN | The Supportive Needs Assessment tool in Cirrhosis is a feasible tool for Identifying Unmet Needs in a US academic cohort | Cristal Brown | Received |
3274-SUN | DIAGNOSIS OF HEPATITIS C IN BABY BOOMERS THROUGH AN AUTOMATIC NOTIFICATION IN THE GREEK PRESCRIPTION SYSTEM | Anthie Chatziioannou | Received |
3275-SUN | Technology Utilization and Health Literacy Assessment in Patients with Chronic Liver Disease (TULAP-CLD) | Zoe Post | Received |
3278-SUN | The Cost of DILI: Exploring How Drug Induced Liver Injury Burdens the U.S. Healthcare System | Danielle Zolotnitsky | Received |
3279-SUN | Symptom burden and management in patients with end stage liver disease versus pancreatic cancer: a comparative analysis. | Mary Bassaly | Received |
3280-SUN | Gender disparities in listing and transplantation in patients with ALD referred for early liver transplantation | Katherine Cooper | Received |
3282-SUN | Advanced care planning in advanced liver disease remains dismally low in Singapore: lessons learned from examining referrals amongst a cohort of hospitalized patients with cirrhosis. | Chanda Ho | Received |
3283-SUN | Liver transplantation (LT) is not commonly broached amongst a cohort of patients with decompensated liver disease in Singapore. | Chanda Ho | Received |
3285-SUN | Patient Voice in MASH Initiative: Foundational Principles for the Conduct of Patient-Centric MASH Research | Michael Betel | Received |
3286-SUN | Cost-effectiveness of expanding eligibility for antiviral prophylaxis to all HBsAg-positive pregnant women inaccessible to HBV DNA or HBeAg testing in China | Xueru Yin | Received |
3288-SUN | New diagnosis of cirrhosis is common in the Emergency Department and associated with higher healthcare utilization. | Swetha Parvataneni | Received |
3289-SUN | Medicare Part D Coverage Restrictions for Drugs Commonly Prescribed for Hepatitis B Treatment, 2019-2023 | Misha Gautam | Received |
3290-SUN | Medicare Part D Coverage Restrictions for Drugs Commonly Prescribed for Hepatitis C Treatment, 2019-2024 | Misha Gautam | Received |
3291-SUN | Increasing Readiness and Self-efficacy for Serious Illness Communication Engagement in Patients with ESLD | Cristal Brown | Received |
3292-SUN | The Indian Metabolic and Liver Disease (IMELD) study: Utilizing Epidemiology and Implementation Sciences to Stratify Population Risk for NAFLD | Kanica Kaushal | Received |
3293-SUN | The patient experience of a new ´referral´ pathway for liver disease in the Somerset Liver Improvement Project | Christina Owen | Received |
3294-SUN | Assessing Economic Burden Among Unique Patient Segments in an HDV-infected Population | Prajakta Bhounsule | Received |
3295-SUN | Utilizing Technology to Risk Stratify Patients with MASLD and Increase Rates of Identification of Clinically Significant Liver Fibrosis | Rachel Orbuch | Received |
3296-SUN | Comparative Analysis of Two Methods of FIB-4 Calculation in Primary Care to Identify Advanced Fibrosis in Patients with Diabetes: Implications for Adherence to the AASLD MASH Care Pathway | Anna Mageras | Received |
3297-SUN | Development of a sexual function assessment tool in men and women with liver disease and liver transplantation | Yooyun Chung | Received |
3298-SUN | Recommendations for Metabolic Dysfunction-Associated Steatohepatitis (MASH) Disease Management: A Modified Delphi Panel | Anna Watzker | Received |
3299-SUN | Achievements and Challenges of HCV mass screening granted by the Italian Ministry of Health dedicated funds | Loreta Kondili | Received |
3301-SUN | A Hepatitis C (HCV) Surveillance Systems Evaluation to Improve Understanding of Local HCV Disease Burden and Its Effects on Impacted Communities in Santa Clara County, California | Amelia Salmanson | Received |
3302-SUN | Caregiver Involvement and Characteristics are Associated with Patient Quality of Life: Baseline Analyses from the PAL LIVER Trial | Eric Orman | Received |
3304-SUN | Contraception counseling and pregnancy after liver transplantation: A single center experience | Juan Gonzalez | Received |
3305-SUN | The Self-Rating Scale Item Is a Valid Measure of Lactulose Adherence in Patients With Hepatic Encephalopathy | Stacey Tam | Received |
3306-SUN | The Hospital Frailty Risk Score Predicts Outcomes in Patients with Hepatic Fibrosis or Cirrhosis | Imran Qureshi | Received |
3307-SUN | Terlipressin Is Associated with Decreased Healthcare Resource Utilization Compared with Midodrine/Octreotide Among Patients with Hepatorenal Syndrome | Alexandra DeSousa | Received |
3308-SUN | Association Between Cirrhosis and Liver Injury and Toxic Metals Exposures | Nikia Smith | Received |
3309-SUN | The Otago Exercise Program Improves Liver Frailty in Pre-Transplant Candidates | Neil Shah | Received |
3311-SUN | Estimating local transmission dynamics of Hepatitis A virus increased incidence among men who have sex with men in New York City and California, 2016-2019 | Oluwatosin Jegede | Received |
3312-SUN | To achieve functional cure for chronic hepatitis B infection- new therapy vs expanding the existing therapy | George Lau | Received |
3313-SUN | Data Driven Clinical Trial Recruitment - From the Common to the Rare | Robert Miller | Received |
3314-SUN | Advance Care Planning Completion Rates and Perceptions Among Adults with End-Stage Liver Disease in a Population-Based Cohort | Arpan Patel | Received |
3315-SUN | Etiological transitions in patients with liver cirrhosis and hepatocellular carcinoma: a single-center study from an institution located in a district with a high prevalence of viral hepatitis | Hirayuki Enomoto | Received |
3317-SUN | Hepatic encephalopathy and acute kidney injury largely drive transfer of patients to higher centers of care: A National Analysis | Chathur Acharya | Received |
3318-SUN | A nationwide cross-sectional survey in viral hepatitis screening for Japanese workers and consultation behavior of positive patients for HCV antibody -13.7 million general checkup applicants | Masaaki Korenaga | Received |
3319-SUN | Exploring Campaign Preference Styles and Trusted Information Sources regarding Hepatitis B and Hepatocellular carcinoma among Adults in the Midwest: A Cross-Sectional Survey with Visual Aids | Erin Mann | Received |
3320-SUN | Premature Mortality for the Spectrum of Steatotic Liver Disease (SLD) in the US populations | James Paik | Received |
3321-SUN | Improvement in time to hepatitis C virus treatment in New Mexico state prisons, 2020-2023 | Juan Ceniceros | Received |
3322-SUN | Impact of Hospice Utilization in Acute Hospital Care of Patients Admitted with Decompensated Cirrhosis and Hepatocellular Carcinoma - A Systematic Review and Meta-Analysis. | Shahryar Khan | Received |
3323-SUN | National Hepatitis Profiles: A Global HBV Report | Jana Manning | Received |
3324-SUN | Evaluating the Role of Palliative Care in Hepatocellular Carcinoma Using the National Inpatient Sample: Cost Savings, Reduced Interventions, and Racial Disparities | Amir Sultan Seid | Received |
3326-SUN | PRISMA (Patient Resonance Intelligence Supporting Medical Analysis): An AI Algorithm in de-ciphering lifestyle factors effects on liver disease | Fatma Barakat | Received |
3327-SUN | Opioid Use after Adult Liver Transplantation: Predicting Incidence, High-Risk Use, and Opioid-Related Complications in a National Cohort | Olgert Bardhi | Received |
3328-SUN | Inadequate viral hepatitis immunization and testing amongst vulnerable patients in the ambulatory setting | Chip Bowman | Received |
3331-SUN | Prevalence of compensated Advanced Chronic Liver Disease (cACLD) in the United States: Insights from NHANES 2017-2020 | Ritik Mahaveer Goyal | Received |
3332-SUN | Assessing Liver Biopsy Methods: Comparing Adequacy and Safety. A Real-World Single-Center Experience | Divya Devabhaktuni | Received |
3333-SUN | Hepatitis Delta Testing and Positivity Rates are Increased in More Highly Resourced Communities in a Large, Urban Cohort: An Analysis of the INSIGHT PCORnet Database in New York City | Lauren Alpert | Received |
3336-SUN | National Hepatitis Profiles: A Global HCV Report | Jana Manning | Received |
3337-SUN | Missed Diagnosis of Ambulatory Community Acute Kidney Injury Is Common and Associated with Major Adverse Kidney Events in Patients With Cirrhosis | Kavish Patidar | Received |
3338-SUN | Advanced Liver Disease Coordinator Improves Hepatocellular and Variceal Surveillance Across a Diverse Veterans Affairs Healthcare Network | Melissa Kaltenbach | Received |
3339-SUN | Comparing Health Related-Quality of Life of Patients Between Compensated and Decompensated Cirrhosis - A Systematic Review and Meta-Analysis | Shahryar Khan | Received |
3340-SUN | Breaking Down Barriers: Investigating Trans Arterial Chemo Embolism (TACE) as a Palliative Measure for Unresectable HCC Along the US-Mexico Border | Swati Mahapatra | Received |
3341-SUN | Cost-Effectiveness of the HepQuant DuO Test for the Management of Patients at Risk for Large Esophageal Varices | Gregory Everson | Received |
3342-SUN | Expanding Access to Liver Transplantation: Effectiveness of a Single-Center Targeted Outreach Program | Sudha Kodali | Received |
3345-SUN | Liver Frailty Index, Not Six-Minute Walk Distance, is Associated with Liver Transplant Waitlist Dropout | Tania Larsen | Received |
3346-SUN | Unveiling Changes in Racial, Ethnic, and Socioeconomic Disparities in Access to Critical Interventions for Hospitalized Patients with Cirrhosis And Portal Hypertension Complications in the U.S. in 2021 | Miriam Sanchez | Received |
3347-SUN | Refining Medication Reconciliation in Liver Clinics: Evidence from a GI Continuity Clinic | Hammad Ashraf | Received |
3348-SUN | Use of GLP1RA in a MASLD Clinic Is Influenced by Type of Insurance Coverage | Meagan Gray | Received |
3350-SUN | Higher risk of proteinuria in atezolizumab plus bevacizumab than lenvatinib as a first-line systemic treatment in unresectable hepatocellular carcinoma | Jiwon Yang | Received |
3351-SUN | Locoregional treatments for bridging patients with hepatocellular carcinoma to liver transplantation | Grace Lee | Received |
3352-SUN | Analysis of factors predicting the real-world efficacy of atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma | CHANG WON HA | Received |
3354-SUN | Stereotactic Ablative Body Radiotherapy versus Ablation for the Treatment of Early-Stage Hepatocellular Carcinoma | Darragh Egan | Received |
3355-SUN | The ASAP score demonstrates high sensitivity for hepatocellular carcinoma (HCC) and is feasible for use in HCC surveillance - a prospective study | Chee-Kiat Tan | Received |
3356-SUN | UCSF criteria and liver dysfunction predict hepatocellular carcinoma (HCC) recurrence after surgery for HCC: A large multicentre study | Conner Blackmore | Received |
3357-SUN | Multi-omics analyses identify a novel HCC subtype with worse prognosis and better response to immune checkpoint inhibitor based therapies | Junjie Xu | Received |
3360-SUN | Resveratrol and tanshinone IIA synergize to suppress hepatocellular carcinoma by modulating stromal cells to remodel tumor microenvironment | Jia Shi | Received |
3361-SUN | Risk of bleeding in hepatocellular carcinoma patients treated with atezolizumab/bevacizumab: A systematic review and meta-analysis | Jeong-Ju Yoo | Received |
3362-SUN | Evaluation of Prophylactic Esophagogastroduodenoscopy versus Beta Blockade in Hepatocellular Carcinoma Patients Undergoing Anti-Angiogenic Cancer Treatments | Panayiotis Kontoyiannis | Received |
3363-SUN | Cholangiocytes´ Primary Cilia Regulates DNA Damage Response and Repair | Estanislao Peixoto | Received |
3365-SUN | Digitalized Precise Screening and Risk Stratified Management Improve Early Diagnosis of Hepatocellular Carcinoma (HCC) in China: a Multi-center Real-world Study | Tianle Li | Received |
3366-SUN | The Histone Lysine Acetyltransferase KAT2B Inhibits Cholangiocarcinoma Growth: Evidence for Interaction with SP1 to Regulate NF2-Yap Signaling | Wenbo Ma | Received |
3367-SUN | RBM39 Enhances Cholangiocarcinoma Growth through Ezh2-Mediated Wnt7b/Β-Catenin Pathway | Nianli Liu | Received |
3368-SUN | Non-viral Hepatocellular Carcinoma Has Similar Prognosis after Radical Treatment as Viral HCC: Analysis of a Nationwide Registry for Advanced Liver Diseases (REAL) | Kazuya Okushin | Received |
3369-SUN | TGF-β Signaling Molecules in Circulating Tumor Cells as Prognostic Biomarker in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab | Yosuke Murata | Received |
3370-SUN | Diagnostic Accuracy of Blood Plasma Spectroscopy for Early Liver Cancer Diagnostics in Obese Patients | Petr Hríbek | Received |
3371-SUN | Outcomes by baseline liver function in EMERALD-1: a Phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma | Helen Sherratt | Received |
3372-SUN | Intraindividual Comparison of Prognostic Imaging Features of Hepatocellular Carcinomas Between MRIs with Extracellular and Hepatobiliary Contrast Agents: Focus on Microvascular Invasion and Early Recurrence | Sunyoung Lee | Received |
3373-SUN | Mechanism of hepatocarcinogenesis due to hepatitis B virus genome integration into host KMT2B locus | Jun Tsuchiya | Received |
3374-SUN | METTL3-mediated m6A modification regulates the polycomb repressive complex 1 (PRC1) components BMI1 and RNF2 in hepatocellular carcinoma cells | Weina Chen | Received |
3375-SUN | Comparison of liver function injury in intermediate and advanced hepatocellular carcinoma patients treated with hepatic arterial infusion chemotherapy versus transcatheter arterial chemoembolization combined with immune checkpoint inhibitors and tyrosine | Mengya Zang | Received |
3376-SUN | The Hippo Pathway Effector TAZ Is Required for Notch-Driven Cholangiocarcinogenesis via METTL3-mediated m6A modification | Wenbo Ma | Received |
3377-SUN | Performance of a Multi-Cancer Early Detection (MCED) Test for Detection of Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis | Darine Daher | Received |
3378-SUN | Prospective study on the improvement of prognosis and suppression of cancer development after administration of zinc preparation in patients with liver cirrhosis | Atsushi Hosui | Received |
3379-SUN | Fever after the administration of atezolizumab and bevacizumab predicts liver injury in patients with unresectable hepatocellular carcinoma: a prospective observational analysis using a multiplex bead-based immunoassay | Takanori Ito | Received |
3380-SUN | Analysis of Varix bleeding complication after Atezolizumab plus Bevacizumab for advanced Hepatocellular carcinoma patients | Hee Kim | Received |
3382-SUN | Multi-omics analysis of patients with hepatocellular carcinoma treated with anti-PD-L1 plus anti-CTLA-4 and locoregional therapy: Correlative study of Phase2 trial | Yuta Myojin | Received |
3384-SUN | Liver transplantation is the major determinant in achieving over 10-year survival for patients with early-stage hepatocellular carcinoma | Joseph Ahn | Received |
3385-SUN | Interaction of solute carrier family 39 member 1 and dynamin related protein 1 to facilitate development of hepatocellular carcinoma by impairing mitochondrial quality control | Li Rui | Received |
3386-SUN | Maintenance of good liver function is important for good post-progression survival with atezolizumab/bevacizumab in advanced hepatocellular carcinoma | Teiji Kuzuya | Received |
3387-SUN | A comparative validation of clinical prediction scores for hepatocellular carcinoma in steatotic liver disease without cirrhosis | Catherine Mezzacappa | Received |
3389-SUN | UBE2D3 negatively regulates hepatocarcinogenesis via suppression of STAT3 signaling | Hideharu Nagasawa | Received |
3390-SUN | RNA-Binding Protein Trx regulates alternative splicing and promotes metastasis of HCC via interacting with LINC00152 | xiangnan teng | Received |
3391-SUN | A Clinicopathological and Artificial Intelligence-Derived Screening Model as a Tool for Distinguishing Patients with Non-Hodgkin Lymphomas from Inflammatory Hepatic Diseases: A Multicentric Learning Approach | Mina Farag | Received |
3392-SUN | Outcomes by comorbidities with tremelimumab and durvalumab in the Phase 3 HIMALAYA study in unresectable hepatocellular carcinoma | Helen Sherratt | Received |
3393-SUN | Trends in HCC deaths and contributing chronic liver disease etiologies - a contemporary analysis of national death certificate data | Andrew Moon | Received |
3394-SUN | Validation of a risk-stratified approach to screening for hepatocellular carcinoma following liver transplantation | Wesley Dixon | Received |
3396-SUN | T cell receptor and immune gene expression pharmacodynamics for durvalumab monotherapy and in combination with tremelimumab or bevacizumab in unresectable hepatocellular carcinoma (uHCC) | Robin Kate Kelley | Received |
3397-SUN | EMERALD-Y90: a Phase 2 study to evaluate transarterial radioembolization (TARE) followed by durvalumab (D) and bevacizumab (B) for the treatment of participants (pts) with unresectable hepatocellular carcinoma (uHCC) eligible for embolization | Helen Sherratt | Received |
3398-SUN | Non-viral etiology subgroup of the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma | Helen Sherratt | Received |
3399-SUN | Statin Use Reduces Tumor Recurrence in Hepatocellular Carcinoma After Curative Radiofrequency Ablation: A Propensity-Matched Analysis | Mazen Almasry | Received |
3400-SUN | Development of an ultra-sensitive TERT promoter mutant DNA detection method and its application in liquid biopsy | Masaru Muraoka | Received |
3402-SUN | The chemoprotective effects of genistein in a rat model of cirrhosis and hepatocellular carcinoma | Maneerat Chayanupatkul | Received |
3403-SUN | Nucleos(t)ide analogues in the treatment of long-term prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after radical surgery: Interim analysis of the phase 3 multi-center prospective trial | Zhongguo Zhou | Received |
3404-SUN | The role of HBV pregenomic RNA in influencing the development of hepatocellular carcinoma | Yifan Han | Received |
3405-SUN | Identification of PRMT5 as a therapeutic target in cholangiocarcinoma | Jasmin Elurbide | Received |
3406-SUN | PIVKA-II as a prognostic factor for patients with hepatocellular carcinoma and with normal serum alpha-fetoprotein levels | Chun-Ting Ho | Received |
3407-SUN | Machine learning-based decision-tree model demonstrating the prognostic value of PIVKA-II and AFP in patients with hepatocellular carcinoma | Chun-Ting Ho | Received |
3412-SUN | Serum soluble DR5 as a Novel biomarker predicts early recurrence of hepatocellular carcinoma in TACE-treated patients with chronic hepatitis B | xuanwei zeng | Received |
3413-SUN | Five-year overall survival and overall survival by tumor response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma | Lorenza Rimassa | Received |
3415-SUN | Role of myeloid-cell derived osteopontin in hepatocellular carcinoma | Chao Wang | Received |
3416-SUN | Circulating tumour DNA markers for prediction of sustained response following the cessation of targeted therapy and immunotherapy in hepatocellular carcinoma (HCC) | Jinzhang Chen | Received |
3417-SUN | The Albumin-Bilirubin Score as an Indicator of Effective Immunotherapy in Elderly Patients with Unresectable Hepatocellular Carcinoma | Shun Kaneko | Received |
3418-SUN | Longitudinal trends in frailty among patients with hepatocellular carcinoma | Madeleine Hu | Received |
3420-SUN | Stem Cell Growth Factor-β as a Predictive Biomarker of Response to Chemotherapy and Prognosis in Patients with Advanced-Stage Hepatocellular Carcinoma: A Retrospective Study | Masamichi Kimura | Received |
3421-SUN | Investigation for a role of non-apoptotic cell death in the development of Hepatocellular carcinoma | Yoshinobu Saito | Received |
3422-SUN | Prognostic value of combination of neutrophil to lymphocyte ratio and albumin- bilirubin grade in patients with hepatocellular carcinoma undergoing transarterial chemoembolization | Young Mi Hong | Received |
3423-SUN | Real-World Study of Adjuvant Therapy After Complete Resection of Early-Stage Hepatocellular Carcinoma | Yue Huang | Received |
3425-SUN | Impact of low level viremia on the efficacy of immune checkpoint inhibitors therapy in patients with unresectable hepatocellular carcinoma | Jinzhang Chen | Received |
3426-SUN | UTILITY OF THE GAAD ALGORITHM IN HEPATOCELLULAR CARCINOMA SURVEILLANCE AMONG A HIGH-RISK COHORT | Emily Larrea | Received |
3428-SUN | Identification of ITGB2 as a Novel MHC-II Neoantigen using Hepatocellular Carcinoma Organoids | Deyuan Zhong | Received |
3433-SUN | Systemic Immune Profiling Identifies Predictive Biomarkers for Response to Combination Immunotherapy in Hepatocellular Carcinoma | Akira Nishio | Received |
3434-SUN | Phase I clinical trial of adjuvant therapy utilizing six tumor-associated antigen-derived peptides and autologous dendritic cells for hepatocellular carcinoma | Hidetoshi Nakagawa | Received |
3435-SUN | Disruption of FGL2 induced TFEB-dependent lysosomal degradation of PD-L1 and Enhanced the efficacy of Anti-PD-1 therapy in Hepatocellular Carcinoma | Meiwen Han | Received |
3436-SUN | Soluble FGL2-FcγR?B axis drived memory CD8+ T cells dysfunction in Hepatocellular Carcinoma | Qianting Guan | Received |
3437-SUN | Investigation for diagnostic value of circulating tumor DNA for the early HBV-derived HCC by profiling fragmentation | Tom Ryu | Received |
3438-SUN | Multi-Omic Risk Prediction for Cholangiocarcinoma | Felix Van Haag | Received |
3439-SUN | Analysis of atezolizumab antidrug antibody in HCC patients treated with Atezolizumab and Bevacizumab | Ouchi Keishi | Received |
3442-SUN | Spatial Omics Analysis of the Proximity of PD-L1(+) Tumor-Associated Macrophage and CD8T cell Interaction Promoting Hepatocellular Carcinoma Progression | Takuto Nosaka | Received |
3443-SUN | Critical Outcomes in Patients with Hepatobiliary Neoplasia during COVID-19: United States Nationwide Analysis | Thanathip Suenghataiphorn | Received |
3444-SUN | Misclassification analysis of a multimodal image-based deep-learning model for predicting post-operative HCC recurrence: Implications for model improvement | Rex Wan-Hin Hui | Received |
3445-SUN | Phase II study of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma and Child-Pugh B: CHALLENGE trial | Takeshi Terashima | Received |
3446-SUN | Hepatocellular Carcinoma Risk in Hispanics with Chronic Hepatitis B | Ariel Lee | Received |
3447-SUN | Impact of Prior Locoregional Therapy (LRT) on Outcome of Patients treated with Single-Dose Tremelimumab Induction Regular Durvalumab (STRIDE) Therapy for Unresectable Hepatocellular Carcinoma (uHCC) in a Real-World Cohort | Shalini Bansal | Received |
3448-SUN | Viral versus Non-Viral Etiology Does Not Impact Outcomes of Unresectable Hepatocellular Carcinoma (uHCC) Patients Treated with Single Tremelimumab Regular Interval Durvalumab (STRIDE) in a Real-World Setting | Shalini Bansal | Received |
3449-SUN | Unraveling immune-activated tumor microenvironment correlated with clinical response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma | MyungJi Goh | Received |
3450-SUN | Identification of Erzhu Jiedu Recipe and its molecular mechanism underlying inhibited human hepatoma cells by UHPLC-MS/MS and network pharmacology | Yang Cheng | Received |
3451-SUN | DNA demethylation in promoter region restores CYGB expression and attenuates hepatocellular carcinoma progression | Hoang Hai | Received |
3452-SUN | Re-classification of combined hepatocellular-cholangiocarcinoma and small duct type intrahepatic cholangiocarcinoma by genetic alterations | Motoko Sasaki | Received |
3453-SUN | MARIJUANA USE IS NOT INDEPENDENTLY ASSOCIATED WITH THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CIRRHOSIS | Tae Hoon Lee | Received |
3455-SUN | Outcomes of Combined Heart and Liver Transplants in Patients with Congestive Hepatopathy and HCC: Analysis of US National Database | Fadl Zeineddine | Received |
3456-SUN | Causal association and prognostic value of tertiary lymphoid structure-related gene signatures in HCC | Lei Pu | Received |
3458-SUN | Prevalence of Chronic Liver Disease in Cholangiocarcinoma: a Meta-Analysis | Ethan Kai Jun Tham | Received |
3459-SUN | Hepatoma-derived growth factor (HDGF) is an oncogene on chromosome 1q in liver cancer | Tsung-Hui Hu | Received |
3461-SUN | Real-world clinical characteristics and treatment patterns among patients with unresectable hepatocellular carcinoma (uHCC) amenable to locoregional therapy (LRT) in the United States (US) | Neehar Parikh | Received |
3463-SUN | Manzamine A Inhibits Proliferation of Human Hepatocellular Carcinoma Cells by Suppression of Mitochondrial and Glycolytic Metabolism | Kenji Takemoto | Received |
3464-SUN | MAFLD etiology and multidisciplinary treatment could achieve a good survival in advanced HCC with cirrhosis - a large retrospective data from India. | Ashok Kumar Choudhury | Received |
3466-SUN | Safety analysis by treatment periods from EMERALD-1: a Phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcino | Helen Sherratt | Received |
3467-SUN | Risks of variceal bleeding in patients with hepatocellular carcinoma receiving immune checkpoint inhibitors and/or tyrosine kinase inhibitors (TIKs) | Jing Liang | Received |
3468-SUN | A patient-derived hepatocellular carcinoma spheroid system harnessing patient serum to model the tumor microenvironment and treatment response | Emilie Crouchet | Received |
3469-SUN | PFAS exposure as a risk factor for hepatocellular carcinoma: are all PFAS the same? | Ana Maretti-Mira | Received |
3470-SUN | Risk factors for post-transarterial chemoembolization hepatic failure in patients with hepatocellular carcinoma: A Systematic Review and Meta-Analysis | Vitchapong Prasitsumrit | Received |
3474-SUN | Multistep accumulation of mismatch repair deficiency-associated mutational signature during the hepatocarcinogenesis revealed by whole-genome sequencing analysis | Haruhiko Takeda | Received |
3475-SUN | High Proximity of Treg-CD8T/CD4T Cell Interactions in Spatial Omics Analysis Regulating Cancer Progression in Patients with Hepatocellular Carcinoma | Junki Yamashita | Received |
3476-SUN | Impact of CRAFITY score on Efficacy and Safety of First-line Atezolizumab plus Bevacizumab Therapy: Multi-center Retrospective Study | Masayuki Ueno | Received |
3477-SUN | Statin Use and Hepatocellular Carcinoma in Participants with Hepatic Fibrosis in the All of Us Research Program | Erik Almazan | Received |
3478-SUN | Exploring the Influence of Aspirin on Hepatocellular Carcinoma : A Nationwide Inpatient Analysis | Manasa Ginjupalli | Received |
3480-SUN | Exosomal miRNA as a Valuable Indicator for Predicting the Response of Atezolizumab and Bevacizumab Combination Therapy in Patients with Advanced Hepatocellular Carcinoma | Eunho Choi | Received |
3481-SUN | The Composition of Circulating Immune Cells Following Treatment with Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma | Eunho Choi | Received |
3482-SUN | In vivo experiments and omics analysis to explore the effect and mechanism of AnLuoHuaXian pills in alleviating the process of hepatitis to hepatocellular carcinoma | Xiaobin Zao | Received |
3483-SUN | Impact of COVID-19 on primary liver cancer-related mortality in the United States | Young Eun Chon | Received |
3485-SUN | Differentiating Hemangiomas from Hepatocellular Carcinomas Using Sonazoid-Enhanced Ultrasonography: A Proposed Two-Step Diagnostic Algorithm | Jeong Ah Hwang | Received |
3486-SUN | Curative Treatment after Immunotherapy Leads to Excellent Outcomes in Patients with Hepatocellular Carcinoma | Gwang Hyeon Choi | Received |
3489-SUN | Epigenetic Regulation of ACSM5 Expression in Hepatocellular Carcinoma | Lei Yang | Received |
3490-SUN | Dendritic cell exosomes decorated with hepatocellular carcinoma-specific antigenic peptides combined with anti PD-L1 boost cancer immunotherapy | Weihua Li | Received |
3491-SUN | Atezolizumab combined with Bevacizumab versus Sorafenib and Lenvatinib for patients with unresectable hepatocellular carcinoma: A systemic review and meta-analysis for randomized controlled trials | Sakditad Saowapa | Received |
3492-SUN | A machine learning model to predict the treatment response of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma | Moon Haeng Hur | Received |
3494-SUN | DPP4 inhibition augments the anti-tumor effect of combined anti-PD-1 antibody/regorafenib in hepatocellular carcinoma | Heejoon Jang | Received |
3495-SUN | Predicting end-stage hepatocellular carcinoma with the ECHO score: refining the definition of Barcelona Clinic Liver Cancer stage D disease in patients treated with immune checkpoint inhibitors | Michael Li | Received |
3496-SUN | Circulating exoPD-L1 predicts the outcome of patients with HCC who received atezolizumab-bevacizumab | Yu Rim Lee | Received |
3497-SUN | Burden of Liver Cancer and Other Major Gastrointestinal Cancers in The Eastern Mediterranean Region | Saleh Alqahtani | Received |
3498-SUN | Beneficial effect of combined radiation therapy in atezolizumab plus bevacizumab treatment of hepatocellular carcinoma patients with main portal vein tumor thrombosis or bile duct invasion. | Hyun Young Woo | Received |
3499-SUN | Machine learning can accurately stratify risk of hepatocellular carcinoma in real-world data | Jan Clusmann | Received |
3500-SUN | Targeting UBE2I-mediated protein hyper-SUMOylation halts cholangiocarcinoma progression and rewires the tumor-stroma crosstalk | Paula Olaizola Rebe | Received |
3501-SUN | The involvement of microRNA-1297 in lenvatinib resistance in hepatocellular carcinoma cells | Takayuki Kogure | Received |
3503-SUN | Transposon-based oncogenes integration in Abcb4 (Mdr2)-/- mice recapitulates high susceptibility to cholangiocarcinoma in primary sclerosing cholangitis | Pinzhu Huang | Received |
3507-SUN | Initial trans-arterial chemo-embolization (TACE) is associated with similar survival outcomes as compared to upfront percutaneous ablation in those with single hepatocellular carcinoma (HCC) <= 3cm: results of a real-world propensity-matched multi-centre | Jonathan Abdelmalak | Received |
3508-SUN | Efficacy and safety of Stereotactic body radiation therapy in elderly patients with cirrhosis and large advanced hepatocellular carcinoma | Deepti Sharma | Received |
3509-SUN | The role of adjuvant therapy in HCC treated with curative intent ablation: a step too far? | Natalie Commins | Received |
3510-SUN | Relationship between Immune Cell Infiltration and Outcomes in Cholangiocarcinoma | Keiko Iwaisako | Received |
3511-SUN | NRF2-mediated immune cold tumor microenvironment contributes to resistance to atezolizumab and bevacizumab in advanced hepatocellular carcinoma | Shuhei Yamamoto | Received |
3512-SUN | Lipophilic Statin Increases Sensitivity for Lenvatinib by Suppressing YAP/TAZ in Hepatocellular Carcinoma Cell Lines and Patient-Derived Organoids | Jae Seung Lee | Received |
3513-SUN | Trimethylamine N-oxide (TMAO) as a novel predictive biomarker in gallstone disease and gallbladder cancer: Insights from human and mice study | Vipin Yadav | Received |
3517-SUN | Sarcopenia impacts treatment tolerance and survival of patients with Hepatocellular carcinoma in cirrhosis | Krishnadas Devadas | Received |
3518-SUN | The Relationship between Fatty Acid Composition and Prognosis in Patients with Hepatocellular Carcinoma: Establishment of a New Nutritional Prognostic Score | Akitoshi Sano | Received |
3519-SUN | The Steatosis- Associated Fibrosis Estimator (SAFE) Score Predicts Hepatocellular Carcinoma in a Cohort of Chronic Liver DIsease of Mixed Etiology | Mai Sedki | Received |
3520-SUN | A comprehensive study employing computational analysis and Mendelian randomization has revealed the impact of key genes on liver cancer | Size Li | Received |
3521-SUN | Genomic profiling and pathological differences in MASLD-related hepatocellular carcinoma with and without cirrhosis. | Ajay Duseja | Received |
3522-SUN | Role of ALBI score in patients with hepatocellular carcinoma undergoing transarterial chemoembolization in Child-Pugh class A and low MELD score | Won Sohn | Received |
3523-SUN | Impact of the SARS-CoV-2 Pandemic on the Diagnosis and Follow-up of Patients with Hepatocellular Carcinoma at Río Hortega University Hospital | Natalia Marcos-Carrasco | Received |
3525-SUN | Survival after Removal from Liver Transplant Waitlist for Hepatocellular Carcinoma Progression: Effects of Immunotherapy and Therapy Type | David Victor | Received |
3527-SUN | AGAP-APRI as a proposed alternative to GALAD or Liver US with AFP for HCC screening in Filipinos | Edhel Tripon | Received |
3529-SUN | Comparative Analysis of Imaging Modalities for Hepatocellular Carcinoma Surveillance | Ahmed El sabagh | Received |
3530-SUN | Transarterial Chemoembolization Offers Survival Advantage Over Radioembolization in Early-stage Unresectable Hepatocellular Carcinoma | Faisal Sanai | Received |
3531-SUN | Altered Cellular Energetics and Dysregulation of NK Cells in Hepatocellular Carcinoma | Pushpa Yadav | Received |
3532-SUN | Baseline liver histological characteristics in patients with chronic hepatitis B who developed into HCC 3- 5 years later | Haina Fan | Received |
3534-SUN | Chemical inhibition of phosphoglycerate mutase 5 attenuates hepatocellular carcinoma viability | Andrea Johnston | Received |
3536-SUN | Characterization of the immune microenvironment in hepatocellular carcinoma before selective internal radiation therapy and its prognostic role in treatment efficacy | Maria Stella Franzè | Received |
3539-SUN | Optimal Treatment Strategies for Hepatocellular Carcinoma: A Meta-Analysis Comparing Transarterial Chemoembolization (TACE) Plus Microwave Ablation (MWA) Versus Microwave Ablation Alone | Muhammad Shahzil | Received |
3543-SUN | Prediction of Immune Checkpoint Inhibitor Treatment Response in Hepatocellular Carcinoma Using CT Radiomics | Ji Hye Min | Received |
3544-SUN | Tumor-derived circulating carbonic anhydrase 9 as a predictor of resistance to atezolizumab and bevacizumab in advanced hepatocellular carcinoma | Yu Sato | Received |